WO2023025248A1 - 一种甾体化合物及其缀合物 - Google Patents
一种甾体化合物及其缀合物 Download PDFInfo
- Publication number
- WO2023025248A1 WO2023025248A1 PCT/CN2022/114855 CN2022114855W WO2023025248A1 WO 2023025248 A1 WO2023025248 A1 WO 2023025248A1 CN 2022114855 W CN2022114855 W CN 2022114855W WO 2023025248 A1 WO2023025248 A1 WO 2023025248A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- group
- compound
- substituted
- alkyl
- Prior art date
Links
- -1 Steroid compound Chemical class 0.000 title claims abstract description 556
- 150000001875 compounds Chemical class 0.000 claims abstract description 411
- 239000000203 mixture Substances 0.000 claims abstract description 114
- 150000003839 salts Chemical class 0.000 claims abstract description 107
- 238000000034 method Methods 0.000 claims abstract description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 251
- 150000002367 halogens Chemical class 0.000 claims description 251
- 229910052739 hydrogen Inorganic materials 0.000 claims description 165
- 125000001072 heteroaryl group Chemical group 0.000 claims description 146
- 239000001257 hydrogen Substances 0.000 claims description 139
- 239000012634 fragment Substances 0.000 claims description 136
- 229910052805 deuterium Inorganic materials 0.000 claims description 124
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 123
- 150000002431 hydrogen Chemical group 0.000 claims description 121
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 119
- 229910052722 tritium Inorganic materials 0.000 claims description 119
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims description 118
- 241000720974 Protium Species 0.000 claims description 118
- 230000027455 binding Effects 0.000 claims description 118
- 239000000427 antigen Substances 0.000 claims description 105
- 108091007433 antigens Proteins 0.000 claims description 105
- 102000036639 antigens Human genes 0.000 claims description 105
- 125000003118 aryl group Chemical group 0.000 claims description 88
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 86
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 74
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims description 69
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 69
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 66
- 125000000623 heterocyclic group Chemical group 0.000 claims description 66
- 239000003446 ligand Substances 0.000 claims description 65
- 125000003107 substituted aryl group Chemical group 0.000 claims description 63
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 62
- 239000000460 chlorine Substances 0.000 claims description 60
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 56
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 54
- 201000010099 disease Diseases 0.000 claims description 51
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 47
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 45
- 229960002964 adalimumab Drugs 0.000 claims description 44
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 43
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 43
- 125000001424 substituent group Chemical group 0.000 claims description 42
- 229910052760 oxygen Inorganic materials 0.000 claims description 41
- 125000002947 alkylene group Chemical group 0.000 claims description 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 38
- 125000004450 alkenylene group Chemical group 0.000 claims description 37
- 125000004419 alkynylene group Chemical group 0.000 claims description 37
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 37
- 239000001301 oxygen Chemical group 0.000 claims description 37
- 125000000732 arylene group Chemical group 0.000 claims description 36
- 229910052801 chlorine Inorganic materials 0.000 claims description 35
- 229910052731 fluorine Inorganic materials 0.000 claims description 35
- 229960000598 infliximab Drugs 0.000 claims description 35
- 125000005717 substituted cycloalkylene group Chemical group 0.000 claims description 35
- 125000005549 heteroarylene group Chemical group 0.000 claims description 34
- 238000002360 preparation method Methods 0.000 claims description 30
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 claims description 30
- 229960003227 afelimomab Drugs 0.000 claims description 29
- 229960001743 golimumab Drugs 0.000 claims description 29
- 125000005647 linker group Chemical group 0.000 claims description 27
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 26
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 26
- 208000024891 symptom Diseases 0.000 claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 22
- 239000004471 Glycine Substances 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 230000008878 coupling Effects 0.000 claims description 17
- 238000010168 coupling process Methods 0.000 claims description 17
- 238000005859 coupling reaction Methods 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000003003 spiro group Chemical group 0.000 claims description 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 13
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 12
- 229910052794 bromium Inorganic materials 0.000 claims description 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 11
- 239000011737 fluorine Substances 0.000 claims description 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 11
- 229950010117 anifrolumab Drugs 0.000 claims description 10
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 10
- 229940121288 iscalimab Drugs 0.000 claims description 10
- 150000001555 benzenes Chemical group 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 7
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 6
- 108010016626 Dipeptides Proteins 0.000 claims description 6
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 claims description 6
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 6
- 229960002173 citrulline Drugs 0.000 claims description 6
- 210000000987 immune system Anatomy 0.000 claims description 6
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 206010001324 Adrenal atrophy Diseases 0.000 claims description 3
- DEFJQIDDEAULHB-UHFFFAOYSA-N Alanyl-alanine Chemical compound CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 208000004300 Atrophic Gastritis Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000036495 Gastritis atrophic Diseases 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000003807 Graves Disease Diseases 0.000 claims description 3
- 208000015023 Graves' disease Diseases 0.000 claims description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 3
- 206010021263 IgA nephropathy Diseases 0.000 claims description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 3
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 3
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 3
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010038460 Renal haemorrhage Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 3
- 206010043781 Thyroiditis chronic Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 201000004995 autoimmune glomerulonephritis Diseases 0.000 claims description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims description 3
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- 208000037880 idiopathic vasculitis Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 2
- OBVVKJDJORDBCH-CZDIJEQGSA-N 2-aminoacetic acid (2S)-2-amino-3-phenylpropanoic acid Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 OBVVKJDJORDBCH-CZDIJEQGSA-N 0.000 claims description 2
- ZEEYNQNRMIBLMK-DFWYDOINSA-N 2-aminoacetic acid;(2s)-2-aminopentanedioic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CCC(O)=O ZEEYNQNRMIBLMK-DFWYDOINSA-N 0.000 claims description 2
- JZNGILSSCUIFMF-UHFFFAOYSA-N 2-azanylethanoic acid Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O.NCC(O)=O JZNGILSSCUIFMF-UHFFFAOYSA-N 0.000 claims description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 claims description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 102100025371 Butyrophilin-like protein 8 Human genes 0.000 claims description 2
- 102100025374 Butyrophilin-like protein 9 Human genes 0.000 claims description 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims description 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims description 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims description 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 claims description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims description 2
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims description 2
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims description 2
- 102100026195 C-type lectin domain family 12 member B Human genes 0.000 claims description 2
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 claims description 2
- 102100040843 C-type lectin domain family 4 member M Human genes 0.000 claims description 2
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 claims description 2
- 102100039521 C-type lectin domain family 9 member A Human genes 0.000 claims description 2
- 108091058539 C10orf54 Proteins 0.000 claims description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 2
- 108010009992 CD163 antigen Proteins 0.000 claims description 2
- 102100024209 CD177 antigen Human genes 0.000 claims description 2
- 102100021992 CD209 antigen Human genes 0.000 claims description 2
- 102100038077 CD226 antigen Human genes 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 2
- 102100032912 CD44 antigen Human genes 0.000 claims description 2
- 102100036008 CD48 antigen Human genes 0.000 claims description 2
- 108010065524 CD52 Antigen Proteins 0.000 claims description 2
- 102100022002 CD59 glycoprotein Human genes 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- 102100022436 CMRF35-like molecule 8 Human genes 0.000 claims description 2
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims description 2
- 102100030886 Complement receptor type 1 Human genes 0.000 claims description 2
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 claims description 2
- 102100033553 Delta-like protein 4 Human genes 0.000 claims description 2
- 102100023471 E-selectin Human genes 0.000 claims description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 2
- 102100038083 Endosialin Human genes 0.000 claims description 2
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 claims description 2
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 claims description 2
- 102100037815 Fas apoptotic inhibitory molecule 3 Human genes 0.000 claims description 2
- 101710088083 Glomulin Proteins 0.000 claims description 2
- 102100035943 HERV-H LTR-associating protein 2 Human genes 0.000 claims description 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000934742 Homo sapiens Butyrophilin-like protein 8 Proteins 0.000 claims description 2
- 101000934743 Homo sapiens Butyrophilin-like protein 9 Proteins 0.000 claims description 2
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 claims description 2
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 2
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 claims description 2
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims description 2
- 101000912622 Homo sapiens C-type lectin domain family 12 member A Proteins 0.000 claims description 2
- 101000912620 Homo sapiens C-type lectin domain family 12 member B Proteins 0.000 claims description 2
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 claims description 2
- 101000749311 Homo sapiens C-type lectin domain family 4 member M Proteins 0.000 claims description 2
- 101000749325 Homo sapiens C-type lectin domain family 7 member A Proteins 0.000 claims description 2
- 101000888548 Homo sapiens C-type lectin domain family 9 member A Proteins 0.000 claims description 2
- 101000980845 Homo sapiens CD177 antigen Proteins 0.000 claims description 2
- 101000897416 Homo sapiens CD209 antigen Proteins 0.000 claims description 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 2
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101000901669 Homo sapiens CMRF35-like molecule 8 Proteins 0.000 claims description 2
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims description 2
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 claims description 2
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims description 2
- 101000622123 Homo sapiens E-selectin Proteins 0.000 claims description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 2
- 101000884275 Homo sapiens Endosialin Proteins 0.000 claims description 2
- 101000878510 Homo sapiens Fas apoptotic inhibitory molecule 3 Proteins 0.000 claims description 2
- 101000876511 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPD Proteins 0.000 claims description 2
- 101001021491 Homo sapiens HERV-H LTR-associating protein 2 Proteins 0.000 claims description 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims description 2
- 101001081176 Homo sapiens Hyaluronan mediated motility receptor Proteins 0.000 claims description 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 2
- 101100232351 Homo sapiens IL12RB1 gene Proteins 0.000 claims description 2
- 101000599613 Homo sapiens Interferon lambda receptor 1 Proteins 0.000 claims description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 2
- 101001003135 Homo sapiens Interleukin-13 receptor subunit alpha-1 Proteins 0.000 claims description 2
- 101001003132 Homo sapiens Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims description 2
- 101001019598 Homo sapiens Interleukin-17 receptor A Proteins 0.000 claims description 2
- 101001019600 Homo sapiens Interleukin-17 receptor B Proteins 0.000 claims description 2
- 101001019602 Homo sapiens Interleukin-17 receptor C Proteins 0.000 claims description 2
- 101001019590 Homo sapiens Interleukin-17 receptor E Proteins 0.000 claims description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
- 101000853012 Homo sapiens Interleukin-23 receptor Proteins 0.000 claims description 2
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims description 2
- 101000960936 Homo sapiens Interleukin-5 receptor subunit alpha Proteins 0.000 claims description 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 2
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 2
- 101001055219 Homo sapiens Interleukin-9 receptor Proteins 0.000 claims description 2
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 claims description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 2
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 2
- 101001134216 Homo sapiens Macrophage scavenger receptor types I and II Proteins 0.000 claims description 2
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims description 2
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 2
- 101000616778 Homo sapiens Myelin-associated glycoprotein Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 2
- 101000633520 Homo sapiens Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 claims description 2
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 claims description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 2
- 101000586618 Homo sapiens Poliovirus receptor Proteins 0.000 claims description 2
- 101000606310 Homo sapiens Pre T-cell antigen receptor alpha Proteins 0.000 claims description 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 2
- 101000583199 Homo sapiens Prokineticin receptor 1 Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 2
- 101000863880 Homo sapiens Sialic acid-binding Ig-like lectin 6 Proteins 0.000 claims description 2
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 claims description 2
- 101000863884 Homo sapiens Sialic acid-binding Ig-like lectin 8 Proteins 0.000 claims description 2
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 claims description 2
- 101000652846 Homo sapiens Single Ig IL-1-related receptor Proteins 0.000 claims description 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims description 2
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 2
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 claims description 2
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims description 2
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 101000801227 Homo sapiens Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 claims description 2
- 101000679921 Homo sapiens Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 claims description 2
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 2
- 101000743488 Homo sapiens V-set and immunoglobulin domain-containing protein 4 Proteins 0.000 claims description 2
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 2
- 101000666934 Homo sapiens Very low-density lipoprotein receptor Proteins 0.000 claims description 2
- 102100027735 Hyaluronan mediated motility receptor Human genes 0.000 claims description 2
- 102100034980 ICOS ligand Human genes 0.000 claims description 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 2
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 claims description 2
- 102100037971 Interferon lambda receptor 1 Human genes 0.000 claims description 2
- 102100020790 Interleukin-12 receptor subunit beta-1 Human genes 0.000 claims description 2
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 claims description 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 2
- 102100035018 Interleukin-17 receptor A Human genes 0.000 claims description 2
- 102100035014 Interleukin-17 receptor B Human genes 0.000 claims description 2
- 102100035012 Interleukin-17 receptor C Human genes 0.000 claims description 2
- 102100035016 Interleukin-17 receptor E Human genes 0.000 claims description 2
- 108010017411 Interleukin-21 Receptors Proteins 0.000 claims description 2
- 102100030699 Interleukin-21 receptor Human genes 0.000 claims description 2
- 102100036672 Interleukin-23 receptor Human genes 0.000 claims description 2
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 claims description 2
- 102100039881 Interleukin-5 receptor subunit alpha Human genes 0.000 claims description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 2
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 2
- 102100026244 Interleukin-9 receptor Human genes 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101710197072 Lectin 1 Proteins 0.000 claims description 2
- 101710197068 Lectin-4 Proteins 0.000 claims description 2
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 claims description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 2
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 claims description 2
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 claims description 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 2
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 claims description 2
- 101710124692 Macrophage mannose receptor 1 Proteins 0.000 claims description 2
- 102100034184 Macrophage scavenger receptor types I and II Human genes 0.000 claims description 2
- 102100025136 Macrosialin Human genes 0.000 claims description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
- 102100039373 Membrane cofactor protein Human genes 0.000 claims description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 2
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 claims description 2
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 claims description 2
- 102100021831 Myelin-associated glycoprotein Human genes 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 101150065403 NECTIN2 gene Proteins 0.000 claims description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims description 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims description 2
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 claims description 2
- 102100035488 Nectin-2 Human genes 0.000 claims description 2
- 102100035487 Nectin-3 Human genes 0.000 claims description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 2
- 101100154895 Oryzias latipes tyr gene Proteins 0.000 claims description 2
- 102100029740 Poliovirus receptor Human genes 0.000 claims description 2
- 102100039824 Pre T-cell antigen receptor alpha Human genes 0.000 claims description 2
- 102100030364 Prokineticin receptor 1 Human genes 0.000 claims description 2
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 2
- 102000018795 RELT Human genes 0.000 claims description 2
- 108010052562 RELT Proteins 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 2
- 102100025831 Scavenger receptor cysteine-rich type 1 protein M130 Human genes 0.000 claims description 2
- 108010029176 Sialic Acid Binding Ig-like Lectin 1 Proteins 0.000 claims description 2
- 102100027164 Sialic acid-binding Ig-like lectin 10 Human genes 0.000 claims description 2
- 101710143293 Sialic acid-binding Ig-like lectin 10 Proteins 0.000 claims description 2
- 102100029947 Sialic acid-binding Ig-like lectin 6 Human genes 0.000 claims description 2
- 102100029964 Sialic acid-binding Ig-like lectin 8 Human genes 0.000 claims description 2
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 claims description 2
- 102100032855 Sialoadhesin Human genes 0.000 claims description 2
- 102100030929 Single Ig IL-1-related receptor Human genes 0.000 claims description 2
- 102100035721 Syndecan-1 Human genes 0.000 claims description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims description 2
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 claims description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 2
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 claims description 2
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims description 2
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 claims description 2
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 claims description 2
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 claims description 2
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims description 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims description 2
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 2
- 102100038296 V-set and immunoglobulin domain-containing protein 4 Human genes 0.000 claims description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 108010079292 betaglycan Proteins 0.000 claims description 2
- 229960000106 biosimilars Drugs 0.000 claims description 2
- 229910052796 boron Inorganic materials 0.000 claims description 2
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 229910052721 tungsten Inorganic materials 0.000 claims description 2
- PTUJJIPXBJJLLV-UHFFFAOYSA-N 2-[[2-[[2-[[2-[(2-methylpropan-2-yl)oxycarbonylamino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(=O)NCC(=O)NC(C(=O)NCC(O)=O)CC1=CC=CC=C1 PTUJJIPXBJJLLV-UHFFFAOYSA-N 0.000 claims 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 2
- OMZPMJRGLDHPDU-QTNFYWBSSA-N 2-aminoacetic acid;(2s)-2-aminopentanedioic acid Chemical compound NCC(O)=O.NCC(O)=O.OC(=O)[C@@H](N)CCC(O)=O OMZPMJRGLDHPDU-QTNFYWBSSA-N 0.000 claims 1
- 102100025429 Butyrophilin-like protein 2 Human genes 0.000 claims 1
- 102100025430 Butyrophilin-like protein 3 Human genes 0.000 claims 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 claims 1
- 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 claims 1
- 101000934738 Homo sapiens Butyrophilin-like protein 2 Proteins 0.000 claims 1
- 101000934741 Homo sapiens Butyrophilin-like protein 3 Proteins 0.000 claims 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 1
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 claims 1
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 claims 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 1
- 102100029957 Sialic acid-binding Ig-like lectin 5 Human genes 0.000 claims 1
- 101710110535 Sialic acid-binding Ig-like lectin 5 Proteins 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 description 110
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 104
- 108090000623 proteins and genes Proteins 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 37
- 235000018102 proteins Nutrition 0.000 description 37
- 102000004169 proteins and genes Human genes 0.000 description 37
- 230000002378 acidificating effect Effects 0.000 description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 31
- 238000006243 chemical reaction Methods 0.000 description 30
- 235000001014 amino acid Nutrition 0.000 description 28
- 125000004432 carbon atom Chemical group C* 0.000 description 27
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 25
- 150000001413 amino acids Chemical class 0.000 description 24
- 239000000562 conjugate Substances 0.000 description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 23
- 229910052757 nitrogen Inorganic materials 0.000 description 23
- 238000006467 substitution reaction Methods 0.000 description 23
- 125000006239 protecting group Chemical group 0.000 description 22
- 125000000217 alkyl group Chemical group 0.000 description 21
- 229910052799 carbon Inorganic materials 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 17
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 16
- 125000003275 alpha amino acid group Chemical group 0.000 description 16
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 238000003776 cleavage reaction Methods 0.000 description 15
- 230000007017 scission Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 125000004429 atom Chemical group 0.000 description 13
- 238000002953 preparative HPLC Methods 0.000 description 13
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 125000003342 alkenyl group Chemical group 0.000 description 12
- 150000001721 carbon Chemical group 0.000 description 12
- 239000003638 chemical reducing agent Substances 0.000 description 12
- 229910052763 palladium Inorganic materials 0.000 description 12
- 238000003419 tautomerization reaction Methods 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 125000000304 alkynyl group Chemical group 0.000 description 11
- 238000009833 condensation Methods 0.000 description 11
- 230000005494 condensation Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 238000004809 thin layer chromatography Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 125000001931 aliphatic group Chemical group 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 10
- 229940126412 litifilimab Drugs 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 229960003115 certolizumab pegol Drugs 0.000 description 9
- 239000003862 glucocorticoid Substances 0.000 description 9
- 229940127121 immunoconjugate Drugs 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- 102000035195 Peptidases Human genes 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 125000002723 alicyclic group Chemical group 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 7
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 108090000371 Esterases Proteins 0.000 description 6
- 108010024636 Glutathione Proteins 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 6
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229960003589 arginine hydrochloride Drugs 0.000 description 6
- ZRBROGSAUIUIJE-UHFFFAOYSA-N azanium;azane;chloride Chemical compound N.[NH4+].[Cl-] ZRBROGSAUIUIJE-UHFFFAOYSA-N 0.000 description 6
- 229960002319 barbital Drugs 0.000 description 6
- 229910021538 borax Inorganic materials 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- NHSCRWJPZDNMBU-UHFFFAOYSA-L dipotassium carbonic acid carbonate Chemical compound [K+].[K+].OC([O-])=O.OC([O-])=O NHSCRWJPZDNMBU-UHFFFAOYSA-L 0.000 description 6
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 6
- SILCDLWESNHZKB-UHFFFAOYSA-L disodium 4-hydroxy-4-oxobutanoate Chemical compound [Na+].[Na+].OC(=O)CCC([O-])=O.OC(=O)CCC([O-])=O SILCDLWESNHZKB-UHFFFAOYSA-L 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 239000007986 glycine-NaOH buffer Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- CPJJXNTZFVBYIA-UHFFFAOYSA-M potassium boric acid chloride Chemical compound [Cl-].[K+].OB(O)O CPJJXNTZFVBYIA-UHFFFAOYSA-M 0.000 description 6
- 239000008057 potassium phosphate buffer Substances 0.000 description 6
- SDRZXZKXVBHREH-UHFFFAOYSA-M potassium;dihydrogen phosphate;phosphoric acid Chemical compound [K+].OP(O)(O)=O.OP(O)([O-])=O SDRZXZKXVBHREH-UHFFFAOYSA-M 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000007974 sodium acetate buffer Substances 0.000 description 6
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 6
- 239000012064 sodium phosphate buffer Substances 0.000 description 6
- 239000004328 sodium tetraborate Substances 0.000 description 6
- DFIWJEVKLWMZBI-UHFFFAOYSA-M sodium;dihydrogen phosphate;phosphoric acid Chemical compound [Na+].OP(O)(O)=O.OP(O)([O-])=O DFIWJEVKLWMZBI-UHFFFAOYSA-M 0.000 description 6
- OTNVGWMVOULBFZ-UHFFFAOYSA-N sodium;hydrochloride Chemical compound [Na].Cl OTNVGWMVOULBFZ-UHFFFAOYSA-N 0.000 description 6
- 239000008362 succinate buffer Substances 0.000 description 6
- 125000004434 sulfur atom Chemical group 0.000 description 6
- MFCIZNVJMNZKLO-UHFFFAOYSA-N tripotassium boric acid borate Chemical compound B([O-])([O-])[O-].[K+].B(O)(O)O.[K+].[K+] MFCIZNVJMNZKLO-UHFFFAOYSA-N 0.000 description 6
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 6
- LEAHFJQFYSDGGP-UHFFFAOYSA-K trisodium;dihydrogen phosphate;hydrogen phosphate Chemical compound [Na+].[Na+].[Na+].OP(O)([O-])=O.OP([O-])([O-])=O LEAHFJQFYSDGGP-UHFFFAOYSA-K 0.000 description 6
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-methylmorpholine Substances CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 125000003282 alkyl amino group Chemical group 0.000 description 5
- 125000004414 alkyl thio group Chemical group 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000000611 antibody drug conjugate Substances 0.000 description 5
- 229940049595 antibody-drug conjugate Drugs 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 125000000000 cycloalkoxy group Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 235000019833 protease Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 125000004423 acyloxy group Chemical group 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 150000001642 boronic acid derivatives Chemical class 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 description 4
- 102000054261 human IFNAR1 Human genes 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 108700012920 TNF Proteins 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 125000005366 cycloalkylthio group Chemical group 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000006317 isomerization reaction Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010504 bond cleavage reaction Methods 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000004452 carbocyclyl group Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000002993 cycloalkylene group Chemical group 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- AXZAYXJCENRGIM-UHFFFAOYSA-J dipotassium;tetrabromoplatinum(2-) Chemical compound [K+].[K+].[Br-].[Br-].[Br-].[Br-].[Pt+2] AXZAYXJCENRGIM-UHFFFAOYSA-J 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 238000006396 nitration reaction Methods 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229910001487 potassium perchlorate Inorganic materials 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 2
- 229960002218 sodium chlorite Drugs 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- MOILFCKRQFQVFS-BDNRQGISSA-N (1r,3s,4r,5r)-4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol Chemical compound C1[C@@H]2C(C)(C)[C@H]1C[C@H](O)[C@@]2(O)C MOILFCKRQFQVFS-BDNRQGISSA-N 0.000 description 1
- MOILFCKRQFQVFS-OORONAJNSA-N (1s,3r,4s,5s)-4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol Chemical compound C1[C@H]2C(C)(C)[C@@H]1C[C@@H](O)[C@]2(O)C MOILFCKRQFQVFS-OORONAJNSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 1
- GOTRMTLAQUQBIQ-UHFFFAOYSA-N (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)boronic acid Chemical compound CC1(C)OB(B(O)O)OC1(C)C GOTRMTLAQUQBIQ-UHFFFAOYSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PPTXVXKCQZKFBN-UHFFFAOYSA-N (S)-(-)-1,1'-Bi-2-naphthol Chemical compound C1=CC=C2C(C3=C4C=CC=CC4=CC=C3O)=C(O)C=CC2=C1 PPTXVXKCQZKFBN-UHFFFAOYSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-L 2-(carboxymethyl)-2-hydroxysuccinate Chemical compound [O-]C(=O)CC(O)(C(=O)O)CC([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-L 0.000 description 1
- MYUNWHTZYXUCIK-WEVVVXLNSA-N 2-[(E)-hydrazinylidenemethyl]phenol Chemical compound N\N=C\C1=CC=CC=C1O MYUNWHTZYXUCIK-WEVVVXLNSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- BMUXBWLKTHLRQC-UHFFFAOYSA-N 2-azanylethanoic acid Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O BMUXBWLKTHLRQC-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- MENYRYNFSIBDQN-UHFFFAOYSA-N 5,5-dibromoimidazolidine-2,4-dione Chemical compound BrC1(Br)NC(=O)NC1=O MENYRYNFSIBDQN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- FQBRXXBMYKCMBZ-UHFFFAOYSA-N B(O)(O)O.CC(C)(CC(C)(O)C)O.CC(C)(CC(C)(O)C)O Chemical compound B(O)(O)O.CC(C)(CC(C)(O)C)O.CC(C)(CC(C)(O)C)O FQBRXXBMYKCMBZ-UHFFFAOYSA-N 0.000 description 1
- BDEIASRRCFZGBR-UHFFFAOYSA-N B(O)(O)O.CC(C)(CC(C)O)O.CC(C)(CC(C)O)O Chemical compound B(O)(O)O.CC(C)(CC(C)O)O.CC(C)(CC(C)O)O BDEIASRRCFZGBR-UHFFFAOYSA-N 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
- MNKAYFFSLUOCSX-DHTOPLTISA-N C(CO)(=O)O.C(C)(C)[C@@]([C@@](C(=O)O)(O)C(C)C)(O)C(=O)O Chemical compound C(CO)(=O)O.C(C)(C)[C@@]([C@@](C(=O)O)(O)C(C)C)(O)C(=O)O MNKAYFFSLUOCSX-DHTOPLTISA-N 0.000 description 1
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000004411 C5-C6 heterocyclyl group Chemical group 0.000 description 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 208000014997 Crohn colitis Diseases 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010054267 Interferon Receptors Proteins 0.000 description 1
- 102000001617 Interferon Receptors Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 241000282842 Lama glama Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- VDYZJHUMTCUMFF-RVYSEXHFSA-N N[C@@H](CCCCCN)C(=O)O.N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound N[C@@H](CCCCCN)C(=O)O.N[C@@H](CC1=CC=CC=C1)C(=O)O VDYZJHUMTCUMFF-RVYSEXHFSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241000863996 Ozola Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 206010050207 Skin fibrosis Diseases 0.000 description 1
- 206010053262 Skin swelling Diseases 0.000 description 1
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000006887 Ullmann reaction Methods 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- YCGSLTNXFOFSOQ-UHFFFAOYSA-K [Cl].[Al](Cl)(Cl)Cl Chemical compound [Cl].[Al](Cl)(Cl)Cl YCGSLTNXFOFSOQ-UHFFFAOYSA-K 0.000 description 1
- RAOSIAYCXKBGFE-UHFFFAOYSA-K [Cu+3].[O-]P([O-])([O-])=O Chemical compound [Cu+3].[O-]P([O-])([O-])=O RAOSIAYCXKBGFE-UHFFFAOYSA-K 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 210000002367 agranular leukocyte Anatomy 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- TWKVUTXHANJYGH-UHFFFAOYSA-L allyl palladium chloride Chemical class Cl[Pd]CC=C.Cl[Pd]CC=C TWKVUTXHANJYGH-UHFFFAOYSA-L 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WXNOJTUTEXAZLD-UHFFFAOYSA-L benzonitrile;dichloropalladium Chemical compound Cl[Pd]Cl.N#CC1=CC=CC=C1.N#CC1=CC=CC=C1 WXNOJTUTEXAZLD-UHFFFAOYSA-L 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005622 butynylene group Chemical group 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- IFMWVBVPVXRZHE-UHFFFAOYSA-M chlorotitanium(3+);propan-2-olate Chemical compound [Cl-].[Ti+4].CC(C)[O-].CC(C)[O-].CC(C)[O-] IFMWVBVPVXRZHE-UHFFFAOYSA-M 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940116318 copper carbonate Drugs 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(I) oxide Inorganic materials [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- WIVXEZIMDUGYRW-UHFFFAOYSA-L copper(i) sulfate Chemical compound [Cu+].[Cu+].[O-]S([O-])(=O)=O WIVXEZIMDUGYRW-UHFFFAOYSA-L 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- SBTSVTLGWRLWOD-UHFFFAOYSA-L copper(ii) triflate Chemical compound [Cu+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F SBTSVTLGWRLWOD-UHFFFAOYSA-L 0.000 description 1
- JIDMEYQIXXJQCC-UHFFFAOYSA-L copper;2,2,2-trifluoroacetate Chemical compound [Cu+2].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F JIDMEYQIXXJQCC-UHFFFAOYSA-L 0.000 description 1
- RSJOBNMOMQFPKQ-UHFFFAOYSA-L copper;2,3-dihydroxybutanedioate Chemical compound [Cu+2].[O-]C(=O)C(O)C(O)C([O-])=O RSJOBNMOMQFPKQ-UHFFFAOYSA-L 0.000 description 1
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 description 1
- HFDWIMBEIXDNQS-UHFFFAOYSA-L copper;diformate Chemical compound [Cu+2].[O-]C=O.[O-]C=O HFDWIMBEIXDNQS-UHFFFAOYSA-L 0.000 description 1
- QYCVHILLJSYYBD-UHFFFAOYSA-L copper;oxalate Chemical compound [Cu+2].[O-]C(=O)C([O-])=O QYCVHILLJSYYBD-UHFFFAOYSA-L 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 229960003280 cupric chloride Drugs 0.000 description 1
- 229940045803 cuprous chloride Drugs 0.000 description 1
- KRFJLUBVMFXRPN-UHFFFAOYSA-N cuprous oxide Chemical compound [O-2].[Cu+].[Cu+] KRFJLUBVMFXRPN-UHFFFAOYSA-N 0.000 description 1
- 229940112669 cuprous oxide Drugs 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004977 cycloheptylene group Chemical group 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000005725 cyclohexenylene group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004978 cyclooctylene group Chemical group 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- YSAVZVORKRDODB-PHDIDXHHSA-N diethyl (2r,3r)-2,3-dihydroxybutanedioate Chemical compound CCOC(=O)[C@H](O)[C@@H](O)C(=O)OCC YSAVZVORKRDODB-PHDIDXHHSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010033706 glycylserine Proteins 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000004995 haloalkylthio group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Inorganic materials Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 description 1
- SKOWZLGOFVSKLB-UHFFFAOYSA-N hypodiboric acid Chemical compound OB(O)B(O)O SKOWZLGOFVSKLB-UHFFFAOYSA-N 0.000 description 1
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical group FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000006713 insertion reaction Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- 229950004563 lucatumumab Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- ZLVYMPOQNJTFSG-QMMMGPOBSA-N monoiodotyrosine Chemical compound OC(=O)[C@@H](NI)CC1=CC=C(O)C=C1 ZLVYMPOQNJTFSG-QMMMGPOBSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229950009675 nerelimomab Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229950004327 ozoralizumab Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 238000000711 polarimetry Methods 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- RLJWTAURUFQFJP-UHFFFAOYSA-N propan-2-ol;titanium Chemical compound [Ti].CC(C)O.CC(C)O.CC(C)O.CC(C)O RLJWTAURUFQFJP-UHFFFAOYSA-N 0.000 description 1
- KBHBDZQAQRNXRB-UHFFFAOYSA-N propan-2-olate;titanium(3+) Chemical compound [Ti+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] KBHBDZQAQRNXRB-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000005550 pyrazinylene group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000005576 pyrimidinylene group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000003579 shift reagent Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005156 substituted alkylene group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- VXUYXOFXAQZZMF-UHFFFAOYSA-N tetraisopropyl titanate Substances CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005556 thienylene group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Definitions
- the present application relates to the field of biomedicine, in particular to a steroid compound and a conjugate thereof.
- Inflammation is an adaptive response triggered by a variety of noxious stimuli and states that underlies many human immune system-related diseases.
- Steroids are a class of anti-inflammatory drugs that may have the potential to affect immune system function, treat or prevent diseases and/or symptoms associated with glucocorticoid receptor signaling, however some existing steroids have anti-inflammatory effects Not strong, other steroids can have many unwanted side effects. Therefore, there is an urgent need to further develop various steroid-forming antibody-conjugated drugs and steroidal compounds as drugs that can exert better curative effect or have better safety.
- the application provides a compound or its tautomer, mesomer, racemate, enantiomer, diastereoisomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof , which can have one or more effects selected from the following groups: (1) have the ability to affect the activity of immune cells; (2) their conjugates have a targeting effect; (3) have plasma stability; (4) It has biological safety; (5) has the ability to affect the cytokine release of immune cells; (6) has the ability to affect the transcription of IFN signaling pathway response genes; (7) has the ability to affect the degree of skin fibrosis; (8) has the ability to affect (9) the ability to affect the collagen content of the skin; (10) the ability to affect the expression level of GRE; (11) the ability to affect the cytokine release of monocytes; (12) ) has the ability to affect contact hypersensitivity; (13) has the ability to affect skin swelling and (14) has the ability to affect arthritis symptoms.
- the application provides immunoconjugates comprising a glucocorticoid receptor agonist linked to a protein (eg, an antibody or antigen-binding fragment thereof and a soluble receptor protein).
- a protein eg, an antibody or antigen-binding fragment thereof and a soluble receptor protein.
- the antibody or antigen-binding fragment thereof is human, humanized, chimeric or murine.
- proteins eg, antibodies, antigen-binding fragments thereof, or soluble receptor proteins
- proteins can bind to targets on the cell surface and become internalized.
- the application provides a compound of formula I:
- R 1 , R 2 , R 3 , R 4 and R 5 are each independently any group
- B does not exist or B is any group
- W does not exist or W is any group
- A1 is a substituted benzene ring
- X is selected from: -O-, -S-, -NR-;
- Y 1 is any group, and m is any integer from 0 to 4.
- the present invention provides a compound represented by the following formula or its tautomer, mesomer, racemate, enantiomer, diastereoisomer, or a mixture thereof, or A pharmaceutically acceptable salt thereof, wherein said compound is selected from:
- R 1 , R 2 , R 3 , R 4 and R 5 are each independently any group
- B does not exist or B is any group
- W does not exist or W is any group
- A2 is a substituted benzene ring
- X is selected from: -O-, -S-, -NR-;
- Y 1 is any group, and m is any integer from 0 to 4.
- Y2 is selected from -O-, -S- and -NR-;
- the present application provides a conjugate comprising the aforementioned compound or its tautomer, mesomer, racemate, enantiomer, diastereoisomer, or in the form of a mixture, or a pharmaceutically acceptable salt thereof.
- the present application provides a pharmaceutical composition, which comprises the aforementioned compound or its tautomer, mesomer, racemate, enantiomer, diastereoisomer, or A mixture thereof, or a pharmaceutically acceptable salt thereof and/or the aforementioned conjugate, and optionally a pharmaceutically acceptable carrier.
- the present application provides a method for affecting the function of the immune system, comprising administering the aforementioned compounds or their tautomers, mesoforms, racemates, enantiomers, non- Enantiomers, or their mixtures, or their pharmaceutically acceptable salts, the aforementioned conjugates and/or the aforementioned pharmaceutical compositions.
- glucocorticoid generally refers to a naturally occurring steroid hormone or a synthetic steroid hormone that interacts with the glucocorticoid receptor.
- halogen generally refers to fluorine, chlorine, bromine, iodine, for example, it may be fluorine, chlorine.
- alkyl generally refers to a residue derived from an alkane by removing a hydrogen atom. Alkyl groups can be substituted or unsubstituted, substituted or unsubstituted.
- alkyl generally refers to a saturated straight or branched chain aliphatic hydrocarbon group having a residue derived by removing a hydrogen atom from the same carbon atom or two different carbon atoms of a parent alkane, which may be in the range of 1 to A linear or branched chain group of 20 carbon atoms, for example an alkyl group containing 1 to 12 carbon atoms, for example an alkyl group containing 1 to 6 carbon atoms.
- alkyl groups include, but are not limited to, methyl, ethyl, propyl, propyl, butyl, and the like.
- Alkyl groups may be substituted or unsubstituted, substituted or unsubstituted, for example when substituted, substituents may be substituted at any available point of attachment, said substituents may be independently optionally selected from alkyl , alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy , heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio and oxo, substituted by one or more substituents, such as hydrogen, protium, deuterium, tritium, halogen, -NO 2 , - CN, -OH,
- alkylene generally refers to a saturated straight-chain or branched aliphatic hydrocarbon group having two hydrogen atoms derived by removing two hydrogen atoms from the same carbon atom or two different carbon atoms of the parent alkane , which may be a straight-chain or branched group containing 1 to 20 carbon atoms, for example, the term “methylene” may refer to a residue derived from a group of 1 carbon atom minus two hydrogen atoms base. A methylene group may be substituted or unsubstituted, substituted or unsubstituted; for example an alkylene group containing 1 to 12 carbon atoms, for example containing 1 to 6 carbon atoms.
- Non-limiting examples of alkylene include, but are not limited to, methylene (-CH 2 -), 1,1-ethylene (-CH(CH 3 )-), 1,2-ethylene (-CH 2 CH 2 )-, 1,1-propylene (-CH(CH 2 CH 3 )-), 1,2-propylene (-CH 2 CH(CH 3 )-), 1,3-propylene (-CH 2 CH 2 CH 2 -), 1,4-butylene (-CH 2 CH 2 CH 2 CH 2 -), and 1,5-butylene (-CH 2 CH 2 CH 2 CH 2 CH 2 -) wait.
- Alkylene may be substituted or unsubstituted, substituted or unsubstituted, for example when substituted, substituents may be substituted at any available point of attachment, said substituents may be independently optionally selected from alkyl radical, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy
- substituents in group, heterocycloalkoxy group, cycloalkylthio group, heterocycloalkylthio group and oxo group such as hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH2 , -C(O)H, -CO2H , -C(O)C(O)H, -C(O) CH
- alkenyl generally refers to a straight or branched chain hydrocarbon group containing one or more double bonds.
- alkenyl groups include allyl, homoallyl, vinyl, crotyl, butenyl, pentenyl, hexenyl, and the like.
- C2-6 alkenyl groups having more than one double bond include butadienyl, pentadienyl, hexadienyl, and hexatrienyl and branched forms thereof.
- the position of the unsaturated bond (double bond) can be any position in the carbon chain.
- Alkenyl groups can be substituted or unsubstituted.
- alkenylene generally refers to a residue derived by removing two hydrogen atoms from an alkene carbon atom.
- alkenylene groups can be substituted or unsubstituted.
- alkynyl generally refers to an unsaturated straight chain or branched chain alkynyl, such as ethynyl, 1-propynyl, propargyl, butynyl and the like. Alkynyl groups can be substituted or unsubstituted.
- alkynylene generally refers to a residue having two hydrogen atoms removed from the carbon atoms of an alkyne.
- alkynylene groups can be substituted or unsubstituted.
- aryl generally refers to a residue derived from an aromatic ring by removing a hydrogen atom.
- aromatic ring may refer to a 6 to 14 membered all-carbon monocyclic or fused polycyclic ring (that is, a ring sharing adjacent pairs of carbon atoms) having a conjugated ⁇ -electron system, which may be 6 to 10 membered, such as benzene and naphthalene.
- the aryl ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring where the ring bonded to the parent structure is an aryl ring.
- Aryl groups may be substituted or unsubstituted, and when substituted, the substituents may be one or more of the following groups independently selected from the group consisting of: alkyl, alkenyl, alkynyl, alkoxy, alk Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , and heterocycloalkylthio.
- Aryl groups can be substituted or unsubstituted.
- arylene generally refers to a residue derived by removing two hydrogen atoms from a carbon atom of an aromatic ring.
- phenylene and naphthylene may be mentioned.
- Arylene groups can be substituted or unsubstituted.
- heteroaryl generally refers to a residue having a hydrogen atom removed from a carbon atom of a heteroaryl ring.
- heteroaryl ring refers to a heteroaromatic system comprising 1 to 4 heteroatoms, 5 to 14 ring atoms, wherein the heteroatoms may be selected from the group consisting of oxygen, sulfur and nitrogen.
- Heteroaryl can be 5 to 10 membered, can be 5 or 6 membered, such as furyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazole Base etc.
- the heteroaryl ring may be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring bonded to the parent structure is a heteroaryl ring.
- Heteroaryl may be optionally substituted or unsubstituted, and when substituted, the substituents may be one or more of the following groups independently selected from the group consisting of: alkyl, alkenyl, alkynyl, alkoxy radical, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, ring Alkylthio, and heterocycloalkylthio.
- Heteroaryl groups can be substituted or unsubstituted.
- heteroarylene generally refers to a residue derived by removing two hydrogen atoms from a carbon atom of a heteroaryl ring.
- it may be a furylylene group, a thienylene group, a pyridylene group, a pyrrolylene group, a pyrimidinylene group, a pyrazinylene group, an imidazolyl group, a tetrazolyl group and the like.
- Heteroarylene groups can be substituted or unsubstituted.
- cycloaliphatic and “cycloalkyl” are used interchangeably, and the term “cycloaliphatic” generally refers to a group having a hydrogen atom removed from the same carbon atom or multiple different carbon atoms of the aliphatic ring. derived residues.
- cycloalkane generally refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon, the carbocycle containing 3 to 20 carbon atoms, may contain 3 to 12 carbon atoms, may contain 3 to 10 carbon atoms, may Contains 3 to 8 carbon atoms.
- Non-limiting examples of cycloaliphatic groups include cyclopropanyl, cyclobutanyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclo Heptatrienyl, cyclooctyl, etc.; polycyclic carbocycles may include spiro, fused and bridged carbocycles. Alicyclic groups may be substituted or unsubstituted.
- the term "carbocyclyl" generally refers to a residue derived from a carbon atom having a carbocyclic ring by removing one hydrogen atom.
- carbocycle generally refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon, the carbocycle contains 3 to 20 carbon atoms, may contain 3 to 12 carbon atoms, may contain 3 to 10 carbon atoms, may Contains 3 to 8 carbon atoms.
- Non-limiting examples of monocyclic carbocycles include cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptatriene, cyclooctane etc.; polycyclic carbocycles may include spiro, fused and bridged carbocycles. Carbocyclyl groups can be substituted or unsubstituted. In some instances, alicyclic and carbocyclic rings can be used interchangeably.
- partially unsaturated generally refers to a ring structure containing at least one double or triple bond between ring molecules.
- partially unsaturated encompasses cyclic structures with multiple sites of unsaturation, but is not intended to include aromatic or heteroaromatic rings as defined herein.
- unsaturated means that the moiety has one or more degrees of unsaturation.
- alicyclic group and “cycloalkylene” can be used interchangeably, and the term “alicyclic group” generally refers to a Residues.
- polycyclic carbocycles may include spiro rings, fused rings and bridged ring carbocycles.
- Alicyclylene groups may be substituted or unsubstituted.
- aliphatic heterocyclic group and “heterocyclic group” can be used interchangeably, and the term “aliphatic heterocyclic group” generally refers to a stable non-aromatic 3-7 membered monocyclic carbon ring structure , fused 7-10-membered bicyclic heterocyclic ring structure or bridged 6-10-membered bicyclic heterocyclic ring structure, these ring structures can be saturated or partially saturated, except for carbon atoms, these rings
- the structure also contains one or more heteroatoms, wherein the heteroatoms can be selected from the following group: oxygen, sulfur and nitrogen. For example, it contains 1-4 heteroatoms as defined above.
- the term "nitrogen” may include substituted nitrogen.
- the aliphatic heterocyclic group can include “heterocycloalkyl", and the heterocycloalkyl group can refer to a stable non-aromatic 3-7-membered monocycloalkane structure, a fused 7-10-membered bicyclic heterocyclic structure or Bridged 6- to 10-membered bicyclic heterocyclic structures, in addition to carbon atoms, these ring structures also contain one or more heteroatoms, wherein the heteroatoms can be selected from the following group: oxygen, sulfur and nitrogen. For example, it contains 1-4 heteroatoms as defined above.
- Heterocycloalkyl groups can be substituted or unsubstituted.
- Alicyclic groups may be substituted or unsubstituted.
- aliphatic heterocyclic group and “heterocyclic group” can be used interchangeably, and the term “aliphatic heterocyclic group” generally refers to a derived residues.
- the heteroalicyclic group may be substituted or unsubstituted.
- ring structures such as cycloalkyl, cycloalkylene, heterocyclyl, heterocyclylene, aryl, arylene, heteroaryl, heteroarylene, etc.
- prefixes for example, C 3 -C 20 , C 3 -C 7 , C 5 -C 6 , etc.
- C 5 -C 6 heterocyclyl as used in this application relates to a heterocyclyl group having 5 or 6 ring atoms.
- C 5 -C 10 heteroaryl described in this application refers to a heteroaryl group having 5 to 10 ring atoms.
- ring atom or "ring atom” generally refers to an atom contained on a ring structure.
- the ring-forming atom may be a carbon atom on a benzene ring, or a nitrogen atom on a pyridine ring.
- the ring-forming atom may be substituted or unsubstituted.
- each independently generally means that the variables apply in any one instance, regardless of the presence or absence of variables with the same or different definitions in the same compound.
- the variable may refer to the type and number of substituents in the compound or the type of atoms in the compound.
- R occurs twice in a compound and R is defined as "independently carbon or nitrogen”
- both R may be carbon, both R may be nitrogen, or one R may be carbon and the other R may be nitrogen.
- a heterocyclic group optionally substituted with an alkyl group means that an alkyl group may but need not be present, and the description may include cases where a heterocyclic group is substituted by an alkyl group and cases where a heterocyclic group is not substituted by an alkyl group. situation.
- substituted generally refers to one or more hydrogen atoms in a group, for example up to 5, for example 1 to 3 hydrogen atoms are independently substituted by a corresponding number of substituents. Substituents are only in their possible chemical positions, and a person skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when bonded to a carbon atom with an unsaturated (eg, ethylenic) bond.
- the substituents of an "optionally substituted" group may include, but are not limited to, one or more substituents independently selected from the following groups or a specified group of groups, alone or in combination: lower alkane lower alkenyl, lower alkynyl, lower alkanoyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower haloalkenyl, lower haloalkynyl, lower perhaloalkyl, lower perhaloalkoxy group, lower cycloalkyl, phenyl, aryl, aryloxy, lower alkoxy, lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower alkylcarbonyl, lower carboxyl ester, lower methyl Amido, cyano, halogen, hydroxy, amino, lower alkylamino, arylamino, amido, nitro, thiol, lower alkylthio, lower
- Two substituents may be joined together to form a five-, six- or seven-membered aromatic or non-aromatic carbocyclic or heterocyclic ring containing one to three heteroatoms, for example to form methylenedioxy or ethylenedioxy.
- Optionally substituted groups can be under-substituted (eg -CH 2 CH 3 ), fully substituted (eg -CF 2 CF 3 ), mono-substituted (-CH 2 CH 2 F) or between fully substituted and mono Any horizontal substitution between substitutions (eg -CH 2 CF 3 ).
- substitutions eg -CH 2 CF 3
- substituent When a substituent is identified as “substituted,” the substituted form is specifically intended. Additionally, different sets of optional substituents for a particular moiety may be defined as desired; in these cases, the optional substitution is defined, usually immediately following the phrase “optionally substituted by".
- the term “lower” when used in connection with an organic group or compound means that the compound or group may be branched or unbranched, having up to and including 7 carbon atoms, eg 1-4 carbon atoms.
- Lower alkyl represents, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl and branched pentyl, n-hexyl and branched hexyl.
- the term 0 or more (eg, 0 or more, 0 or 1, 0) methylene units are "substituted" generally refers to when the structure contains 1 or more
- alkyl alkenyl
- cycloalkyl and the like can be preceded by a mark to indicate the presence of The number of atoms, for example, C 1 -C 4 alkyl, C 3 -C 7 cycloalkoxy, C 1 -C 4 alkylcarbonylamino, etc., the subscript numbers following "C” indicate the presence in the group number of carbon atoms.
- C3 alkyl refers to an alkyl group having three carbon atoms (e.g., n-propyl, isopropyl); in C1-10 , the members of the group can have any number falling within the range of 1-10 of carbon atoms.
- One or more hydrogen atoms in a group eg up to 5, eg 1 to 3 hydrogen atoms are independently substituted by a corresponding number of substituents.
- Substituents are only in their possible chemical positions, and a person skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort.
- an amino or hydroxyl group with free hydrogen may be unstable when bonded to a carbon atom with an unsaturated (eg, ethylenic) bond.
- the term "compound” generally refers to a substance having two or more different elements.
- the compound of the present application can be an organic compound, for example, the compound of the present application can be a compound with a molecular weight of 500 or less, a compound with a molecular weight of 1,000 or less, or a compound with a molecular weight of 1,000 or more, or a compound with a molecular weight of 10,000 or more, or 100,000 or more. compound.
- a compound may also refer to a compound connected by a chemical bond, for example, a compound in which one or more molecules with a molecular weight below 1000 are connected to a biomacromolecule through a chemical bond, and the biomacromolecule may be a polysaccharide, protein , nucleic acids, peptides, etc.
- the compound of the present application may include a compound in which a protein is linked to one or more molecules with a molecular weight below 1000, may include a compound in which a protein is linked to one or more molecules with a molecular weight below 10,000, or may include a compound in which a protein is linked to one or more molecules with a molecular weight of Compounds with less than 100,000 molecules connected.
- the pharmaceutical composition can be in the form of a sterile injectable aqueous or oily suspension for intramuscular and subcutaneous administration.
- This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
- the sterile injectable preparation can also be a sterile injectable solution or suspension prepared in a non-toxic parenterally acceptable diluent or solvent, for example a solution in 1,3-butanediol.
- sterile fixed oils are conveniently employed as a solvent or suspending medium. For example, any blend of fixed oils including synthetic mono- or diglycerides may be employed.
- fatty acids such as oleic acid are prepared as injectables.
- the compounds of the present application include tautomers, mesoforms, racemates, enantiomers, and/or diastereoisomers of the compounds.
- the term “diastereomer” generally refers to stereoisomers that have two or more chiral centers and whose molecules are not mirror images of each other. Diastereoisomers can have different physical properties, eg, melting points, boiling points, spectral properties and reactivity.
- the terms “tautomer” or “tautomeric form” are used interchangeably and generally refer to structural isomers of different energies that are interconvertible through a low energy barrier.
- proton tautomers also known as prototropic tautomers
- proton tautomers include interconversions via migration of a proton, such as keto-enol isomerization and imine-enol isomerization Amine isomerization.
- Valence tautomers include interconversions by recombination of some of the bonding electrons.
- the term “mesoform” generally refers to an atom containing asymmetry in a molecule, but having a symmetry factor so that the total optical rotation in the molecule is zero.
- racemate or “racemic mixture” refers to a composition consisting of equimolar amounts of two enantiomeric species.
- certain atoms of the compounds of the present application may occur in more than one isotopic form.
- hydrogen may exist as protium ( 1 H), deuterium ( 2 H), and tritium ( 3 H), and carbon may occur naturally as three different isotopes ( 12 C, 13 C, and 14 C).
- isotopes that may be incorporated into compounds of the present application also include, but are not limited to , 15 N, 18 O, 17 O, 18 F, 32 P, 33 P, 129 I, 131 I, 123 I, 124 I, 125 I, or the like isotopes. Accordingly, compounds of the present application may be enriched in one or more of these isotopes relative to their natural abundance.
- Such isotopically enriched compounds are useful for a variety of purposes, as is known to those skilled in the art.
- substitution with heavy isotopes such as deuterium ( 2H ) may afford certain therapeutic advantages, possibly due to greater metabolic stability.
- deuterium ( 2H ) has a natural abundance of about 0.015%. Therefore, there is one deuterium atom for about every 6500 hydrogen atoms in nature. Accordingly, deuterium-containing compounds of the present invention have a deuterium abundance at one or more positions (as the case may be) greater than 0.015%.
- structures depicted herein may also include compounds that differ only in the presence or absence of one or more isotopically enriched atoms. For example, except that the hydrogen atom is replaced by deuterium or tritium, or the carbon atom is replaced by carbon 13 or carbon 14, the compounds whose structure is consistent with the present application are within the scope of the present application.
- isomers generally refer to different compounds having the same molecular formula.
- Stepoisomers generally refer to isomers that differ only in the arrangement of their atoms in space.
- the term “isomer” includes any and all geometric isomers and stereoisomers.
- isomers include geometric double bond cis and trans isomers, also known as E- and Z-isomers; R- and S-enantiomers; diastereomers, (d)-isomers and (l)-isomers, racemic mixtures thereof; and other mixtures thereof falling within the scope of the present disclosure.
- enantiomer generally refers to a pair of stereoisomers that are non-superimposable mirror images of each other.
- a 1:1 mixture of a pair of enantiomers is a “racemic” mixture.
- the term “( ⁇ )” is used to denote a racemic mixture.
- “Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but are not mirror images of each other. Absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system. The stereochemistry at each chiral carbon may be designated by R or S when the compound is a pure enantiomer.
- Resolved compounds whose absolute configuration is unknown can be assigned (+) or (-) according to the direction in which they rotate plane polarized light (dextrorotatory or levorotatory) at the wavelength of the sodium D line.
- Certain compounds described herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers and other stereoisomeric forms that can be defined in terms of absolute stereochemistry, such as (R)- or (S)-.
- the chemical entities, pharmaceutical compositions and methods of the present application are intended to embrace all such possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures.
- Optically active (R)- and (S)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
- the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless otherwise indicated, it is intended that the compounds include both E and Z geometric isomers.
- the term "enantiomeric purity” generally refers to the relative amount, expressed as a percentage, of a particular enantiomer present relative to the other enantiomer. For example, if a compound that may have (R)- or (S)-isomeric configuration exists as a racemic mixture, then for either (R)- or (S)-isomer, the The enantiomeric purity was about 50%. If one conformational form of the compound is superior to the other, for example, 80% (S)- and 20% (R)-, then the enantiomeric purity of the compound with respect to the (S)-isomeric form is 80 %.
- the enantiomeric purity of a compound can be determined by a variety of means known in the art, including but not limited to chromatography using chiral supports, polarimetry by rotation of polarized light, using chiral shift reagents (including but not limited to those containing NMR spectroscopy of chiral complexes of lanthanides or Pirkle alcohols), or derivatization of compounds with chiral compounds such as Mosher acids followed by chromatography or NMR spectroscopy.
- tautomer generally refers to a type of isomer that includes at least one form of migration from a hydrogen atom and at least one change in valency (e.g., a single bond to a double bond , triple bond to double bond or triple bond to single bond, and vice versa) resulting in two or more interconvertible compounds.
- Tautomerization includes prototropic or proton-moving tautomerization, which is considered a subset of acid-base chemistry.
- Prototropic tautomerization or “proton shift tautomerization” involves the migration of protons with a concomitant change in bond order. The exact ratio of tautomers depends on many factors including temperature, solvent and pH.
- Tautomerization ie, a reaction affording a pair of tautomers
- exemplary tautomerisms include, but are not limited to, keto-enol; amide-imide; lactam-lactim; enamine-imine; and enamine-(different)enamine tautomerisms structure.
- keto-enol tautomerization is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers.
- tautomerization is phenol-keto tautomerization.
- a specific example of phenol-keto tautomerization is the interconversion of pyridin-4-ol and pyridin-4(1H)-one tautomers.
- the term "pharmaceutical composition” generally refers to a mixture containing one or more compounds described in this application or their physiologically/pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components Classes such as physiological/pharmaceutically acceptable carriers and excipients.
- the pharmaceutical composition can promote the administration to the living body, facilitate the absorption of the active ingredient and thus exert the biological activity.
- the preparation of conventional pharmaceutical compositions can be found in Chinese Pharmacopoeia.
- the term "pharmaceutically acceptable salt” or “pharmaceutically acceptable salt” generally refers to the salt of the compound or the ligand-drug conjugate of the present application, or the salt of the compound described in the present application, Such salts may have safety and/or effectiveness when used in mammals, and may have proper biological activity.
- the antibody-antibody drug conjugate compound of the present application may form a salt with an acid, and the pharmaceutically acceptable salt
- Non-limiting examples include: hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, citrate, acetate, succinate, ascorbate, oxalate, nitrate, pear salt, hydrogen phosphate, dihydrogen phosphate, salicylate, hydrogen citrate, tartrate, maleate, fumarate, formate, benzoate, methanesulfonate, ethyl Sulfonate, benzenesulfonate, p-toluenesulfonate.
- Immunoconjugates can also be defined by the following general formula in reverse order: A-(Q-L-SM)n.
- linker generally refers to any chemical moiety capable of linking a protein (eg, antibody, antibody fragment (eg, antigen-binding fragment) or functional equivalent) to a glucocorticoid.
- the linker may be sensitive to cleavage ("cleavable linker"), thereby facilitating the release of the glucocorticoid.
- cleavable linkers may be sensitive to acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage under conditions in which glucocorticoids and/or antibodies remain active .
- the linker can be substantially resistant to cleavage ("non-cleavable linker").
- drug antibody ratio refers to the ratio of A (i.e. protein, such as antibody or antigen-binding fragment thereof, anti-TNF protein, anti-TNF-alpha antibody or fragment thereof, soluble receptor or soluble TNF receptor)-linked SMs (ie, groups derived from small molecule glucocorticoid receptor agonists (eg, glucocorticoids)).
- A i.e. protein, such as antibody or antigen-binding fragment thereof, anti-TNF protein, anti-TNF-alpha antibody or fragment thereof, soluble receptor or soluble TNF receptor
- SMs ie, groups derived from small molecule glucocorticoid receptor agonists (eg, glucocorticoids)
- DAR When referring to a compound of formula (SM-L-Q)n-A representing an individual immunoconjugate, DAR generally refers to the number of SMs attached to an individual A (eg, n is an integer from 1 to 10).
- DAR When referring to a compound of formula (SM-L-Q)n-A representing a variety of immunoconjugates, DAR generally refers to the average number of SMs attached to A (eg, n is an integer or fraction from 1 to 10). Thus, by way of example, a DAR of a compound of formula (SM-L-Q)n-A comprising a first immunoconjugate containing 3 SMs per A and a second immunoconjugate containing 4 SMs per A (ie, "n") was 3.5.
- a non-cleavable linker is generally any chemical moiety capable of linking a glucocorticoid to an antibody in a stable covalent manner and does not fall off under the categories listed above for cleavable linkers.
- a non-cleavable linker is substantially resistant to acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- non-cleavable means that the chemical bonds in or adjacent to the linker are subjected to cleavage by acids, photolabile cleavage agents, peptidases, esterases, or cleavage disulfides without the glucocorticoid and/or antibody losing their activity.
- acids photolabile cleavage agents
- peptidases peptidases
- esterases or cleavage disulfides without the glucocorticoid and/or antibody losing their activity.
- the ability of a bond to be cleaved induced by a chemical or physiological compound.
- cleavable linkers are cleaved by peptidases ("peptidase cleavable linkers"). Only certain peptides are prone to cleavage inside or outside the cell, see e.g. Trout et al., Proc. Natl. Acad. Sci. USA [Proc. [International Journal of Cancer], 677-684 (1989). Furthermore, peptides are composed of ⁇ -amino acid units and peptide bonds, which are chemically amide bonds between the carboxylic acid of one amino acid and the amino group of a second amino acid. Other amide bonds (such as the bond between the carboxylic acid of lysine and the ⁇ -amino acid group) are understood not to be peptide bonds and are considered non-cleavable.
- linkers are cleaved by esterases ("esterase cleavable linkers"). Only certain esters can be cleaved by esterases present inside or outside the cell. Esters are formed by the condensation of carboxylic acids and alcohols. Simple esters are those produced with simple alcohols such as aliphatic alcohols and small cyclic and small aromatic alcohols.
- the cleavable linker component may comprise a peptide comprising 1 to 10 amino acid residues.
- the peptide allows proteases to cleave the linker, thereby promoting the release of glucocorticoids upon exposure to intracellular proteases such as lysosomal enzymes (Doronina et al. (2003) Nat.Biotechnol. [Natural Biotechnology] 21 :778-784).
- Exemplary peptides include, but are not limited to, dipeptides, tripeptides, tetrapeptides, and pentapeptides.
- Exemplary dipeptides include, but are not limited to, alanine-alanine (ala-ala); valine-citrulline (vc or val-cit); alanine-phenylalanine (af or ala-phe ); phenylalanine-lysine (fk or phe-lys); phenylalanine-homolysine (phe-homolys); and N-methyl-valine-citrulline (Me-val -cit).
- Exemplary tripeptides include, but are not limited to, glycine-valine-citrulline (glv-val-cit) and glycine-glycine-glycine (gly-gly-gly).
- a peptide may comprise naturally occurring amino acid residues and/or non-natural amino acid residues.
- naturally occurring amino acid generally refers to Ala, Asp, Cys, Glu, Phe, Gly, His, He, Lys, Leu, Met, Asn, Pro, Gin, Arg, Ser, Thr, Val, Trp, and Tyr.
- non-natural amino acids include homoserine, homoarginine, citrulline, phenylglycine, taurine, iodotyrosine, seleno Cysteine, Norleucine ("Nle”), Norvaline (“Nva”), Beta-Alanine, L-Naphthylalanine or D-Naphthylalanine, Ornithine (“Orn”) etc.
- Peptides can be designed and optimized for enzymatic cleavage by specific enzymes (eg, tumor-associated proteases, cathepsins B, C, and D, or plasmin proteases).
- Amino acids can also include D-forms of natural and unnatural amino acids.
- D- indicates an amino acid having a “D” (dextrorotatory) configuration, as opposed to the configuration in naturally occurring (“L-”) amino acids.
- Natural and unnatural amino acids are either commercially available (Sigma Chemical Co., Advanced Chemtech) or can be synthesized using methods known in the art.
- the term "pharmaceutically acceptable carrier” generally refers to a vehicle for administering therapeutic agents, such as antibodies or polypeptides, genes and other therapeutic agents.
- the term refers to any pharmaceutical carrier that does not itself induce antibody production deleterious to the individual receiving the composition and that can be administered without undue toxicity.
- Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acid, polyglycolic acid, polyamino acids, amino acid copolymers, lipid aggregates and inactivated virus particles. Such vectors are well known to those skilled in the art.
- Pharmaceutically acceptable carriers in therapeutic compositions can include liquids such as water, saline, glycerol and ethanol. Auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may also be present in these carriers.
- anti-TNF ⁇ protein generally refers to a protein capable of (i) binding to TNF ⁇ and (ii) inhibiting the binding of soluble TNF- ⁇ to cell surface TNF receptors (p55 and/or p75) and/or in the presence of complement
- the protein is lysed in vitro from cells expressing surface TNF ⁇ or TNF ⁇ receptors.
- Anti-TNFa proteins include, for example, anti-TNF antibodies or antigen-binding fragments thereof (eg, adalimumab or infliximab) and soluble TNF receptors (eg, etanercept).
- antibody generally refers to an immunoglobulin reactive with a specified protein or peptide or a fragment thereof.
- Antibodies can be antibodies from any class, including but not limited to IgG, IgA, IgM, IgD, and IgE, and antibodies from any subclass (eg, IgGl, IgG2, IgG3, and IgG4).
- the antibody can have a heavy chain constant region selected from, for example, IgGl, IgG2, IgG3, or IgG4.
- Antibodies may also have light chains selected from eg kappa ( ⁇ ) or lambda ( ⁇ ).
- Antibodies of the present application may be derived from any species.
- the term "antibody” may include intact polyclonal antibodies, intact monoclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising antibodies, and any other modified immunoglobulin molecule so long as these antibodies exhibit produce the desired biological activity.
- an antigen binding domain generally refers to a portion of an antibody molecule comprising the amino acids responsible for the specific binding between the antibody and the antigen.
- the portion of an antigen that is specifically recognized and bound by an antibody is called an "epitope" as described above.
- an antigen binding domain may typically comprise an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH); however, it need not necessarily comprise both.
- Fd fragments for example, have two VH regions and typically retain some antigen-binding function of the full antigen-binding domain.
- antigen-binding fragments of antibodies include (1) Fab fragments, monovalent fragments having VL, VH, constant light chain (CL) and CH1 domains; (2) F(ab')2 fragments, having two Bivalent fragment of two Fab fragments connected by sulfur bridge; (3) Fd fragment with two VH and CH1 domains; (4) Fv fragment with VL and VH domains of antibody single arm, (5) dAb fragment (Ward et al., "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted From Escherichia coli," Nature 341:544-546 (1989), which is incorporated herein by reference in its entirety), which has a VH domain; ( 6) Isolated Complementarity Determining Regions (CDRs); (7) Single-chain Fv (scFv), for example derived from a scFv-library.
- Fab fragments monovalent fragments having VL, VH, constant light chain (CL) and CH1 domain
- the two domains VL and VH of the Fv fragment are encoded by separate genes, they can be joined using recombinant methods by a synthetic linker that allows it to be produced as a single protein in which the VL and VH regions pair to form a monovalent molecule chain (termed single-chain Fv (scFv)) (see, e.g., Huston et al., "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in Escherichia coli," Proc. Natl.
- VHH relates to a variable antigen-binding domain from a heavy chain antibody of Camelidae (camel, dromedary, llama, alpaca, etc.) (see Nguyen V.K. et al., 2000, The EMBO Journal, 19, 921-930; Muyldermans S., 2001, J Biotechnol., 74, 277-302 and review Vanlandschoot P. et al., 2011, Antiviral Research 92, 389-407) . VHHs may also be referred to as Nanobodies (Nb).
- variable region or “variable domain” generally refers to the domains of the heavy or light chain of an antibody that participate in the binding of the antibody to an antigen.
- variable generally means that certain parts of the sequence of variable domains of antibodies vary strongly, resulting in the binding and specificity of various specific antibodies to their specific antigens. The variability is not evenly distributed throughout the variable regions of antibodies. It is concentrated in three segments in the light chain variable region and the heavy chain variable region, called complementarity determining regions (CDR) or hypervariable regions (HVR), respectively LCDR1, LCDR2, LCDR3, HCDR1, HCDR2 and HCDR3. The more highly conserved portions of variable domains are called the framework regions (FR).
- CDR complementarity determining regions
- HVR hypervariable regions
- variable domains of native heavy and light chains each comprise four FR regions (H-FR1, H-FR2, H-FR3, H-FR4, L-FR1, L-FR2, L-FR3, L-FR4) , most adopt a ⁇ -sheet configuration, connected by three CDR structural loop regions.
- the CDRs in each chain are in close proximity together by the FR regions and, together with the CDRs from the other chain, form the antigen-binding site of the antibody.
- variable regions of antibodies can be encoded or the CDRs of antibodies can be delimited by various methods, such as the Kabat numbering scheme and definition rules based on sequence variability (see, Kabat et al., Protein Sequences in Immunology, 5th ed., National Institutes of Health, Bethesda, MD (1991), Chothia numbering scheme and definition rules based on the location of structural loop regions (see, A1-Lazikani et al., JMol Biol 273:927-48, 1997 ), efranc et al.'s IMGT numbering scheme and definition rules based on the amino acid sequence alignment of germline V genes, as well as Honneger's numbering scheme (AHo's), Martin numbering scheme, Gelfand numbering scheme, etc., can be found in Mathieu Dondelinger et al., Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition, Front. Immuno
- percent (%) sequence identity generally refers to the amino acids with which two or more aligned amino acid sequences are identical compared to the number of amino acid residues that make up the total length of these amino acid sequences The number of matches ("hits") for .
- alignment is used, for two or more sequences, when the sequences are compared and aligned for maximum correspondence (as measured using sequence comparison algorithms known in the art), or when manually aligned and visually Upon inspection, the percentage of amino acid residues that are identical (eg, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity) can be determined.
- sequences compared to determine sequence identity can be distinguished by one or more amino acid substitutions, additions or deletions.
- Suitable programs for aligning protein sequences are known to those skilled in the art.
- the percent sequence identity of protein sequences can be determined, for example, with programs such as CLUSTALW, Clustal Omega, FASTA or BLAST, for example using the NCBI BLAST algorithm (AltschulSF et al. (1997), Nucleic Acids Res. 25:3389-3402) .
- antibody analogue is generally used in the broadest sense and encompasses in particular molecules which specifically bind a target molecule with a monospecificity and which differ structurally from natural antibodies.
- antibody analog refers to an antibody comprising a segment of substantial identity to a portion of the amino acid sequence and having at least one of the following properties : (1) specific binding to PD-1 or PD-L1 under appropriate binding conditions, (2) ability to inhibit at least one biological activity of PD-1 or PD-L1.
- antibody analogs contain conservative amino acid substitutions (or insertions or deletions) relative to the native sequence.
- Analogs are typically at least 20 or 25 amino acids in length, at least 50, 60, 70, 80, 90, 100, 150, or 200 amino acids in length or longer, and typically can be as long as a full-length heavy or light chain of an antibody .
- Some examples include antibody analogs having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 substitutions compared to the germline amino acid sequence .
- the term "effective amount” or “therapeutically effective amount” generally refers to the amount of the compound or pharmaceutical composition described in the application that is sufficient to achieve the intended application described below, including but not limited to disease treatment .
- the therapeutically effective amount can vary according to: the intended application (in vivo or in vitro); or the subject and the condition to be treated, for example, the weight and age of the subject, the severity of the condition; the mode of administration, etc., which can be determined by ordinary skill in the art Personnel are easily identified.
- the term also applies to doses that will induce a specific response in target cells, such as platelet adhesion and/or cell migration.
- the specific dosage will vary according to, for example, the particular compound chosen, the dosing regimen followed, whether it is administered in combination with other agents, the time of administration, the tissue to which it is administered, and the physical delivery system by which it is delivered.
- in vivo generally refers to events that occur within the body of a subject.
- an in vitro assay generally refers to events that occur outside the body of a subject.
- an in vitro assay includes any assay performed outside of a subject.
- In vitro assays include cell-based assays in which live or dead cells are employed.
- In vitro assays also include cell-free assays, in which intact cells are not used.
- treatment and “treating” generally refer to a method of obtaining a beneficial or desired result, including, but not limited to, a therapeutic benefit.
- a therapeutic benefit includes, but is not limited to, eradicating, inhibiting, reducing or ameliorating the underlying disorder being treated. Additionally, therapeutic benefit is achieved by eradicating, reducing or ameliorating one or more physiological symptoms associated with the underlying disorder such that improvement is observed in a patient, but the patient may still suffer from the underlying disorder.
- prevention and preventing generally refer to methods of obtaining beneficial or desired results, including but not limited to prophylactic benefits.
- pharmaceutical compositions may be administered to patients at risk of developing a particular disease or to patients reporting one or more physical symptoms of a disease, even if the disease has not yet been diagnosed.
- the term "subject” or “patient” generally refers to a human (i.e., male or female of any age group, e.g., a pediatric subject (e.g., an infant, child, adolescent) or an adult subject (e.g., a young humans, middle-aged or elderly)) and/or other primates (e.g., cynomolgus monkeys, rhesus monkeys); mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or dogs; and/or birds, including commercially related birds such as chickens, ducks, geese, quail, and/or turkeys.
- a human i.e., male or female of any age group, e.g., a pediatric subject (e.g., an infant, child, adolescent) or an adult subject (e.g., a young humans, middle-aged or elderly)) and/or other primates (e.g.
- the terms “about” or “approximately” generally refer to an acceptable error for a particular value as determined by one of ordinary skill in the art, depending in part on the manner in which the value was measured or determined. In certain embodiments, the term “about” or “approximately” generally refers to 1, 2, 3 or 4 standard deviations. In certain embodiments, the term “about” or “approximately” generally refers to 50%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5% of a given value or range , 4%, 3%, 2%, 1%, 0.5% or 0.05%.
- Figure 1 Inhibitory effect of drug conjugates of the present invention on R848-induced IFN ⁇ , TNF ⁇ , IL-6 and IL-8 in human peripheral blood mononuclear cells.
- FIG. 1 Bioactivity assay in a mouse model of fluorescein isothiocyanate (FITC)-induced delayed type IV hypersensitivity.
- FITC fluorescein isothiocyanate
- Figure 3 Arthritis scores in the DBA/1 mouse arthritis model induced by bovine collagen type II mixed adjuvant. 3a: arthritis score; 3b: AUC of arthritis score.
- R 1 , R 2 , R 3 , R 4 and R 5 are each independently any group
- B does not exist or B is any group
- W does not exist or W is any group
- A1 is a substituted benzene ring
- X is selected from: -O-, -S-, -NR-;
- Y 1 is any group, and m is any integer from 0 to 4.
- R 1 , R 2 , R 3 , R 4 and R 5 are each independently any group
- B does not exist or B is any group
- W does not exist or W is any group
- A1 is a substituted benzene ring
- X is selected from: -O-, -S-, -NR-;
- Y 1 is any group, m is 0 or 1;
- R 4 and R 5 together form an optionally substituted cycloalkyl or an optionally substituted heterocyclyl.
- a compound of the present invention or a tautomer, meso, racemate, enantiomer, diastereoisomer, or a mixture thereof, or a pharmaceutically acceptable A salt for use, wherein said R 4 and R 5 are each independently selected from: H, F, Cl, -OH, -NH 2 , C 1 -C 6 alkyl, or said R 4 and R 5 together form C 3 -C 6 cycloalkyl or 3-6 membered heterocyclyl; said n is selected from 1, 2 or 3.
- a compound of the present invention or a tautomer, meso, racemate, enantiomer, diastereoisomer, or a mixture thereof, or a pharmaceutically acceptable
- the salt used, wherein said -(CR 4 R 5 ) n - are each independently selected from: -CH 2 -, -CH 2 CH 2 -,
- Y 1 is absent or selected from: protium, deuterium, tritium, halogen, -OR, -SR, -NHR, -N(R) 2 , -PHR, -P(R) 2.
- each R is independently selected from hydrogen, protium, deuterium, tritium, oxygen, hydroxyl, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen substituted C 1 -C 6 alkyl, and halogen substituted C 1 -C 6 alkoxy.
- Y 1 is absent or selected from: protium, deuterium, tritium, halogen, -OR, -SR, -NHR, -N(R) 2 , optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 alkoxy; wherein each R is independently selected from hydrogen, protium, deuterium, tritium, hydroxyl, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy radical, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen substituted C 1 -C 6 alkyl, and halogen substituted C 1 -C 6 alkoxy.
- Y 1 is absent or selected from: hydroxyl, mercapto, amino and optionally substituted C 1 -C 6 alkyl.
- A1 structural unit
- R 1 and R 2 are each independently selected from: H, F, Cl, Br and optionally substituted C 1 -C 6 alkyl.
- R 1 and R 2 can be independently selected from: H, F, Cl, Br and optionally substituted methyl.
- R 3 is selected from the group consisting of: hydrogen, optionally substituted -OH, optionally substituted -SH, and optionally substituted C 1 -C 6 alkyl.
- said R 31 is selected from the group consisting of hydrogen, halogen, optionally substituted -OH, and optionally substituted -SH.
- said R 311 is selected from the group consisting of hydrogen, optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted
- said R 32 is selected from the group consisting of hydrogen, and optionally substituted C 1 -C 6 alkyl.
- said R 321 is selected from the group consisting of hydrogen, halogen, -CN, and optionally substituted C 1 -C 6 alkyl.
- said R 321 is selected from the group consisting of hydrogen, F, Cl, -CN, and optionally substituted methyl.
- said R 33 is selected from the group consisting of hydrogen and optionally substituted C 1 -C 6 alkyl.
- said R 33 is optionally substituted methyl.
- said R 331 is selected from the group consisting of hydrogen, chlorine, fluorine, and -CN.
- R 3 can be selected from: optionally substituted -CH 2 Cl, optionally substituted -CH 2 SH, optionally substituted -CH 2 OH, optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted -OH, optionally substituted -OCH3 , optionally substituted -OCH2F , optionally substituted -OCH2Cl , optionally substituted -OCH2CN , optionally substituted -OCH2CH 3.
- Optionally substituted mercapto optionally substituted -SCH 2 F, optionally substituted -SCH 2 Cl, optionally substituted -SCH 2 CF 3 , and optionally substituted -SCH 2 CN.
- said R 1 and R 2 are each independently selected from hydrogen, protium, deuterium, tritium and halogen
- said R 3 is selected from -CH 2 OH, -SCH 2 F
- optionally substituted Optionally substituted Optionally substituted X is selected from the group consisting of N and optionally substituted CH.
- said R6 is selected from the group consisting of hydrogen and optionally substituted -OH.
- said R 61 is selected from the group consisting of H and optionally substituted C 1 -C 6 alkyl.
- the X 1 is selected from the group consisting of CH, C(-O-CH 3 ), and N.
- said B is selected from:
- Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted X2 and X3 are each independently selected from the group consisting of O, S and optionally substituted NH.
- said R 71 is selected from the group consisting of H and optionally substituted C 1 -C 6 alkyl.
- said X2 or X3 is selected from the group consisting of NH, N( CH3 ), O and S.
- said B can be selected from:
- a compound of the present invention or a tautomer, meso, racemate, enantiomer, diastereoisomer, or a mixture thereof, or a pharmaceutically acceptable
- the salt used, wherein said B is selected from:
- the R 8 is optionally substituted methyl.
- said R 81 is selected from the group consisting of halogen and optionally substituted cycloalkyl.
- said R 81 is selected from the group consisting of F and optionally substituted cyclopropyl.
- said W may be absent or W may be selected from:
- a compound of the present invention or a tautomer, meso, racemate, enantiomer, diastereoisomer, or a mixture thereof, or a pharmaceutically acceptable
- the salt used, wherein said W does not exist or W is
- said B may not exist or be selected from:
- Said W may be absent or W is selected from:
- the A1 can be selected from:
- a compound of the present invention or a tautomer, meso, racemate, enantiomer, diastereoisomer, or a mixture thereof, or a pharmaceutically acceptable
- the salt used is selected from
- the X is selected from -O-, -S- and -NH-;
- R 4 and R 5 are each independently selected from the following group: H, F, Cl, -OH, -NH 2 and C 1 -C 6 alkyl;
- n is selected from 1, 2 or 3;
- Said Y does not exist or is selected from: hydroxyl, mercapto, amino and C 1 -C 6 alkyl;
- the R 1 and R 2 are each independently selected from hydrogen, fluorine, chlorine and methyl;
- the R 3 is selected from: -CH 2 Cl, -CH 2 SH, -CH 2 OH, -OCH3 , -OCH2F , -OCH2Cl , -OCH2CN, -OCH2CH3 , -SH, -SCH2F , -SCH2Cl , -SCH2CF3 , and -SCH2CN .
- the present invention provides a compound represented by the following formula or its tautomer, mesomer, racemate, enantiomer, diastereoisomer, or a mixture thereof, or A pharmaceutically acceptable salt thereof, wherein said compound is selected from:
- R 1 , R 2 , R 3 , R 4 and R 5 are each independently any group
- B does not exist or B is any group
- W does not exist or W is any group
- A2 is a substituted benzene ring
- X is selected from: -O-, -S-, -NR-;
- Y 1 is any group, and m is any integer from 0 to 4.
- Y2 is selected from -O-, -S- and -NR-;
- the wavy line in formula IIa or IIb Indicates that it is directly connected to the ligand through the X or Y2 group, or connected to the ligand through the Linker fragment.
- R 4 and R 5 together form an optionally substituted cycloalkyl or an optionally substituted heterocyclyl.
- said R4 and R5 may together form cyclopropyl or cyclobutyl.
- the compounds of the present invention or their tautomers, mesoforms, racemates, enantiomers, diastereoisomers, or mixtures thereof, or pharmaceutically acceptable A salt for use wherein said R 4 and R 5 are each independently selected from the following groups: H, F, Cl, -OH, -NH 2 and C 1 -C 6 alkyl; said n is selected from 1, 2 or 3.
- Y 1 is selected from the group consisting of: protium, deuterium, tritium, halogen, -OR, -SR, -NHR, -N(R) 2 , optionally substituted C 1 -C 6 alkyl , optionally substituted C 1 -C 6 alkoxy; wherein each R is independently selected from hydrogen, protium, deuterium, tritium, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, aryl, Heteroaryl, cycloalkyl, heterocycloalkyl, halogen substituted C 1 -C 6 alkyl, and halogen substituted C 1 -C 6 alkoxy.
- said Y 1 is absent or selected from: -OR, -SR, -N(R) 2 and optionally substituted C 1 -C 6 alkyl; wherein each R is independently selected from hydrogen, Protium, deuterium, tritium, C 1 -C 6 alkyl, C 1 -C 6 alkoxy.
- said Y 1 is absent or selected from: hydroxyl, mercapto, amino and C 1 -C 6 alkyl.
- said Y 2 includes -NR-; wherein each R is independently selected from hydrogen, protium, deuterium, tritium, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, aryl radical, heteroaryl, cycloalkyl, heterocycloalkyl, halogen substituted C 1 -C 6 alkyl, and halogen substituted C 1 -C 6 alkoxy.
- the A2 (structural unit ) can be selected from:
- R 1 and R 2 are each independently selected from: H, F, Cl, Br and optionally substituted C 1 -C 6 alkyl.
- R 1 and R 2 are each independently selected from: H, F, Cl, Br and optionally substituted methyl.
- R 3 is selected from the group consisting of: hydrogen, optionally substituted -OH, optionally substituted -SH, and optionally substituted C 1 -C 6 alkyl.
- said R 31 is selected from the group consisting of hydrogen, halogen, optionally substituted -OH, and optionally substituted -SH.
- said R 311 is selected from the group consisting of hydrogen, optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted
- said R 32 is selected from the group consisting of hydrogen, and optionally substituted C 1 -C 6 alkyl.
- said R 321 is selected from the group consisting of hydrogen, halogen, -CN, and optionally substituted C 1 -C 6 alkyl.
- said R 321 is selected from the group consisting of hydrogen, F, Cl, -CN, and optionally substituted methyl.
- said R 33 is selected from the group consisting of hydrogen, and optionally substituted C 1 -C 6 alkyl.
- said R331 is selected from the group consisting of hydrogen, chlorine, fluorine and -CN.
- R 3 can be selected from: optionally substituted -CH 2 Cl, optionally substituted -CH 2 SH, optionally substituted -CH 2 OH, optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted -OH, optionally substituted -OCH3 , optionally substituted -OCH2F , optionally substituted -OCH2Cl , optionally substituted -OCH2CN , optionally substituted -OCH2CH 3.
- Optionally substituted mercapto optionally substituted -SCH 2 F, optionally substituted -SCH 2 Cl, optionally substituted -SCH 2 CF 3 , and optionally substituted -SCH 2 CN.
- the compounds of the present invention or tautomers, mesoforms, racemates, enantiomers, diastereoisomers, or mixtures thereof, or A pharmaceutically acceptable salt, wherein said R 3 is selected from: -CH 2 Cl, -CH 2 SH, -CH 2 OH, -OCH3 , -OCH2F , -OCH2Cl , -OCH2CN, -OCH2CH3 , -SH, -SCH2F , -SCH2Cl , -SCH2CF3 , and -SCH2CN .
- said R 1 and R 2 are each independently selected from hydrogen, protium, deuterium, tritium and halogen
- said R 3 is selected from -CH 2 -OH, -SCH 2 F
- optionally substituted Optionally substituted Optionally substituted X is selected from the group consisting of N and optionally substituted CH.
- said R6 is selected from the group consisting of hydrogen and optionally substituted -OH.
- said R 61 is selected from the group consisting of H and optionally substituted C 1 -C 6 alkyl.
- the X 1 is selected from the group consisting of CH, C(—O—CH 3 ) and N.
- said B can be selected from: optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted X2 and X3 are each independently selected from the group consisting of O, S and optionally substituted NH.
- said R 7 is selected from the group consisting of hydrogen and optionally substituted C 1 -C 6 alkyl.
- said R 71 is selected from the group consisting of H and optionally substituted C 1 -C 6 alkyl.
- said X2 or X3 is selected from the group consisting of NH, N( CH3 ), O and S.
- said B is selected from:
- a compound of the present invention or a tautomer, meso, racemate, enantiomer, diastereoisomer, or a mixture thereof, or a pharmaceutically acceptable
- the salt used, wherein said B is selected from:
- the R 8 is optionally substituted methyl.
- said R 81 is selected from the group consisting of halogen and optionally substituted cycloalkyl.
- said R 81 is selected from the group consisting of F and optionally substituted cyclopropyl.
- W may be absent or W is selected from:
- a compound of the present invention or a tautomer, meso, racemate, enantiomer, diastereoisomer, or a mixture thereof, or a pharmaceutically acceptable
- the salt used, wherein said W does not exist or W is
- said B may be absent or selected from:
- Said W may be absent or W is selected from:
- the A2 can be selected from:
- a compound of the present invention or a tautomer, meso, racemate, enantiomer, diastereoisomer, or a mixture thereof, or a pharmaceutically acceptable
- the salt used is selected from
- the X is selected from -O-, -S- and -NH-;
- R 4 and R 5 are each independently selected from the following group: H, F, Cl, -OH, -NH 2 and C 1 -C 6 alkyl;
- n is selected from 1, 2 or 3;
- Said Y does not exist or is selected from: hydroxyl, mercapto, amino and C 1 -C 6 alkyl;
- the R 1 and R 2 are each independently selected from hydrogen, fluorine, chlorine and methyl;
- the R 3 is selected from: -CH 2 Cl, -CH 2 SH, -CH 2 OH, -OCH3 , -OCH2F , -OCH2Cl , -OCH2CN, -OCH2CH3 , -SH, -SCH2F , -SCH2Cl , -SCH2CF3 , and -SCH2CN .
- a compound of the present invention or a tautomer, meso, racemate, enantiomer, diastereoisomer, or a mixture thereof, or a pharmaceutically acceptable A salt for use, wherein the compound is selected from the group consisting of:
- the compound of formula IIa or IIb or its tautomers, mesoforms, racemates, enantiomers, diastereoisomers, or mixtures thereof form, or a pharmaceutically acceptable salt thereof also includes a Trigger fragment (Tr), and said compound includes the following structure:
- Tr is selected from the following structures:
- R 1 , R 2 , R 3 , R 4 and R 5 are each independently any group
- B does not exist or B is any group
- W does not exist or W is any group
- X is selected from: -O-, -S-, -NR-;
- Y 1 is any group, and m is any integer from 0 to 4.
- Y2 is selected from -O-, -S- and -NR-;
- R 1 and R 2 can be independently selected from: H, F, Cl, Br and optionally substituted methyl.
- R 3 can be selected from: optionally substituted -CH 2 Cl, optionally substituted -CH 2 SH, optionally substituted -CH 2 OH, optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted -OH, optionally substituted -OCH3 , optionally substituted -OCH2F , optionally substituted -OCH2Cl , optionally substituted -OCH2CN , optionally substituted -OCH2CH 3.
- Optionally substituted mercapto optionally substituted -SCH 2 F, optionally substituted -SCH 2 Cl, optionally substituted -SCH 2 CF 3 , and optionally substituted -SCH 2 CN.
- said B can be selected from:
- said W may be absent or W may be selected from:
- the Linker fragment includes L1 fragment, L2 fragment and/or L3 fragment, and the compound has the following structure:
- Tr does not exist or Tr is any group
- L3 is selected from polypeptide fragments
- L2 is absent or selected from a linking fragment
- L is selected from a coupling unit
- R 1 , R 2 , R 3 , R 4 and R 5 are each independently any group
- B does not exist or B is any group
- W does not exist or W is any group
- X is selected from: -O-, -S-, -NR-;
- Y 1 is any group, and m is any integer from 0 to 4.
- Y2 is selected from -O-, -S- and -NR-;
- L3 is selected from dipeptides, tripeptides and tetrapeptides.
- the dipeptide is selected from the group consisting of: GA, GG, AG, EG, EA, GE, DG, DA, GD, VC, VA, AA and VK.
- the tripeptide is selected from the group consisting of: EAG, EGG, GEG, GEA, DAG, DGG, GDG, GDA, GGA, GAG, GFG, AAG, AAA, VAG, VCG, VKG.
- tetrapeptide is selected from the group consisting of: GGFG, GGAG, GGGG, GEGG, GEAG, GDGG, GDAG, AAAG, and EAGG.
- said L3 is selected from the group consisting of glycine-glycine-phenylalanine-glycine (GGFG), alanine-alanine-alanine-glycine (AAAG), glycine-glycine - Glycine-Glycine (GGGG), Valine-Alanine-Glycine (VAG), Valine-Citrulline-Glycine (VCG), Alanine-Alanine-Glycine (AAG), Alanine -Alanine-Alanine (AAA), Valine-Alanine (VA), Valine-Citrulline (VC), Alanine-Alanine (AA), Glutamate-Alanine Acid-Glycine-Glycine (EAGG), Glycine-Glutamate-Alanine-Glycine (GEAG), Glycine-Glutamate-Glycine-Glycine (GEGG), Glutamate-Glycine-Glycine (EGG), Glutamine Amino-Alanine-
- L2 includes or does not include PEG branched chains or PEG linear chains.
- said L when said L does not comprise PEG, said L is selected from:
- said L 2 when said L 2 comprises a PEG linear chain, said L 2 is selected from:
- p is any integer from 1 to 20.
- said L 2 when said L 2 comprises a PEG linear chain, said L 2 is selected from:
- said L2 when said L2 comprises a PEG branch, said L2 is selected from:
- q is selected from any integer from 1 to 30.
- said L2 when said L2 comprises a PEG branch, said L2 is selected from:
- said L when L is coupled via a sulfhydryl group of a ligand, said L is selected from:
- said R L1a , R L1b , R L1c are each independently selected from: hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O) H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O ) NH2 , -SO2NH2 , -OC(O)H, -N(H) SO2H , alkyl, alkenyl, alkynyl, alicyclic, heterocyclyl, aryl and heteroaryl.
- each of R L1a , R L1b , R L1c is independently selected from the group consisting of hydrogen, optionally substituted methyl, optionally substituted ethyl, optionally substituted aryl, and optionally substituted benzyl.
- said L when L is coupled to a ligand through an amino group, said L is selected from:
- said L when L is coupled by click chemistry, said L is selected from:
- a compound of the present invention or a tautomer, meso, racemate, enantiomer, diastereoisomer, or a mixture thereof, or a pharmaceutically acceptable A salt for use, wherein the compound of formula IVa or IVb is selected from the following structures:
- a compound of the present invention or a tautomer, meso, racemate, enantiomer, diastereoisomer, or a mixture thereof, or a pharmaceutically acceptable A salt for use, wherein the compound also includes a Linker fragment, the compound of the formula IIa or IIb can be coupled with a ligand through the Linker fragment, and the compound has the following structure:
- Tr does not exist or Tr is any group
- L3 is selected from polypeptide fragments
- L2 is absent or selected from a linking fragment
- L 1 is selected from the coupling unit; L 1 is connected in the general formula IVa-1 and IVb-1;
- R 1 , R 2 , R 3 , R 4 , R 5 , B, W, CR 4 R 5 , n, X, Y 1 and Y 2 are as described in any one of the present invention
- wavy line Indicates that it is connected to the ligand through the L group.
- a compound of the present invention or a tautomer, meso, racemate, enantiomer, diastereoisomer, or a mixture thereof, or a pharmaceutically acceptable
- the salt used, wherein said structural unit -Tr-L 3 -L 2 -L 1 - is selected from:
- the present application provides a conjugate comprising the aforementioned compound or its tautomer, mesomer, racemate, enantiomer, diastereoisomer, or in the form of a mixture, or a pharmaceutically acceptable salt thereof.
- the conjugate can include an antibody-drug conjugate.
- the ligand comprises an antibody or antigen-binding fragment thereof.
- the antibody is selected from the group consisting of human antibodies, humanized antibodies, chimeric antibodies, multispecific antibodies, monoclonal antibodies and polyclonal antibodies.
- said antigen-binding fragment is selected from the group consisting of: Fab, Fab', F(ab')2, Fv, scFv, diabody, Fd, dAb, VHH, large antibody and complementarity determining region (CDR) fragment.
- said ligand specifically binds an antigen selected from the group consisting of AXL, BAFFR, BCMA, BCR-list components (BCR-list components), BDCA2, BDCA4, BTLA, BTNL2BTNL3, BTNL8, BTNL9, C10orf54, CCR1, CCR3, CCR4, CCR5, CCR6, CCR7, CCR9, CCR10, CD11c, CD137, CD138, CD14, CD163, CD168, CD177, CD19, CD20, CD209, CD209L, CD22, CD226, CD248, CD25 , CD27, CD274, CD276, CD28, CD30, CD300A, CD33, CD37, CD38, CD4, cluster of differentiation 40 (CD40), CD44, CD45, CD46, CD47, CD48, CD5, CD52, CD55, CD56, CD59, CD62E , CD68, CD69, CD70, CD74, CD79a, CD79b, CD8, CD80
- said ligand specifically binds: TNF ⁇ , CD40, and/or IFNAR1.
- the ligand is selected from the group consisting of anti-TNF ⁇ antibody or antigen-binding fragment thereof, anti-CD40 antibody or antigen-binding fragment thereof, and anti-IFNAR1 antibody or antigen-binding fragment thereof. In certain embodiments, wherein the ligand is selected from the group consisting of: anti-TNF ⁇ antibody or antigen-binding fragment thereof, anti-CD40 antibody or antigen-binding fragment thereof, anti-BDCA2 antibody or antigen-binding fragment thereof and anti-IFNAR1 antibody or antigen-binding fragment thereof .
- the ligand can be selected from: anti-TNF ⁇ monoclonal antibody, anti-CD40 monoclonal antibody, and anti-IFNAR1 monoclonal antibody.
- the present disclosure also provides immunoconjugates comprising a glucocorticoid receptor agonist linked to an anti-TNF ⁇ protein.
- the anti-TNF ⁇ protein is an antibody or antigen-binding fragment thereof.
- the anti-TNFa protein is an antibody or antigen-binding fragment thereof that binds TNFa (eg, soluble TNFa and/or membrane-bound TNFa).
- the anti-TNFa protein is a soluble TNF receptor protein, eg, a soluble TNF receptor protein fused to a heavy chain constant domain or fragment thereof (eg, Fc).
- an anti-TNF ⁇ protein eg, an anti-TNF antibody, an antigen-binding fragment thereof, or a soluble TNF receptor
- an anti-TNF ⁇ protein can bind to TNF ⁇ on the surface of a cell and become internalized.
- an anti-TNF ⁇ protein eg, an anti-TNF antibody, an antigen-binding fragment thereof, or a soluble TNF receptor
- US2014/0294813 discloses anti-TNF proteins that exhibit internalization upon binding to cell surface human TNF.
- the antibody or antigen-binding fragment thereof binds human and/or mouse TNF-alpha.
- Antibodies and antigen-binding fragments that bind TNF- ⁇ are known in the art.
- Anti-TNF- ⁇ antibodies and antigen-binding fragments thereof include, for example, adalimumab, infliximab, certolizumab pegol, afelimomab, nerelimomab, ozola Ozoralizumab, praculumab, golimumab and anti-mouse TNF ⁇ mlgG2a. Additional anti-TNF- ⁇ antibodies and antigen-binding fragments are provided, for example, in WO 2013/087912, WO 2014/152247, and WO 2015/073884, each of which is incorporated herein by reference in its entirety.
- Adalimumab is described in US Patent No. 6,258,562, which is incorporated herein by reference in its entirety. Infliximab is described in US Patent No. 5,656,272, which is incorporated herein by reference in its entirety. Certolizumab is discussed in WO01/94585, which is hereby incorporated by reference in its entirety. Afelimomab (also known as MAK195) is discussed in Vincent, Int. J. Clin. Pract. [International Journal of Clinical Practice] 54: 190-193 (2000), which is incorporated by reference in its entirety This article. Ozolazumab (also known as ATN-103) is a nanobody. It contains three heavy chain variable regions fused by a GlySer linker.
- Variable regions 1 and 3 are identical, and ozolazumab does not contain a heavy chain.
- Ozolazumab is discussed in WO 2012/131053, which is hereby incorporated by reference in its entirety.
- Pracurumab (also known as CEP-37247) is a domain antibody consisting of a dimer of VL-pCH1-CH2-CH3 or [V- ⁇ ]2-Fc, and was described in Gay et al., Mabs 2 : 625-638 (2010), which is incorporated herein by reference in its entirety.
- Golimumab (also known as CNTO 148) is discussed in WO2013/087912 and the sequences are provided in GenBank: DI496971.1 and GenBank DI 496970.1, each of which is incorporated herein by reference in its entirety.
- Anti-mouse TNF ⁇ mlgG2a described in McRae BL et al. J Crohns Colitis 10(1):69-76 (2016), each of which is incorporated herein by reference in its entirety.
- Anti-TNF- ⁇ antibodies and their antigen-binding fragments also include competitively inhibited adalimumab, infliximab, certolizumab, afelimomab, nerimomab, ozolazumab, Antibodies and antigen-binding fragments of pracurumab or golimumab binding to TNF- ⁇ .
- Anti-TNF- ⁇ antibodies and their antigen-binding fragments also include adalimumab, infliximab, certolizumab, afelimomab, nerimomab, ozolatuzumab, pula Antibodies and antigen-binding fragments of culumab or golimumab that bind the same TNF- ⁇ epitope.
- the anti-TNF- ⁇ antibody or antigen-binding fragment thereof competitively inhibits the binding of adalimumab to TNF- ⁇ . In certain embodiments, the anti-TNF- ⁇ antibody or antigen-binding fragment thereof binds to the same TNF- ⁇ epitope as adalimumab. In certain embodiments, the anti-TNF- ⁇ antibody or antigen-binding fragment thereof is adalimumab or an antigen-binding fragment thereof. In certain embodiments, the anti-TNF- ⁇ antibody or antigen-binding fragment thereof is adalimumab.
- the anti-TNF- ⁇ antibody or antigen-binding fragment thereof comprises adalimumab, infliximab, certolizumab, afelimomab, nerimomab, ozolazumab Sequences of mAb, pracurumab or golimumab, such as complementarity determining regions (CDRs), variable heavy chain domains (VH) and/or variable light chain domains (VL).
- CDRs complementarity determining regions
- VH variable heavy chain domains
- VL variable light chain domains
- said anti-TNF ⁇ antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) of an antibody
- said heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, each of which is associated with the following HCDR1, HCDR2, HCDR3 of the molecule have at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% sequence identity: adalimumab ( Adalimumab), Infliximab, Afelimomab, or golimumab.
- the anti-TNF ⁇ antibody or antigen-binding fragment thereof comprises a heavy chain variable region of an antibody, wherein the heavy chain variable region is at least about 80% identical to the heavy chain variable region of each of , About 85%, About 90%, About 95%, About 96%, About 97%, About 98%, About 99% sequence identity: Adalimumab (Adalimumab), Infliximab (Infliximab), A Afelimomab or golimumab.
- the anti-TNF ⁇ antibody or antigen-binding fragment thereof comprises a heavy chain of an antibody, wherein the heavy chain has at least about 80%, about 85%, about 90%, About 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Adalimumab, Infliximab, Afelimomab or Ge Golimumab.
- said anti-TNF ⁇ antibody or antigen-binding fragment thereof comprises a light chain variable region (VL) of an antibody
- said light chain variable region comprises LCDR1, LCDR2, LCDR3, which are each associated with the following LCDR1, LCDR2, LCDR3 of the molecules have at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% sequence identity: adalimumab ( Adalimumab), Infliximab, Afelimomab, or golimumab.
- said anti-TNF ⁇ antibody or antigen-binding fragment thereof comprises a light chain variable region of an antibody, wherein said light chain variable region shares at least about 80% with the light chain variable region of each of , About 85%, About 90%, About 95%, About 96%, About 97%, About 98%, About 99% sequence identity: Adalimumab (Adalimumab), Infliximab (Infliximab), A Afelimomab or golimumab.
- said anti-TNF ⁇ antibody or antigen-binding fragment thereof comprises a light chain of an antibody, wherein said light chain has at least about 80%, about 85%, about 90%, About 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Adalimumab, Infliximab, Afelimomab or Ge Golimumab.
- the present application provides antibodies or antigen-binding fragments thereof, which can specifically bind TNF- ⁇ and comprise adalimumab, infliximab, certolizumab, afelimomab, Chothia VL CDR of the VL of nerimumab, ozolatuzumab, pracurumab, or golimumab.
- antibodies or antigen-binding fragments thereof that specifically bind TNF-alpha and comprising adalimumab, infliximab, certolizumab, afelimomab, nerimumab Chothia VH CDR of the VH of anti, ozolazumab, pracurumab, or golimumab.
- antibodies or antigen-binding fragments thereof that specifically bind TNF-alpha and comprising adalimumab, infliximab, certolizumab, afelimomab, nerimumab Chothia VL CDR of the VL of anti, ozolazumab, pracurumab, or golimumab and contains adalimumab, infliximab, certolizumab, afelimomab Chothia VH CDR of the VH of , nerimumab, ozolazumab, pracurumab, or golimumab.
- said anti-TNF ⁇ antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) of an antibody
- said heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, each of which is associated with the following HCDR1, HCDR2, HCDR3 of the molecule have at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% sequence identity: adalimumab ( Adalimumab, Infliximab, Afelimomab, Golimumab or anti-mouse TNF ⁇ mlgG2a 8c11.
- the anti-TNF ⁇ antibody or antigen-binding fragment thereof comprises a heavy chain variable region of an antibody, wherein the heavy chain variable region is at least about 80% identical to the heavy chain variable region of each of , About 85%, About 90%, About 95%, About 96%, About 97%, About 98%, About 99% sequence identity: Adalimumab (Adalimumab), Infliximab (Infliximab), A Afelimomab, golimumab or anti-mouse TNF ⁇ mIgG2a 8c11.
- the anti-TNF ⁇ antibody or antigen-binding fragment thereof comprises a heavy chain of an antibody, wherein the heavy chain has at least about 80%, about 85%, about 90%, About 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Adalimumab, Infliximab, Afelimomab, Ge Golimumab or anti-mouse TNF ⁇ mIgG2a 8c11.
- said anti-TNF ⁇ antibody or antigen-binding fragment thereof comprises a light chain variable region (VL) of an antibody
- said light chain variable region comprises LCDR1, LCDR2, LCDR3, which are each associated with the following LCDR1, LCDR2, LCDR3 of the molecules have at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% sequence identity: adalimumab ( Adalimumab, Infliximab, Afelimomab, Golimumab or anti-mouse TNF ⁇ mlgG2a 8c11.
- the anti-TNF ⁇ antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL) of an antibody
- the heavy chain variable region comprises HCDR1, HCDR2, HCDR3
- the The light chain variable region comprises LCDR1, LCDR2, LCDR3, each of which has at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Adalimumab (Adalimumab), Infliximab (Infliximab), Afelimomab (Afelimomab), Golimumab ( golimumab) or anti-mouse TNF ⁇ mIgG2a 8c11.
- said anti-TNF ⁇ antibody or antigen-binding fragment thereof comprises a light chain variable region of an antibody, wherein said light chain variable region shares at least about 80% with the light chain variable region of each of , About 85%, About 90%, About 95%, About 96%, About 97%, About 98%, About 99% sequence identity: Adalimumab (Adalimumab), Infliximab (Infliximab), A Afelimomab, golimumab or anti-mouse TNF ⁇ mIgG2a 8c11.
- said anti-TNF ⁇ antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region of an antibody, wherein said heavy chain variable region and said light chain variable region are respectively Having at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% sequence identity to the light chain variable region of: adalimumab Anti-(Adalimumab), Infliximab (Infliximab), Afelimomab (Afelimomab), Golimumab (golimumab) or anti-mouse TNF ⁇ mIgG2a 8c11.
- said anti-TNF ⁇ antibody or antigen-binding fragment thereof comprises a light chain of an antibody, wherein said light chain has at least about 80%, about 85%, about 90%, About 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Adalimumab, Infliximab, Afelimomab, Ge Golimumab or anti-mouse TNF ⁇ mIgG2a 8c11.
- the anti-TNF ⁇ antibody or antigen-binding fragment thereof comprises a heavy chain and a light chain of an antibody, wherein the heavy chain and light chain share at least about 80%, about 85%, about 90%, respectively, of the light chain of , about 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Adalimumab, Infliximab, Afelimomab, Golimumab or anti-mouse TNF ⁇ mIgG2a 8c11.
- the antibody or antigen-binding portion thereof is an antagonist antibody or antigen-binding portion thereof that elicits CD40 activity or function compared to CD40 activity or function in the absence of said antibody or antigen-binding portion thereof. Reduced functionality.
- the antibody or antigen-binding portion thereof is substantially free of agonist activity, i.e., the antibody or antigen-binding portion thereof does not elicit the same activity as CD40 in the absence of the antibody or antigen-binding portion thereof or The magnitude of CD40 activity or function is increased compared to function.
- the anti-CD40 antibody is a polyclonal antibody, monoclonal antibody, chimeric antibody, humanized antibody, human antibody, or an antigen-binding portion thereof.
- the anti-CD40 antibody is Iscalimab (CFZ533) (Novartis; as described in US Pat. Nos. 8828396 and 9221913); the anti-CD40 antibody is lucatumumab (Novartis; as described in US Pat. 8277810); antibodies 5D12, 3A8 and 3C6, or humanized versions thereof (Novartis; as described in U.S. Patent No. 5874082); antibody 15B8 (Novartis; as described in U.S. Patent No. 7445780 described); Antibody 4 D1 1 (Kyowa Hakko Kirin; as described in U.S. Patent No.
- Temeliximab (Bristol Myers Squibb; as described in U.S. Patent No. 6,051,228); Antibody PG102 (PanGenetics; as described in U.S. Patent No. 8669352); antibody 2C10 (Primatope; U.S. Patent Application Publication No. 20140093497); anti-CD40 antibody described in U.S. Patent Nos. 8591900 and 8778345 (Boehringer Ingelheim) ; an anti-CD40 antibody (Amgen) as described in US Patent No. 5801227; or APX005 (Boehringer Ingelheim; as described in US Patent Application Publication No. 20120301488.
- the anti-CD40 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) of an antibody
- the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, which are each associated with the following HCDR1, HCDR2, HCDR3 of the molecule have at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Iscalimab (CFZ533).
- the anti-CD40 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of an antibody, wherein the heavy chain variable region is at least about 80% identical to the heavy chain variable region of each of , about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Iscalimab (CFZ533).
- the anti-CD40 antibody or antigen-binding fragment thereof comprises a heavy chain of an antibody, wherein the heavy chain has at least about 80%, about 85%, about 90%, About 95%, about 96%, about 97%, about 98%, about 99% sequence identity Iscalimab (CFZ533).
- said anti-CD40 antibody or antigen-binding fragment thereof comprises an antibody light chain variable region (VL), wherein said light chain variable region comprises LCDR1, LCDR2, LCDR3, each of which is associated with the following LCDR1, LCDR2, LCDR3 of the molecules have at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Iscalimab (CFZ533).
- VL antibody light chain variable region
- the anti-CD40 antibody or antigen-binding fragment thereof comprises a light chain variable region of an antibody, wherein the light chain variable region is at least about 80% identical to the light chain variable region of each of , about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Iscalimab (CFZ533).
- the anti-CD40 antibody or antigen-binding fragment thereof comprises a light chain of an antibody, wherein the light chain has at least about 80%, about 85%, about 90%, About 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Iscalimab (CFZ533).
- an antibody of the invention is specific for (ie specifically binds to) IFNAR1. Such antibodies may also be referred to herein as "anti-IFNAR1 antibodies of the invention".
- the antibodies of the invention are specific for human IFNAR1.
- the anti-IFNAR1 antibodies of the invention may cross-react with IFNAR1 of species other than human or other proteins structurally related to human IFNAR1 (eg, human IFNAR1 homologues).
- the anti-IFNAR1 antibodies of the invention may be specific only for human IFNAR1 and exhibit no species or other types of cross-reactivity.
- the anti-IFNAR1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) of an antibody
- the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, which are each associated with the following HCDR1, HCDR2, HCDR3 of the molecule share at least about 80% sequence identity: Anifrolumab (MEDI-546).
- said anti-IFNAR1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of an antibody, wherein said heavy chain variable region shares at least about 80% with the heavy chain variable region of each of , about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Anifrolumab (MEDI-546).
- the anti-IFNAR1 antibody or antigen-binding fragment thereof comprises a heavy chain of an antibody, wherein the heavy chain has at least about 80%, about 85%, about 90%, About 95%, about 96%, about 97%, about 98%, about 99% sequence identity Anifrolumab (MEDI-546).
- said anti-IFNAR1 antibody or antigen-binding fragment thereof comprises a light chain variable region (VL) of an antibody
- said light chain variable region comprises LCDR1, LCDR2, LCDR3, which are each associated with the following LCDR1, LCDR2, LCDR3 of the molecules have at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Anifrolumab (MEDI-546 ).
- said anti-IFNAR1 antibody or antigen-binding fragment thereof comprises a light chain variable region of an antibody, wherein said light chain variable region shares at least about 80% with the light chain variable region of each of , about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Anifrolumab (MEDI-546).
- said anti-IFNAR1 antibody or antigen-binding fragment thereof comprises a light chain of an antibody, wherein said light chain has at least about 80%, about 85%, about 90%, About 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Anifrolumab (MEDI-546).
- said anti-BDCA2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of an antibody, wherein said heavy chain variable region shares at least about 80% with the heavy chain variable region of each of Sequence identity for: Litifilimab (BIIB059).
- said anti-BDCA2 antibody or antigen-binding fragment thereof comprises a light chain variable region of an antibody, wherein said light chain variable region shares at least about 80% with the light chain variable region of each of Sequence identity for: Litifilimab (BIIB059).
- the anti-BDCA2 antibody or antigen-binding fragment thereof comprises a heavy chain of an antibody, wherein each of the heavy chains has at least about 80% sequence identity to the heavy chain of: Litifilimab (BIIB059) .
- the anti-BDCA2 antibody or antigen-binding fragment thereof comprises a light chain of an antibody, wherein each of the light chains has at least about 80% sequence identity to a light chain of the following molecule: Litifilimab (BIIB059) .
- said anti-BDCA2 antibody or antigen-binding fragment thereof comprises an antibody heavy chain variable region (VH), wherein said heavy chain variable region has at least About 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Litifilimab (BIIB059).
- VH antibody heavy chain variable region
- said anti-BDCA2 antibody or antigen-binding fragment thereof comprises a light chain variable region (VL) of an antibody, wherein said light chain variable region has at least About 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Litifilimab (BIIB059).
- said anti-BDCA2 antibody or antigen-binding fragment thereof comprises a heavy chain of an antibody, wherein said heavy chain shares at least about 80%, about 85%, about 90%, About 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Litifilimab (BIIB059).
- said anti-BDCA2 antibody or antigen-binding fragment thereof comprises a light chain of an antibody, wherein said light chain has at least about 80%, about 85%, about 90%, About 95%, about 96%, about 97%, about 98%, about 99% sequence identity: Litifilimab (BIIB059).
- variants and equivalents that are substantially homologous to the anti-TNF- ⁇ antibody, anti-CD40 antibody, or anti-IFNAR1 antibody set forth herein.
- variants and equivalents may contain, for example, conservative substitution mutations, ie, one or more amino acids are replaced by similar amino acids.
- conservative substitution refers to the substitution of an amino acid by another amino acid within the same general class, such as one acidic amino acid by another acidic amino acid, one basic amino acid by another basic amino acid, or one A neutral amino acid is replaced by another neutral amino acid.
- the purpose of conservative amino acid substitutions is well known in the art.
- Antibodies can be recombinant, natural or synthetic polypeptides of antibodies.
- the present application further includes variants of polypeptides which exhibit significant activity or which comprise regions of antibodies.
- Such mutants include deletions, insertions, inversions, duplications and type substitutions.
- the ligand is selected from: Adalimumab, Iscalimab (CFZ533), Anifrolumab (MEDI-546), Infliximab (Infliximab), Afelimomab (Afelimomab ), Golimumab, anti-mouse TNF ⁇ mIgG2a 8c11, Litifilimab (BIIB059), derivatives thereof, and biosimilars thereof.
- Adalimumab Iscalimab (CFZ533), Anifrolumab (MEDI-546), Infliximab (Infliximab), Afelimomab (Afelimomab ), Golimumab, anti-mouse TNF ⁇ mIgG2a 8c11, Litifilimab (BIIB059), derivatives thereof, and biosimilars thereof.
- the ligand is selected from: Adalimumab, Iscalimab (CFZ533) and Anifrolumab (MEDI-546).
- ligand-drug conjugate has the following structure:
- Ab represents a ligand capable of binding to a target, including but not limited to antibodies and antigen-binding fragments thereof;
- N aI is any number from 1 to 10;
- Tr does not exist or Tr is any group
- L3 is selected from polypeptide fragments
- L2 is absent or selected from a linking fragment
- L is selected from a coupling unit
- R 1 , R 2 , R 3 , R 4 and R 5 are each independently any group
- B does not exist or B is any group
- W does not exist or W is any group
- X is selected from: -O-, -S-, -NR-;
- Y 1 is any group, and m is any integer from 0 to 4.
- Y2 is selected from -O-, -S- and -NR-;
- ligand generally means any molecule capable of specifically binding and or reactively binding or complexing a target molecule, such as a receptor, substrate, antigenic determinant or other binding site on a target cell or tissue.
- ligands include antibodies and fragments thereof (such as monoclonal antibodies or fragments thereof), enzymes (such as fibrinolytic enzymes), biological response modifiers (such as interleukins, interferons, erythropeoitin, or colony-stimulating factors), peptide hormones and antigen-binding fragments thereof, polysaccharides, lipids, oligonucleotides, polynucleotides, synthetic molecules, inorganic molecules, organic molecules, and any combination thereof.
- target or “target molecule” can include a wide variety of substances and molecules, ranging from simple molecules to complex targets.
- a target molecule can be a protein, nucleic acid, lipid, carbohydrate, or any other molecule that can be recognized by a polypeptide domain.
- target molecules can include compounds (i.e., non-biological compounds such as organic molecules, inorganic molecules, or molecules with both organic and inorganic atoms, but excluding polynucleotides and proteins), mixtures of compounds, spatially localized compounds Arrays of biomacromolecules, phage peptide display libraries, polysomal peptide display libraries, extracts made from biological materials such as bacterial, plant, fungal, or animal (e.g., mammalian) cells or tissues, proteins, toxins , peptide hormones, cells, viruses, etc.
- Other target molecules include, for example, whole cells, whole tissues, mixtures of related or unrelated proteins, mixtures of viral or bacterial strains, and the like.
- telomere binding generally refers to a measurable and reproducible interaction, such as between a target and an antibody, that can determine a target in the presence of a heterogeneous population of molecules, including biomolecules The presence.
- an antibody that specifically binds a target (which may be an epitope) can be an antibody that binds that target with greater affinity, avidity, greater ease, and/or for a greater duration than it binds other targets .
- an antibody specifically binds an epitope on a protein that is conserved among proteins of different species.
- specific binding can include, but does not require exclusive binding.
- the structure of the coupling unit L1 can change before and after coupling with the ligand, that is, in the Linker-Payload structure (such as formula IVa or formula IVb) and the drug-ligand conjugate structure (such as formula Va or formula Vb),
- the structure of L1 will vary and such variations can be readily determined by one of ordinary skill in the art.
- L1 when L1 is coupled to a ligand through a sulfhydryl group, the structure of L1 changes as follows:
- the mercapto group can come from a ligand
- the R L1a , R L1b , R L1c are each independently selected from: hydrogen, an optionally substituted alkyl group, and an optionally substituted aryl group; for example, the R L1a , R L1b , R L1c may each be independently selected from hydrogen, optionally substituted methyl, optionally substituted ethyl, optionally substituted aryl, and optionally substituted benzyl.
- L1 when L1 is coupled to a ligand through an amino group, the structure of L1 changes as follows:
- amino group can come from the ligand.
- L1 when L1 is coupled to a ligand by click chemistry, the structure of L1 changes as follows:
- R 1 and R 2 can be independently selected from: H, F, Cl, Br and optionally substituted methyl.
- R 3 can be selected from: optionally substituted -CH 2 Cl, optionally substituted -CH 2 SH, optionally substituted -CH 2 OH, optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted Optionally substituted -OH, optionally substituted -OCH3 , optionally substituted -OCH2F , optionally substituted -OCH2Cl , optionally substituted -OCH2CN , optionally substituted -OCH2CH 3.
- Optionally substituted mercapto optionally substituted -SCH 2 F, optionally substituted -SCH 2 Cl, optionally substituted -SCH 2 CF 3 , and optionally substituted -SCH 2 CN.
- said B can be selected from:
- said W may be absent or W may be selected from:
- conjugate can be selected from the following structures:
- N aI is any number from 1 to 10.
- the conjugate of the present invention wherein the ligand-drug conjugate has the following structure:
- Ab represents a ligand capable of binding to a target, preferably an antibody or an antigen-binding fragment thereof;
- N aI is any number from 1 to 10;
- the X is selected from -O-, -S- and -NH-;
- R 4 and R 5 are each independently selected from the following group: H, F, Cl, -OH, -NH 2 and C 1 -C 6 alkyl;
- n is selected from 1, 2 or 3;
- Said Y does not exist or is selected from: hydroxyl, mercapto, amino and C 1 -C 6 alkyl;
- the R 1 and R 2 are each independently selected from hydrogen, fluorine, chlorine and methyl;
- the R 3 is selected from: -CH 2 Cl, -CH 2 SH, -CH 2 OH, -OCH3 , -OCH2F , -OCH2Cl , -OCH2CN, -OCH2CH3 , -SH, -SCH2F , -SCH2Cl , -SCH2CF3 , and -SCH2CN .
- the conjugate of the present invention is selected from the following structures:
- N aI is any number from 1 to 10
- Ab is selected from antibodies or antigen-binding fragments thereof.
- the conjugate of the present invention is selected from the following structures:
- N aI is any number in 1 to 10.
- the active metabolite of the conjugate comprises the aforementioned compound.
- the present application provides a pharmaceutical composition, which comprises the aforementioned compound or its tautomer, mesomer, racemate, enantiomer, diastereoisomer, or A mixture thereof, or a pharmaceutically acceptable salt thereof and/or the aforementioned conjugate, and optionally a pharmaceutically acceptable carrier.
- the present application provides a method for affecting the function of the immune system, comprising administering the aforementioned compounds or their tautomers, mesoforms, racemates, enantiomers, non- Enantiomers, or their mixtures, or their pharmaceutically acceptable salts, the aforementioned conjugates and/or the aforementioned pharmaceutical compositions.
- said affecting the function of the immune system comprises affecting the function of immune cells.
- the immune cells are selected from the group consisting of granular leukocytes and agranular leukocytes.
- the immune cells are selected from the group consisting of neutrophils, eosinophils, and basophils.
- the immune cells are selected from the group consisting of lymphocytes and phagocytes.
- the immune cells are selected from the group consisting of B cells, T cells, natural killer cells, monocytes, macrophages, mast cells, and dendritic cells.
- the present application provides the aforementioned compound or its tautomer, mesomer, racemate, enantiomer, diastereoisomer, or a mixture thereof, or a pharmaceutically acceptable
- the disease and/or condition comprises a disease and/or condition associated with glucocorticoid receptor signaling.
- the disease and/or condition is selected from the group consisting of proliferative disease and/or condition, metabolic disease and/or condition, inflammatory disease and/or condition and neurodegenerative disease and/or condition .
- the disease and/or symptoms are selected from the group consisting of systemic autoimmune diseases and/or symptoms, blood system related diseases and/or symptoms, neuromuscular system related diseases and/or symptoms, digestive system Related diseases and/or symptoms, urinary system related diseases and/or symptoms, endocrine system related diseases and/or symptoms, skin muscular system related diseases and/or symptoms, and respiratory system related diseases and/or symptoms.
- the disease and/or condition is selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, scleroderma, Sjogren's syndrome, ankylosing spondylitis, Wegener's granulomatosis, and systemic sexual sclerosis.
- the disease and/or condition is selected from the group consisting of autoimmune hemolytic anemia, pernicious anemia, idiopathic thrombocytopenic purpura, idiopathic thrombocytopenia, and vasculitis.
- the disease and/or condition is selected from the group consisting of multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome.
- the disease and/or condition is selected from the group consisting of ulcerative colitis, Crohn's disease, autoimmune liver disease, and atrophic gastritis.
- the disease and/or condition is selected from the group consisting of IgA nephropathy, primary nephrotic syndrome, autoimmune glomerulonephritis, pulmonary renal hemorrhage syndrome, and lupus nephritis.
- the disease and/or condition is selected from the group consisting of type 1 diabetes, Grave's disease, Hashimoto's thyroiditis, primary adrenal atrophy, and chronic thyroiditis.
- the disease and/or condition is selected from the group consisting of psoriasis, pediospora vulgaris, cutaneous lupus erythematosus, dermatomyositis, and polymyalgia rheumatica.
- the disease and/or condition is asthma.
- the present application provides a method for preventing and/or treating diseases and/or symptoms, the method comprising administering the aforementioned compound or its tautomer, mesomer to a subject in need thereof , racemate, enantiomer, diastereoisomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof, the aforementioned conjugate and/or the aforementioned pharmaceutical composition.
- the disease and/or condition comprises a disease and/or condition associated with glucocorticoid receptor signaling.
- the disease and/or condition is selected from the group consisting of proliferative disease and/or condition, metabolic disease and/or condition, inflammatory disease and/or condition and neurodegenerative disease and/or condition .
- the disease and/or symptoms are selected from the group consisting of systemic autoimmune diseases and/or symptoms, blood system related diseases and/or symptoms, neuromuscular system related diseases and/or symptoms, digestive system Related diseases and/or symptoms, urinary system related diseases and/or symptoms, endocrine system related diseases and/or symptoms, skin muscular system related diseases and/or symptoms, and respiratory system related diseases and/or symptoms.
- the disease and/or condition is selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, scleroderma, Sjogren's syndrome, ankylosing spondylitis, Wegener's granulomatosis, and systemic sexual sclerosis.
- the disease and/or condition is selected from the group consisting of autoimmune hemolytic anemia, pernicious anemia, idiopathic thrombocytopenic purpura, idiopathic thrombocytopenia, and vasculitis.
- the disease and/or condition is selected from the group consisting of multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome.
- the disease and/or condition is selected from the group consisting of ulcerative colitis, Crohn's disease, autoimmune liver disease, and atrophic gastritis.
- the disease and/or condition is selected from the group consisting of IgA nephropathy, primary nephrotic syndrome, autoimmune glomerulonephritis, pulmonary renal hemorrhage syndrome, and lupus nephritis.
- the disease and/or condition is selected from the group consisting of type 1 diabetes, Grave's disease, Hashimoto's thyroiditis, primary adrenal atrophy, and chronic thyroiditis.
- the disease and/or condition is selected from the group consisting of psoriasis, pediospora vulgaris, cutaneous lupus erythematosus, dermatomyositis, and polymyalgia rheumatica.
- the disease and/or condition is asthma.
- the following examples are only for illustrating the compounds, preparation methods and uses of the present application, and are not intended to limit the scope of the present invention.
- Reagents that provide brominated conditions include but are not limited to bromine water, N-bromosuccinimide, dibromohydantoin, phosphorus tribromide, liquid bromine, liquid bromine/triphenylphosphine, hydrobromic acid, tetrabromide carbon;
- Titanium catalysts include but are not limited to tetraisopropyl titanate, triisopropoxytitanium chloride, titanium tetrachloride, titanium triisopropoxide;
- Palladium catalysts include, but are not limited to, palladium tetrakistriphenylphosphine, palladium acetate, palladium chloride, bis(triphenylphosphine)palladium dichloride, tris(dibenzylideneacetone)dipalladium, bis(dibenzylideneacetone) )dipalladium, bis(acetonitrile)palladium dichloride, [1,1'-bis ⁇ diphenylphosphino ⁇ ferrocene]palladium dichloride, [1,1'-bis ⁇ diphenylphosphino ⁇ Ferrocene]palladium dichloride dichloromethane complex, dibenzonitrile palladium dichloride, 1,4-bis(diphenylphosphine)butane-palladium chloride, allyl palladium chloride dimer, Allyl cyclopentadienyl palladium;
- Borate dimers include but are not limited to pinacol diboronate, neopentyl glycol diboronate, bis(2-methyl-2,4-pentanediol) borate, bis-phthalate Phenol borate, bis(diisopropyl-L-diethyltartrate) diboronate, bis[(-)pinanediol]diboronate, bis(1S,2S,3R,5S)(+ )-Pinanediol Diborate, Tetramethylaminodiborane, Bis(N,N,N',N'-tetramethyl-D-tartrate amide glycolate)diboron, Tetrahydroxydiborane , bis(N,N,N',N'-tetramethyl-L-tartrate amide glycolate) diboron, bis(diisopropyl-D-tartrate glycolate) diboronate, bis (D-diethyl
- Metallic copper salts include but are not limited to copper sulfate, copper sulfate pentahydrate, cuprous sulfate, cupric chloride, cuprous chloride, copper carbonate, copper phosphate, copper acetate and its hydrate, copper oxalate, copper fluoroborate and its hydrate Copper Dimethoxide, Copper Tartrate, Copper Formate, Cuprous Iodide, Copper Trifluoroacetate, Copper Trifluoromethanesulfonate, Copper Basic Carbonate, Copper Bromide, Cuprous Bromide, Cuprous Oxide;
- Ligands can be selected from any commonly used ligands for Ullmann reaction, including but not limited to L-proline, tyrosine, phenylalanine, 1,10-phenanthroline, N,N'-dimethylethyl Diamine, ethylene glycol, 1,1'-binaphthyl-2,2'diol, ethyl 2-carbonylcyclohexylcarboxylate, salicylaldehyde hydrazone;
- the condensing agent can be selected from 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholine chloride, 1-hydroxybenzotriazole and 1 -(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide , O-benzotriazole-N,N,N',N'-tetramethylurea tetrafluoroborate, 1-hydroxybenzotriazole, 1-hydroxy-7-azobenzotriazole , O-benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate, 2-(7-azobenzotriazole))-N,N,N',N '-Tetramethyluronium hexafluorophosphate, benzotriazol-1-
- Reagents providing alkaline conditions include organic bases and inorganic bases
- the organic bases include but not limited to triethylamine, diethylamine, N-methylmorpholine, pyridine, hexahydropyridine, N,N-diisopropyl ethylamine, n-butyllithium, lithium diisopropylamide, potassium acetate, sodium tert-butoxide, potassium tert-butoxide, etc.
- the inorganic base includes but not limited to sodium hydride, potassium carbonate, sodium carbonate, cesium carbonate, Sodium Hydroxide, Lithium Hydroxide, Sodium Phosphate, Potassium Phosphate;
- Reagents providing acidic conditions include protic acids and Lewis acids
- said protic acids include but are not limited to hydrochloric acid, sulfuric acid, nitric acid, nitrous acid, sulfurous acid, phosphoric acid, phosphorous acid, formic acid, acetic acid, propionic acid, butyric acid, citric acid, Benzoic acid, p-toluenesulfonic acid, p-nitrobenzoic acid, methanesulfonic acid, trifluoromethanesulfonic acid, trifluoroacetic acid;
- such Lewis acids include but are not limited to boron trifluoride, zinc chloride, magnesium chloride, chlorine Aluminum chloride, tin chloride, ferric chloride;
- Hydrogenation conditions include but are not limited to: Pb/C/hydrogen, Pt/C/hydrogen, palladium chloride/hydrogen, Raney nickel/hydrogen, palladium hydroxide carbon/hydrogen, palladium hydroxide/hydrogen;
- Reagents that provide oxidation conditions include but are not limited to Dess Martin oxidizers, hydrogen peroxide, sodium chlorite, sodium hypochlorite, potassium perchlorate;
- Reagents providing reducing conditions include, but are not limited to, sodium hydride, calcium hydride, lithium hydride, lithium aluminum hydride, sodium borohydride, lithium borohydride, sodium triethylborohydride, sodium triacetoxyborohydride, sodium cyanoborohydride ;
- Reagents that provide oxidizing conditions include, but are not limited to, Dess Martin oxidizing agents, hydrogen peroxide, sodium chlorite, sodium hypochlorite, and potassium perchlorate.
- NMR nuclear magnetic resonance
- MS mass spectroscopy
- UPLC UPLC
- a Waters AcquityUPLCSQD liquid mass spectrometer (Poroshell 120 EC-C18, 2.1mm x 50mm, 1.9 micron chromatographic column).
- HPLC high pressure liquid chromatograph
- UV was measured using a Thermonodrop2000 UV spectrophotometer.
- EnVision microplate reader (PerkinElmer Company) was used for enzyme-linked immunoassay.
- the thin-layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate, the specification of the silica gel plate used in thin-layer chromatography (TLC) is 0.15mm0.2mm, and the specification of thin-layer chromatography separation and purification product is 0.4mm0. 5mm silica gel board.
- the known starting materials of the present application can be used or synthesized according to methods known in the art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Shaoyuan Chemical Technology (AccelaChemBioInc), Darui Chemicals and other companies.
- the argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a volume of about 1 L.
- the hydrogen atmosphere means that the reaction bottle is connected to a hydrogen balloon with a capacity of about 1L.
- the solution in the reaction refers to an aqueous solution.
- the temperature of the reaction is room temperature. Room temperature is the most suitable reaction temperature, and the temperature range is 20°C to 30°C.
- the eluent system of the column chromatography and the developer system of the thin-layer chromatography of the purified compound include: A: dichloromethane and isopropanol system, B: dichloromethane and methanol system, C: sherwood oil and In the ethyl acetate system, the volume ratio of the solvent is adjusted according to the polarity of the compound, and it can also be adjusted by adding a small amount of triethylamine and acidic or alkaline reagents.
- TOF-LC/MS uses an Agilent 6230 time-of-flight mass spectrometer and an Agilent 1290-Infinity ultra-high performance liquid chromatograph.
- the exemplary preparation route of the present application is as follows:
- the first step the compound of general formula (P1) introduces a bromine atom on the benzene ring under optional bromination conditions;
- the second step the compound of the general formula (P2) is reacted with the borate dimer under optional palladium reagent catalyst conditions to obtain the compound of the general formula (P3);
- the third step the compound of general formula (P3) reacts with the compound of general formula (Y1) under optional palladium reagent catalytic conditions to obtain the compound of general formula (P4);
- the fourth step the compound of general formula (P4) reacts with the compound of general formula (Y2) under optional acidic or basic conditions to obtain the compound of general formula (P5);
- Step 5 The compound of general formula (P5) is optionally removed from the protecting group PG under acidic or basic conditions, and separated by preparative HPLC to obtain the compound of general formula (P6).
- PG can be the protecting group of common hydroxyl
- Ring B is optionally substituted aryl or heteroaryl
- -B(OR) 2 is a borate-based monomer, in which two Rs can be connected to form a heterocyclic ring, a heterobridged ring or a heterospiro ring, and the ring can be optionally covered by C 1 -C 6 alkyl, aryl, Heteroaryl, carboxyl or acyloxy C 1 -C 6 alkyl substitution;
- X is chlorine, bromine or iodine
- each R is independently selected from hydrogen, protium, deuterium, tritium, oxygen, hydroxyl, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, aryl, heteroaryl, cycloalkyl, heterocycle Alkyl, halogen substituted C 1 -C 6 alkyl, and halogen substituted C 1 -C 6 alkoxy;
- R, R 1 , R 2 and R 3 can be as any formula (I), formula (IIa), formula (IIb), formula (IIIa), formula (IIIb), formula (IVa) or formula (IVb) in this application respectively R, R 1 , R 2 and R 3 are as defined.
- the first step the compound of the general formula (Y1) reacts with the compound (P1) under optional metal copper salt and optional ligand catalysis under optional basic conditions to obtain the compound of the general formula (P2);
- Second step the compound of general formula (P2) is reacted under optional reducing conditions to obtain general formula (P3);
- the third step the compound of general formula (P3) obtains general formula (P4) under optional oxidation conditions;
- the fourth step the compound of the general formula (P4) reacts with the compound of the general formula (Y2) under optional acidic or basic conditions to obtain the compound of the general formula (P5);
- Step 5 The compound of general formula (P5) is optionally removed from the protecting group PG under acidic or basic conditions, and separated by preparative HPLC to obtain the compound of general formula (P6).
- PG can be the protecting group of common hydroxyl
- Ring B is optionally substituted aryl or heteroaryl
- R 1 , R 2 and R 3 can be shown in any formula (I), formula (IIa), formula (IIb), formula (IIIa), formula (IIIb), formula (IVa) or formula (IVb) respectively in this application defined by R 1 , R 2 and R 3 .
- the first step the compound of the general formula (P1) undergoes a carbonyl insertion reaction under optional palladium reagent catalysis conditions to obtain the compound of the general formula (P2);
- Second step the compound of general formula (P2) is reacted under optional reducing conditions to obtain general formula (P3);
- the third step the compound of the general formula (P3) is optionally brominated to obtain the compound of the general formula (P4);
- the fourth step the compound of general formula (P4) reacts with the compound of general formula (Y1) under optional basic conditions to obtain the compound of general formula (P5);
- the sixth step the compound of the general formula (P6) is optionally oxidized to obtain the general formula (P7);
- the seventh step the compound of general formula (P7) reacts with the compound of general formula (Y2) under optional acidic or basic conditions to obtain the compound of general formula (P8);
- the eighth step the compound of the general formula (P8) is optionally removed under acidic or basic conditions, and the protecting group PG is removed, and separated by preparative HPLC to obtain the compound of the general formula (P9).
- PG 1 and PG 2 can be protecting groups for common hydroxyl or ester groups
- R can be optionally substituted C 1 -C 6 alkyl
- Ring B is optionally substituted aryl or heteroaryl
- R, R 1 , R 2 and R 3 can be as any formula (I), formula (IIa), formula (IIb), formula (IIIa), formula (IIIb), formula (IVa) or formula (IVb) in this application respectively R, R 1 , R 2 and R 3 are as defined.
- the first step the compound of the general formula (P1) is optionally brominated, and a bromine atom is introduced at the methyl group to obtain the compound of the general formula (P2);
- the second step the compound of general formula (P2) reacts with the compound of general formula (Y1) under optional palladium reagent catalytic conditions to obtain the compound of general formula (P3);
- the third step the compound of general formula (P3) reacts with the compound of general formula (Y2) under optional acidic or basic conditions to obtain the compound of general formula (P4);
- the fourth step the compound of the general formula (P4) is optionally removed from the protecting group PG under acidic or basic conditions, and separated by preparative HPLC to obtain the compound of the general formula (P5).
- PG 1 can be a protecting group for common hydroxyl groups
- Ring B is optionally substituted aryl or heteroaryl
- R 1 , R 2 and R 3 can be shown in any formula (I), formula (IIa), formula (IIb), formula (IIIa), formula (IIIb), formula (IVa) or formula (IVb) respectively in this application defined by R 1 , R 2 and R 3 ;
- the first step the compound of general formula (P1) is reacted under optional reducing conditions to obtain general formula (P2);
- the second step the compound of the general formula (P2) is optionally under acidic or basic conditions, and the protecting group PG is added to obtain the general formula (P3);
- the third step the compound of general formula (P3) reacts with the compound of general formula (Y1) under optional alkaline conditions to obtain the compound of general formula (P4);
- the fourth step the compound of general formula (P4) is reacted under optional reducing conditions to obtain general formula (P5);
- the fifth step the compound of the general formula (P5) is optionally oxidized to obtain the general formula (P6);
- the sixth step the compound of general formula (P6) reacts with the compound of general formula (Y2) under optional acidic or basic conditions to obtain the compound of general formula (P7);
- the seventh step the compound of the general formula (P7) is optionally removed under acidic or basic conditions, and the protecting group PG is removed, and separated by preparative HPLC to obtain the compound of the general formula (P8).
- Ring B is optionally substituted aryl or heteroaryl
- PG 1 and PG 2 can be common hydroxyl or hydroxyl protecting groups
- R 1 , R 2 and R 3 can be shown in any formula (I), formula (IIa), formula (IIb), formula (IIIa), formula (IIIb), formula (IVa) or formula (IVb) respectively in this application defined by R 1 , R 2 and R 3 ;
- the first step the compound of general formula (P1) reacts with the compound of general formula (Y1) under optional condensation conditions to obtain the compound of general formula (P2)
- Second step the compound of general formula (P2) is reacted under optional reducing conditions to obtain the compound of general formula (P3);
- the third step the compound of general formula (P3) is reacted under optional oxidation conditions to obtain the compound of general formula (P4);
- the fourth step the compound of the general formula (P4) reacts with the compound of the general formula (Y2) under optional acidic or basic conditions to obtain the compound of the general formula (P5);
- the fifth step the compound of general formula (P5) is reacted under optional reducing conditions to obtain the compound of general formula (P6);
- PG 1 and PG 2 can be protecting groups for common hydroxyl or ester groups
- Ring B is optionally substituted aryl or heteroaryl
- R 1 , R 2 and R 3 can be shown in any formula (I), formula (IIa), formula (IIb), formula (IIIa), formula (IIIb), formula (IVa) or formula (IVb) respectively in this application defined by R 1 , R 2 and R 3 ;
- the first step the compound of general formula (P1) is introduced into the nitro group on the benzene ring under nitration conditions to obtain the compound of general formula (P2);
- the second step the compound of the general formula (P2) is reacted with the borate dimer under optional palladium reagent catalyst conditions to obtain the compound of the general formula (P3);
- the third step the compound of general formula (P3) reacts with the compound of general formula (Y1) under optional palladium reagent catalytic conditions to obtain the compound of general formula (P4);
- the fourth step the compound of general formula (P4) reacts with the compound of general formula (Y2) under optional acidic or basic conditions to obtain the compound of general formula (P5);
- the fifth step the compound of the general formula (P5) is optionally hydrogenated to obtain the compound of the general formula (P6);
- Step 6 The compound of general formula (P6) is optionally deprotected by PG under acidic or basic conditions, and separated by preparative HPLC to obtain the compound of general formula (P7).
- PG can be the protecting group of common hydroxyl
- -B(OR) 2 is a borate-based monomer, in which two Rs can be connected to form a heterocyclic ring, a heterobridged ring or a heterospiro ring, and the ring can be optionally covered by C 1 -C 6 alkyl, aryl, Heteroaryl, carboxyl or acyloxy C 1 -C 6 alkyl substitution;
- each R is independently selected from hydrogen, protium, deuterium, tritium, oxygen, hydroxyl, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, aryl, heteroaryl, cycloalkyl, heterocycle Alkyl, halogen substituted C 1 -C 6 alkyl, and halogen substituted C 1 -C 6 alkoxy;
- Ring B is optionally substituted aryl or heteroaryl
- R 1 , R 2 and R 3 can be shown in any formula (I), formula (IIa), formula (IIb), formula (IIIa), formula (IIIb), formula (IVa) or formula (IVb) respectively in this application defined by R 1 , R 2 and R 3 ;
- the first step the compound of general formula (P1) is introduced into the nitro group on the benzene ring under nitration conditions to obtain the compound of general formula (P2);
- the second step the compound of the general formula (P2) is reacted with an ethyl Grignard reagent under optional titanium catalysis conditions to obtain the compound of the general formula (P3);
- the third step the compound of the general formula (P2) reacts with the borate dimer under optional palladium reagent catalyst conditions to obtain the compound of the general formula (P3);
- the fourth step the compound of general formula (P3) reacts with the compound of general formula (Y1) under optional palladium reagent catalytic conditions to obtain the compound of general formula (P4);
- the fifth step the compound of general formula (P4) reacts with the compound of general formula (Y2) under optional acidic or basic conditions to obtain the compound of general formula (P5);
- Step 6 The compound of the general formula (P5) is optionally hydrogenated, the nitro group is reduced, and separated by preparative HPLC to obtain the compound of the general formula (P6).
- Ring B is optionally substituted aryl or heteroaryl
- -B(OR) 2 is a borate-based monomer, in which two Rs can be connected to form a heterocyclic ring, a heterobridged ring or a heterospiro ring, and the ring can be optionally covered by C 1 -C 6 alkyl, aryl, Heteroaryl, carboxyl or acyloxy C 1 -C 6 alkyl substitution;
- each R is independently selected from hydrogen, protium, deuterium, tritium, oxygen, hydroxyl, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, aryl, heteroaryl, cycloalkyl, heterocycle Alkyl, halogen substituted C 1 -C 6 alkyl, and halogen substituted C 1 -C 6 alkoxy;
- R 1 , R 2 and R 3 can be shown in any formula (I), formula (IIa), formula (IIb), formula (IIIa), formula (IIIb), formula (IVa) or formula (IVb) respectively in this application defined by R 1 , R 2 and R 3 ;
- the first step the compound of general formula (P1) reacts with the compound of general formula (Y1) under optional basic conditions to obtain the compound of general formula (P2);
- Second step the compound of general formula (P2) is reacted under optional reducing conditions to obtain general formula (P3);
- the third step the compound of general formula (P3) obtains general formula (P4) under optional oxidation conditions;
- the fourth step the compound of the general formula (P4) reacts with the compound of the general formula (Y2) under optional acidic or basic conditions to obtain the compound of the general formula (P5)
- Step 5 The compound of general formula (P5) is optionally removed from the protecting group PG under acidic or basic conditions, and separated by preparative HPLC to obtain the compound of general formula (P6).
- PG can be the protecting group of common hydroxyl
- Ring B is optionally substituted aryl or heteroaryl
- R 1 , R 2 and R 3 can be shown in any formula (I), formula (IIa), formula (IIb), formula (IIIa), formula (IIIb), formula (IVa) or formula (IVb) respectively in this application defined by R 1 , R 2 and R 3 ;
- the first step the compound of general formula (P1) reacts with the compound of general formula (Y1) under optional palladium catalysis conditions to obtain the compound of general formula (P2);
- Second step the compound of general formula (P2) is reacted under optional reducing conditions to obtain general formula (P3);
- the third step the compound of general formula (P3) obtains general formula (P4) under optional oxidation conditions;
- the fourth step the compound of the general formula (P4) reacts with the compound of the general formula (Y2) under optional acidic or basic conditions to obtain the compound of the general formula (P5)
- Step 5 The compound of general formula (P5) is optionally removed from the protecting group PG under acidic or basic conditions, and separated by preparative HPLC to obtain the compound of general formula (P6).
- X is NR or -O-, R is optionally substituted C 1 -C 6 alkyl;
- PG can be the protecting group of common hydroxyl
- Ring B is optionally substituted aryl or heteroaryl
- R 1 , R 2 and R 3 can be shown in any formula (I), formula (IIa), formula (IIb), formula (IIIa), formula (IIIb), formula (IVa) or formula (IVb) respectively in this application defined by R 1 , R 2 and R 3 ;
- the first step the compound of general formula (P1) reacts with the compound of general formula (Y1) under optional condensation conditions to obtain the compound of general formula (P2)
- Second step the compound of general formula (P2) is reacted under optional reducing conditions to obtain the compound of general formula (P3);
- the third step the compound of general formula (P3) is reacted under optional oxidation conditions to obtain the compound of general formula (P4);
- the fourth step the compound of the general formula (P4) reacts with the compound of the general formula (Y2) under optional acidic or basic conditions to obtain the compound of the general formula (P5);
- the fifth step the compound of general formula (P5) is reacted under optional reducing conditions, and separated by preparative HPLC to obtain the compound of general formula (P6);
- PG can be the protecting group of common hydroxyl
- R 1 , R 2 and R 3 can be shown in any formula (I), formula (IIa), formula (IIb), formula (IIIa), formula (IIIb), formula (IVa) or formula (IVb) respectively in this application defined by R 1 , R 2 and R 3 ;
- the first step the compound of general formula (P1) reacts with the compound of general formula (Y1) under optional condensation conditions to obtain the compound of general formula (P2);
- the second step the compound of the general formula (P2) is optionally deprotected under acidic or basic conditions to obtain the compound of the general formula (P3).
- the third step the compound of general formula (P3) reacts with the compound of general formula (Y2) under optional condensation conditions to obtain the compound of general formula (P4);
- the fourth step the compound of the general formula (P4) is optionally under acidic or basic conditions, and the protecting group PG 1 is removed to obtain the compound of the general formula (P5);
- the fifth step the compound of general formula (P5) reacts with the compound of general formula (Y3) under optional condensation conditions to obtain the compound of general formula (P6);
- Step 6 The compound of the general formula (P6) is optionally removed from the protecting group PG 1 under acidic or basic conditions to obtain the compound of the general formula (P7);
- the seventh step the compound of the general formula (P7) is reacted with the compound of the general formula (Y3) under optional condensation conditions, and separated by preparative HPLC to obtain the compound of the general formula (P8).
- Ring B is optionally substituted aryl or heteroaryl
- W does not exist or W is any group
- X is -CH 2 -, -CH(CH 3 )-, -CH 2 CH 2 - or
- Y is hydrogen, hydroxy, fluorine, chlorine, methyl, hydroxy or methoxy
- R 1 , R 2 and R 3 can be defined as R 1 , R 2 and R 3 shown in any formula (I), formula (II), formula ( III ) or formula (IV) of this application, respectively;
- LG 1 , LG 2 , LG 3 and LG 4 can be hydroxyl groups of common activated esters or carboxyl groups;
- PG 1 , PG 2 and PG 3 can be common amino protecting groups
- R 1 , R 2 and R 3 can be shown in any formula (I), formula (IIa), formula (IIb), formula (IIIa), formula (IIIb), formula (IVa) or formula (IVb) respectively in this application defined by R 1 , R 2 and R 3 ;
- Tr does not exist or Tr is any group
- L3 is selected from polypeptide fragments
- L2 is absent or selected from a linking fragment
- L 1 is selected from coupling units.
- the first step the compound of general formula (P1) is reacted with the compound of general formula (Y1) under optional condensation conditions, and separated by preparative HPLC to obtain the compound of general formula (P2).
- Ring B is optionally substituted aryl or heteroaryl
- W does not exist or W is any group
- X is -CH 2 -, -CH(CH 3 )-, -CH 2 CH 2 - or
- Y is -O-, -S- or -NH-;
- R 1 , R 2 and R 3 can be shown in any formula (I), formula (IIa), formula (IIb), formula (IIIa), formula (IIIb), formula (IVa) or formula (IVb) respectively in this application defined by R 1 , R 2 and R 3 ;
- LG 1 can be a hydroxyl group of a common activated ester or a carboxyl group
- Tr does not exist or Tr is any group
- L3 is selected from polypeptide fragments
- L2 is absent or selected from a linking fragment
- L 1 is selected from coupling units.
- the first step the compound of general formula (P1) reacts with the compound of general formula (Y1) under optional condensation conditions to obtain the compound of general formula (P2);
- the second step the compound of the general formula (P2) is optionally deprotected under acidic or basic conditions to obtain the compound of the general formula (P3).
- the third step the compound of general formula (P3) reacts with the compound of general formula (Y2) under optional condensation conditions to obtain the compound of general formula (P4);
- the fourth step the compound of the general formula (P4) is optionally under acidic or basic conditions, and the protecting group PG 1 is removed to obtain the compound of the general formula (P5);
- the fifth step the compound of the general formula (P5) is reacted with the compound of the general formula (Y3) under optional condensation conditions, and separated by preparative HPLC to obtain the compound of the general formula (P6).
- Ring B is optionally substituted aryl or heteroaryl
- W does not exist or W is any group
- X is -CH 2 -, -CH(CH 3 )-, -CH 2 CH 2 - or
- Y is -O-, -S- or -NH-;
- LG 1 , LG 2 and LG 3 can be hydroxyl groups of common activated esters or carboxyl groups;
- PG 1 , PG 2 and PG 3 can be common amino protecting groups
- R 1 , R 2 and R 3 can be shown in any formula (I), formula (IIa), formula (IIb), formula (IIIa), formula (IIIb), formula (IVa) or formula (IVb) respectively in this application defined by R 1 , R 2 and R 3 ;
- Tr does not exist or Tr is any group
- L3 is selected from polypeptide fragments
- L2 is absent or selected from a linking fragment
- L 1 is selected from coupling units.
- Ligand Ab reacts with any compound represented by formula (IVa) or formula (IVb) in this application in an acidic, neutral or alkaline buffer to obtain a compound represented by formula (Va) or formula (Vb);
- Ab is a ligand containing at least one free sulfhydryl group (-SH), wherein the free sulfhydryl group can be obtained by reducing the ligand through a reducing agent;
- the reducing agent includes but is not limited to tris(2-carboxyethyl)phosphine, mercaptoethanol, Dithiothreitol, cysteine, reduced glutathione, etc.; in particular, can reduce the disulfide bond (-S-S-) between ligand chains to form free sulfhydryl groups; wherein formula (I-C) or formula ( The S atom in the compound shown in II-C) and the sulfhydryl group that can be derived from Ab;
- Tr, L 1 , L 2 , L 3 can be defined as Tr, L 1 , L 2 , L 3 in the compound shown in any formula (IVa) or formula (IVb) of this application respectively;
- Ab, N aI can be respectively as follows In the compound shown by any formula (Va) or formula (Vb) in the present application, Ab and N a- I are defined;
- L 1x represents the structure after coupling with L 1 coupled with thiol.
- the buffer is selected from the following buffers at pH 2 to 12, citric acid-sodium citrate buffer, phosphate-sodium phosphate buffer, phosphate-potassium phosphate buffer, sodium dihydrogen phosphate-disodium hydrogen phosphate buffer, dibasic phosphate Potassium Hydrogen-Dipotassium Phosphate Buffer, Succinic Acid-Sodium Succinate Buffer, Acetic Acid-Sodium Acetate Buffer, Boric Acid-Borax Buffer, Boric Acid-Potassium Borate Buffer, Borax-Sodium Hydroxide Buffer, Histidine - HCl buffer, Glycine-NaOH buffer, Arginine-HCl buffer, Sodium bicarbonate-Sodium carbonate buffer, Potassium bicarbonate-Potassium carbonate buffer, Tris-HCl buffer, Ammonia-Ammonium chloride Buffer, barbital sodium-hydrochloric acid buffer, borax-sodium carbonate buffer, boric acid-potassium chloride buffer,
- the ligand Ab reacts with the compound shown in any formula (IVa) or formula (IVb) of the present application in an acidic, neutral or alkaline buffer to obtain the compound shown in formula (Va) or formula (Vb).
- Ab is a ligand containing at least one free sulfhydryl group (-SH), wherein the free sulfhydryl group can be obtained by reducing the ligand through a reducing agent;
- the reducing agent includes but is not limited to tris(2-carboxyethyl)phosphine, mercaptoethanol, Dithiothreitol, cysteine, reduced glutathione, etc.; in particular, can reduce the disulfide bond (-S-S-) between ligand chains to form free sulfhydryl groups; wherein formula (Va) or formula ( The S atom in the compound shown in Vb) and the mercapto group that can be derived from Ab;
- the compound shown in any formula (Va) or formula (Vb) of the present application is incubated for a certain period of time in an alkaline buffer at a selected temperature to obtain another compound of any formula (Va) of the present application. ) or a compound shown in formula (Vb);
- Tr, L 2 , L 3 can be defined as Tr, L 2 , L 3 in the compound shown in any formula (IVa) or formula (IVb) of the present application;
- Ab, NaI can be defined as in any formula (Va ) or the compounds represented by formula (Vb) as defined by Ab and NaI .
- the buffer is selected from the following buffers at pH 2 to 12, citric acid-sodium citrate buffer, phosphate-sodium phosphate buffer, phosphate-potassium phosphate buffer, sodium dihydrogen phosphate-disodium hydrogen phosphate buffer, dibasic phosphate Potassium Hydrogen-Dipotassium Phosphate Buffer, Succinic Acid-Sodium Succinate Buffer, Acetic Acid-Sodium Acetate Buffer, Boric Acid-Borax Buffer, Boric Acid-Potassium Borate Buffer, Borax-Sodium Hydroxide Buffer, Histidine - HCl buffer, Glycine-NaOH buffer, Arginine-HCl buffer, Sodium bicarbonate-Sodium carbonate buffer, Potassium bicarbonate-Potassium carbonate buffer, Tris-HCl buffer, Ammonia-Ammonium chloride Buffer, barbital sodium-hydrochloric acid buffer, borax-sodium carbonate buffer, boric acid-potassium chloride buffer,
- Ligand Ab reacts with any compound shown in formula (IVa) or formula (IVb) of this application that can be coupled with two sulfhydryl groups in an acidic, neutral or alkaline buffer to obtain formula (Va) Or the compound shown in formula (Vb);
- Ab is a ligand containing at least 2 free sulfhydryl groups (-SH), wherein the free sulfhydryl groups can be obtained by reducing the ligand through a reducing agent;
- the reducing agent includes but is not limited to tris(2-carboxyethyl)phosphine, mercaptoethanol, Dithiothreitol, cysteine, reduced glutathione, etc.; in particular, can reduce the disulfide bond (-S-S-) between ligand chains to form free sulfhydryl groups; wherein formula (Va) or formula ( The S atom in the compound shown in Vb) and the mercapto group that can be derived from Ab;
- Tr, L 1 , L 2 , L 3 can be defined as Tr, L 1 , L 2 , L 3 in the compound shown in any formula (IVa) or formula (IVb) of this application respectively;
- Ab, N aI can be respectively as follows In the compound shown in any formula (Va) or formula (Vb) of the present application, Ab and N a- I are defined;
- L 1y represents the structure after coupling with L 1 coupled with 2 sulfhydryl groups.
- the compound shown by formula (Va) or formula (Vb) having a group capable of coupling with 2 mercapto groups may comprise a L 1y group selected from the group consisting of: Wherein each R L1a , R L1b and R L1c are each independently selected from the group consisting of hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O )H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C( O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, alkyl, alkenyl, alkynyl, alicyclic, heterocyclic, aryl, and heteroaryl .
- the buffer is selected from the following buffers at pH 2 to 12, citric acid-sodium citrate buffer, phosphate-sodium phosphate buffer, phosphate-potassium phosphate buffer, sodium dihydrogen phosphate-disodium hydrogen phosphate buffer, dibasic phosphate Potassium Hydrogen-Dipotassium Phosphate Buffer, Succinic Acid-Sodium Succinate Buffer, Acetic Acid-Sodium Acetate Buffer, Boric Acid-Borax Buffer, Boric Acid-Potassium Borate Buffer, Borax-Sodium Hydroxide Buffer, Histidine - HCl buffer, Glycine-NaOH buffer, Arginine-HCl buffer, Sodium bicarbonate-Sodium carbonate buffer, Potassium bicarbonate-Potassium carbonate buffer, Tris-HCl buffer, Ammonia-Ammonium chloride Buffer, barbital sodium-hydrochloric acid buffer, borax-sodium carbonate buffer, boric acid-potassium chloride buffer,
- Ligand Ab reacts with any compound shown in formula (IVa) or formula (IVb) of this application that can be coupled with two sulfhydryl groups in an acidic, neutral or alkaline buffer to obtain formula (Va) Or the compound shown in formula (Vb);
- Ab is a ligand containing at least one free sulfhydryl group (-SH), wherein the free sulfhydryl group can be obtained by reducing the ligand through a reducing agent;
- the reducing agent includes but is not limited to tris(2-carboxyethyl)phosphine, mercaptoethanol, Dithiothreitol, cysteine, reduced glutathione, etc.; in particular, can reduce the disulfide bond (-S-S-) between ligand chains to form free sulfhydryl groups; wherein formula (Va) or formula ( The S atom in the compound shown in Vb) and the mercapto group that can be derived from Ab;
- Tr, L 1 , L 2 , L 3 can be defined as Tr, L 1 , L 2 , L 3 in the compound shown in any formula (IVa) or formula (IVb) of this application respectively;
- Ab, N aI can be respectively as follows In the compound shown by any formula (Va) or formula (Vb) in the present application, Ab and N a- I are defined;
- L 1x represents the structure after coupling with L 1 coupled with thiol.
- the buffer is selected from the following buffers at pH 2 to 12, citric acid-sodium citrate buffer, phosphate-sodium phosphate buffer, phosphate-potassium phosphate buffer, sodium dihydrogen phosphate-disodium hydrogen phosphate buffer, dibasic phosphate Potassium Hydrogen-Dipotassium Phosphate Buffer, Succinic Acid-Sodium Succinate Buffer, Acetic Acid-Sodium Acetate Buffer, Boric Acid-Borax Buffer, Boric Acid-Potassium Borate Buffer, Borax-Sodium Hydroxide Buffer, Histidine - HCl buffer, Glycine-NaOH buffer, Arginine-HCl buffer, Sodium bicarbonate-Sodium carbonate buffer, Potassium bicarbonate-Potassium carbonate buffer, Tris-HCl buffer, Ammonia-Ammonium chloride Buffer, barbital sodium-hydrochloric acid buffer, borax-sodium carbonate buffer, boric acid-potassium chloride buffer,
- the ligand Ab reacts with the compound shown in any formula (IVa) or formula (IVb) of the present application in an acidic, neutral or alkaline buffer to obtain the compound shown in formula (Va) or formula (Vb).
- Ab is a ligand containing at least one free sulfhydryl group (-SH), wherein the free sulfhydryl group can be obtained by reducing the ligand through a reducing agent;
- the reducing agent includes but is not limited to tris(2-carboxyethyl)phosphine, mercaptoethanol, Dithiothreitol, cysteine, reduced glutathione, etc.; in particular, can reduce the disulfide bond (-S-S-) between ligand chains to form free sulfhydryl groups; wherein formula (Va) or formula ( The S atom in the compound shown in Vb) and the mercapto group that can be derived from Ab;
- the compound shown in any formula (Va) or formula (Vb) of the present application is incubated for a certain period of time in an alkaline buffer at a selected temperature to obtain another compound of any formula (Va) of the present application. ) or a compound shown in formula (Vb);
- Tr, L 2 , L 3 can be defined as Tr, L 2 , L 3 in the compound shown in any formula (IVa) or formula (IVb) of the present application;
- Ab, NaI can be defined as in any formula (Va ) or the compounds represented by formula (Vb) as defined by Ab and NaI .
- the buffer is selected from the following buffers at pH 2 to 12, citric acid-sodium citrate buffer, phosphate-sodium phosphate buffer, phosphate-potassium phosphate buffer, sodium dihydrogen phosphate-disodium hydrogen phosphate buffer, dibasic phosphate Potassium Hydrogen-Dipotassium Phosphate Buffer, Succinic Acid-Sodium Succinate Buffer, Acetic Acid-Sodium Acetate Buffer, Boric Acid-Borax Buffer, Boric Acid-Potassium Borate Buffer, Borax-Sodium Hydroxide Buffer, Histidine - HCl buffer, Glycine-NaOH buffer, Arginine-HCl buffer, Sodium bicarbonate-Sodium carbonate buffer, Potassium bicarbonate-Potassium carbonate buffer, Tris-HCl buffer, Ammonia-Ammonium chloride Buffer, barbital sodium-hydrochloric acid buffer, borax-sodium carbonate buffer, boric acid-potassium chloride buffer,
- Ligand Ab reacts with any compound shown in formula (IVa) or formula (IVb) of this application that can be coupled with two sulfhydryl groups in an acidic, neutral or alkaline buffer to obtain formula (Va) Or the compound shown in formula (Vb);
- Ab is a ligand containing at least 2 free sulfhydryl groups (-SH), wherein the free sulfhydryl groups can be obtained by reducing the ligand through a reducing agent;
- the reducing agent includes but is not limited to tris(2-carboxyethyl)phosphine, mercaptoethanol, Dithiothreitol, cysteine, reduced glutathione, etc.; in particular, can reduce the disulfide bond (-S-S-) between ligand chains to form free sulfhydryl groups; wherein formula (Va) or formula ( The S atom in the compound shown in Vb) and the mercapto group that can be derived from Ab;
- Tr, L 1 , L 2 , L 3 can be defined as Tr, L 1 , L 2 , L 3 in the compound shown in any formula (IVa) or formula (IVb) of this application respectively;
- Ab, N aI can be respectively as follows In the compound shown in any formula (Va) or formula (Vb) of the present application, Ab and N a- I are defined;
- L 1y represents the structure after coupling with L 1 coupled with 2 sulfhydryl groups.
- the compound shown by formula (Va) or formula (Vb) having a group capable of coupling with 2 mercapto groups may comprise a L 1y group selected from the group consisting of: Wherein each R L1a , R L1b and R L1c are each independently selected from the group consisting of hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O )H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C( O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, alkyl, alkenyl, alkynyl, alicyclic, heterocyclic, aryl, and heteroaryl .
- the buffer is selected from the following buffers at pH 2 to 12, citric acid-sodium citrate buffer, phosphate-sodium phosphate buffer, phosphate-potassium phosphate buffer, sodium dihydrogen phosphate-disodium hydrogen phosphate buffer, dibasic phosphate Potassium Hydrogen-Dipotassium Phosphate Buffer, Succinic Acid-Sodium Succinate Buffer, Acetic Acid-Sodium Acetate Buffer, Boric Acid-Borax Buffer, Boric Acid-Potassium Borate Buffer, Borax-Sodium Hydroxide Buffer, Histidine - HCl buffer, Glycine-NaOH buffer, Arginine-HCl buffer, Sodium bicarbonate-Sodium carbonate buffer, Potassium bicarbonate-Potassium carbonate buffer, Tris-HCl buffer, Ammonia-Ammonium chloride Buffer, barbital sodium-hydrochloric acid buffer, borax-sodium carbonate buffer, boric acid-potassium chloride buffer,
- Step 2 Dissolve compound 2B (1.0 g, 3.2 mmol) in THF (10 mL), replace with N 2 and cool down to 0° C., add BH 3 /THF (6.4 mL, 6.4 mmol), and LCMS shows that the reaction is complete after 17 hours.
- the reaction solution was added into methanol (40 mL) (kept in an ice bath at 0° C.), quenched BH 3 and then spin-dried to obtain 500 mg of colorless oil 2C, yield: 52%.
- MS-ESI m/z 298.1 [M+H] + .
- Step 3 Dissolve compound 2C (500mg, 1.68mmol) in dichloromethane (8mL). After cooling down to 0°C, add Dess-Martin reagent (1.43g, 3.36mmol). After 1.5 hours, LCMS showed that the reaction was complete. The reaction solution was diluted with water (100 mL), extracted twice with ethyl acetate (100 mL+50 mL), combined the organic phases and washed with saturated brine, dried over anhydrous sodium sulfate and spin-dried to obtain 250 mg of white solid 2D, yield: 50% . MS-ESI: m/z 296.0 [M+H] + .
- Step 5 Take compound 2E (100mg, 0.18mmol), iron powder (100mg, 1.8mmol), add it to ethanol (4mL), dissolve NH 4 Cl (96mg, 1.8mmol) in water, add it to ethanol, replace with N 2 and raise the temperature The reaction was carried out at 60° C. for 2 hours, and LCMS showed that the reaction was complete. The reaction solution was filtered with diatomaceous earth, the filter cake was rinsed with ethanol three times, and the mother liquor was spin-dried for preparation. After preparation, 40 mg of white solid powder 2 and 5 mg of white solid powder 2S were obtained, with yields of 42% and 5%, respectively.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
仪器 | Agilent Technologies 6224 TOF LC/MS |
电离模式 | Positive |
气体温度 | 350℃ |
气流 | 13L/min |
喷雾器压力 | 45psig |
毛细管电压 | 5000V |
破碎电压 | 250V |
锥孔电压 | 65V |
八极杆上射频电压的峰峰 | 750V |
采集模式 | MS(seg) |
质量范围 | 500-8000m/z |
采集速率 | 1spectra/s |
采集时间 | 1.4-7.0min |
实验转染材料 | 体积(μL) |
pGL5质粒(100ng/uL) | 25 |
pBIND-GR(100ng/uL) | 25 |
Opti-MEM培养基 | 250.0 |
P3000 | 10.00 |
Opti-MEM培养基 | 250.0 |
Lipofectamine | 7.5 |
化合物编号 | EC50(nM) |
Dexamethasone | 2.11 |
化合物14(参照化合物P1) | 0.19 |
化合物4 | 0.04 |
化合物4S | 1.42 |
化合物编号 | EC50(nM) |
化合物14(参照化合物P1) | 0.43 |
化合物6 | 0.12 |
实验转染材料 | 体积(μL) |
pGL5质粒(100ng/uL) | 25 |
pBIND-GR(100ng/uL) | 25 |
Opti-MEM培养基 | 250.0 |
P3000 | 10.00 |
Opti-MEM培养基 | 250.0 |
Lipofectamine | 7.5 |
实验转染材料 | 体积(μL) |
pGL5质粒(100ng/uL) | 25 |
pBIND-MR(100ng/uL) | 25 |
Opti-MEM培养基 | 250.0 |
P3000 | 10.00 |
Opti-MEM培养基 | 250.0 |
Lipofectamine | 7.5 |
Compound ID | MR EC50(nM) |
Dexamethasone(地塞米松) | >1000.00 |
化合物4 | >1000.00 |
化合物5 | >1000.00 |
化合物3 | >1000.00 |
实验转染材料 | 体积(μL) |
pGL5质粒(100ng/uL) | 25 |
pBIND-ERα(100ng/uL) | 25 |
Opti-MEM培养基 | 250.0 |
P3000 | 10.00 |
Opti-MEM培养基 | 250.0 |
Lipofectamine | 7.5 |
Compound ID | ERαEC50(nM) |
Dexamethasone | >1000.00 |
化合物4 | >1000.00 |
化合物5 | >1000.00 |
化合物3 | >1000.00 |
Claims (73)
- 式I的化合物:或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中,R 1、R 2、R 3、R 4和R 5各自独立地为任意基团;B不存在或B为任意基团;W不存在或W为任意基团;A1为取代的苯环;CR 4R 5单元各自独立地不被替代或被选自以下组替代:-O-、-S-、-NR-、-S(O)-、-S(O) 2-、-C(=O)-、-C=C-和-C≡C-,其中R 4和R 5可一起形成任选取代的环烷基、任选取代的杂环基、任选取代的桥环基、任选取代的杂桥环基、任选取代的螺环基和任选取代的杂螺环基,n为1-20中的任意整数;X选自:-O-,-S-,-NR-;Y 1为任意基团,m为0至4中的任意整数;其中取代基选自:氕、氘、氚、卤素、-CN、=O、=N-OH、=N-OR、=N-R、-OR、-C(O)R、-C(O)OR、-OC(O)R、-OC(O)OR、-C(O)NHR、-C(O)NR 2、-OC(O)NHR、-OC(O)NR 2、-SR、-S(O)R、-S(O) 2R、-NHR、-N(R) 2、-NHC(O)R、-NRC(O)R、-NHC(O)OR、-NRC(O)OR、-S(O) 2NHR、-S(O) 2N(R) 2、-NHS(O) 2NR 2、-NRS(O) 2NR 2、-NHS(O) 2R、-NRS(O) 2R、C 1-C 6烷基、C 1-C 6烷氧基、芳基、杂芳基、环烷基、杂环烷基、卤素取代的C 1-C 6烷基、和卤素取代的C 1-C 6烷氧基,其中各R独立选自氢、氕、氘、氚、氧、羟基、卤素、C 1-C 6烷基、C 1-C 6烷氧基、芳基、杂芳基、环烷基、杂环烷基、卤素取代的C 1-C 6烷基、和卤素取代的C 1-C 6烷氧基。
- 根据权利要求1所述的式I的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其选自:其中,R 1、R 2、R 3、R 4和R 5各自独立地为任意基团;B不存在或B为任意基团;W不存在或W为任意基团;A1为取代的苯环;CR 4R 5单元各自独立地不被替代或被选自以下组替代:-O-、-S-、-NR-、-S(O)-、-S(O) 2-、-C(=O)-、-C=C-和-C≡C-,其中R 4和R 5可一起形成任选取代的环烷基、任选取代的杂环基、任选取代的桥环基、任选取代的杂桥环基、任选取代的螺环基和任选取代的杂螺环基,n为1-20中的任意整数;X选自:-O-,-S-,-NR-;Y 1为任意基团,m为0或1;其中取代基选自:氕、氘、氚、卤素、-CN、=O、=N-OH、=N-OR、=N-R、-OR、-C(O)R、-C(O)OR、-OC(O)R、-OC(O)OR、-C(O)NHR、-C(O)NR 2、-OC(O)NHR、-OC(O)NR 2、-SR、-S(O)R、-S(O) 2R、-NHR、-N(R) 2、-NHC(O)R、-NRC(O)R、-NHC(O)OR、-NRC(O)OR、-S(O) 2NHR、-S(O) 2N(R) 2、-NHS(O) 2NR 2、-NRS(O) 2NR 2、-NHS(O) 2R、-NRS(O) 2R、C 1-C 6烷基、C 1-C 6烷氧基、芳基、杂芳基、环烷基、杂环烷基、卤素取代的C 1-C 6烷基和卤素取代的C 1-C 6烷氧基,其中各R独立选自氢、氕、氘、氚、氧、羟基、卤素、C 1-C 6烷基、C 1-C 6烷氧基、芳基、杂芳基、环烷基、杂环烷基、卤素取代的C 1-C 6烷基、和卤素取代的C 1-C 6烷氧基。
- 根据权利要求1-2中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中X为-O-、-S-或-NH-。
- 根据权利要求1-3中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述CR 4R 5单元各自独立地不被替代或被选自以下组替代:-O-、-S-和-C(=O)-。
- 根据权利要求1-4中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R 4和R 5各自独立地选自以下组:氢、氕、氘、氚、卤素、任选取代的-C(=O)H、任选取代的-OH、任选取代的-SH、任选取代的-NH 2、任选取代的烷基、任选取代的烯基、任选取代的炔基、任选取代的环烷基、任选取代的杂环烷基、任选取代的芳基和任选取代的杂芳基;其中,当R 4和R 5包含亚甲基单元时,所述R 4和R 5的所述亚甲基单元各自独立地不被替代、或所述R 4和R 5的所述亚甲基单元各自独立地被选自以下组替代:-S(=O)-、-S(=O) 2-、-O-、-S-、-C(=O)-、任选取代的-PH-、任选取代的-P(=O)H-、任选取代的-NH-、任选取代的亚烷基、任选取代的亚烯基、任选取代的亚炔基、任选取代的亚环烷基、任选取代的亚杂环烷基、任选取代的亚芳基和任选取代的亚杂芳基。
- 根据权利要求5所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 4和R 5各自独立地选自:H、F、Cl、-OH、-NH 2和C 1-C 6烷基,或所述R 4和R 5一起形成C 3-C 6环烷基或3-6元杂环基;所述n选自1、2或3。
- 根据权利要求1-7中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述Y 1不存在或选自:氕、氘、氚、卤素、-OR、-SR、-NHR、-N(R) 2、任选取代的C 1-C 6烷基、任选取代的C 1-C 6烷氧基;其中各R独立选自氢、氕、氘、氚、羟基、卤素、C 1-C 6烷基、C 1-C 6烷氧基、芳基、杂芳基、环烷基、杂环烷基、卤素取代的C 1-C 6烷基、和卤素取代的C 1-C 6烷氧基。
- 根据权利要求1-8中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述Y 1不存在或选自:羟基、巯基、氨基和任选取代的C 1-C 6烷基。
- 根据权利要求1-10中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 1,R 2各自独立的选自:H,F,Cl,Br和任选取代的C 1-C 6烷基。
- 根据权利要求1-11中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 1,R 2各自独立的选自:H,F,Cl,Br和任选取代的甲基。
- 根据权利要求1-12中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 3选自:氢、任选取代的-OH、任选取代的-SH和任选取代的C 1-C 6烷基。
- 根据权利要求1-13中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 3选自:任选取代的-CH 2Cl、任选取代的-CH 2SH、任选取代的-CH 2OH、任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的-OH、任选取代的-OCH 3、任选取代的-OCH 2F、任选取代的-OCH 2Cl、任选取代的-OCH 2CN、任选取代的-OCH 2CH 3、任选取代的巯基、任选取代的-SCH 2F、任选取代的-SCH 2Cl、任选取代的-SCH 2CF 3、和任选取代的-SCH 2CN。
- 根据权利要求1-15中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述B选自:任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 其中取代基选自:氕、氘、氚、卤素、-CN、=O、=N-OH、=N-OR、=N-R、-OR、-C(O)R、-C(O)OR、-OC(O)R、-OC(O)OR、-C(O)NHR、-C(O)NR 2、-OC(O)NHR、-OC(O)NR 2、-SR、-S(O)R、-S(O) 2R、-NHR、-N(R) 2、-NHC(O)R、-NRC(O)R、-NHC(O)OR、-NRC(O)OR、-S(O) 2NHR、-S(O) 2N(R) 2、-NHS(O) 2NR 2、-NRS(O) 2NR 2、-NHS(O) 2R、-NRS(O) 2R、C 1-C 6烷基、C 1-C 6烷氧基、芳基、杂芳基、环烷基、杂环烷基、卤素取代的C 1-C 6烷基、和卤素取代的C 1-C 6烷氧基,其中各R独立选自氢、氕、氘、氚、氧、卤素、C 1-C 6烷基、C 1-C 6烷氧基、芳基、杂芳基、环烷基、杂环烷基、卤素取代的C 1-C 6烷基和卤素取代的C 1-C 6烷氧基。
- 根据权利要求1-18中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述W不存在或W选自:-S(=O)-、-S(=O) 2-、-O-、-S-、-C(=O)-、任选取代的-CH 2NHC(=O)-、任选取代的-NHC(=O)CH 2-、任选取代的-C(=O)NH-、任选取代的-NH-、任选取代的-CH=CH-、-C≡C-、任选取代的C 1-C 6亚烷基、任选取代的-OCH 2-、任选取代的-CH 2O-、任选取代的-SCH 2-、任选取代的-CH 2S-、任选取代的-NHC(=O)-、任选取代的-C(=O)CH 2-、任选取代的-CH 2NH-、任选取代的-NHCH 2-、任选取代的 任选取代的 任选取代的 任选取代的 和任选取代的
- 根据权利要求1-22中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其选自其中,所述X选自-O-,-S-和-NH-;R 4和R 5各自独立地选自以下组:H、F、Cl、-OH、-NH 2和C 1-C 6烷基;所述n选自1、2或3;所述Y 1不存在或选自:羟基、巯基、氨基和C 1-C 6烷基;所述R 1和R 2各自独立地选自氢、氟、氯和甲基;
- 式IIa或IIb的化合物:或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中,R 1、R 2、R 3、R 4和R 5各自独立地为任意基团;B不存在或B为任意基团;W不存在或W为任意基团;A2为取代的苯环;CR 4R 5单元各自独立地不被替代或被选自以下组替代:-O-、-S-、-NR-、-S(O)-、-S(O) 2-、-C(=O)-、-C=C-和-C≡C-,其中R 4和R 5可一起形成任选取代的环烷基、任选取代的杂环基、任选取代的桥环基、任选取代的杂桥环基、任选取代的螺环基和任选取代的杂螺环基,n为1-20中的任意整数;X选自:-O-,-S-,-NR-;Y 1为任意基团,m为0至4中的任意整数;Y 2选自-O-,-S-和-NR-;其中取代基选自:氕、氘、氚、卤素、-CN、=O、=N-OH、=N-OR、=N-R、-OR、-C(O)R、-C(O)OR、-OC(O)R、-OC(O)OR、-C(O)NHR、-C(O)NR 2、-OC(O)NHR、-OC(O)NR 2、-SR、-S(O)R、-S(O) 2R、-NHR、-N(R) 2、-NHC(O)R、-NRC(O)R、-NHC(O)OR、-NRC(O)OR、-S(O) 2NHR、-S(O) 2N(R) 2、-NHS(O) 2NR 2、-NRS(O) 2NR 2、-NHS(O) 2R、-NRS(O) 2R、C 1-C 6烷基、C 1-C 6烷氧基、芳基、杂芳基、环烷基、杂环烷基、卤素取代的C 1-C 6烷基、和卤素取代的C 1-C 6烷氧基;其中各R独立选自氢、氕、氘、氚、氧、卤素、C 1-C 6烷基、C 1-C 6烷氧基、芳基、杂芳基、 环烷基、杂环烷基、卤素取代的C 1-C 6烷基、和卤素取代的C 1-C 6烷氧基;
- 根据权利要求26所述的式IIa或IIb的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 4和R 5各自独立地选自以下组:氢、氕、氘、氚、卤素、任选取代的-C(=O)H、任选取代的-OH、任选取代的-SH、任选取代的-NH 2、任选取代的烷基、任选取代的烯基、任选取代的炔基、任选取代的环烷基、任选取代的杂环烷基、任选取代的芳基和任选取代的杂芳基;其中,当R 4和R 5包含亚甲基单元时,所述R 4和R 5的所述亚甲基单元各自独立地不被替代、或所述R 4和R 5的所述亚甲基单元各自独立地被选自以下组替代:-S(=O)-、-S(=O) 2-、-O-、-S-、-C(=O)-、任选取代的-PH-、任选取代的-P(=O)H-、任选取代的-NH-、任选取代的亚烷基、任选取代的亚烯基、任选取代的亚炔基、任选取代的亚环烷基、任选取代的亚杂环烷基、任选取代的亚芳基和任选取代的亚杂芳基。
- 根据权利要求27所述的式IIa或IIb的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 4和R 5各自独立地选自以下组:H、F、Cl、-OH、-NH 2和C 1-C 6烷基;所述n选自1、2或3。
- 根据权利要求26-28中任一项所述的式IIa或IIb的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,所述Y 1不存在或选自:-OR、-SR、-N(R) 2和任选取代的C 1-C 6烷基;其中各R独立选自氢、氕、氘、氚、C 1-C 6烷基、C 1-C 6烷氧基。
- 根据权利要求29所述的式IIa或IIb的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,所述Y 1不存在或选自:羟基、巯基、氨基和C 1-C 6烷基。
- 根据权利要求26-31中任一项所述的式IIa或IIb的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 1,R 2各自独立的选自:H,F,Cl,Br和任选取代的C 1-C 6烷基。
- 根据权利要求26-33中任一项所述的式IIa或IIb的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 1,R 2各自独立的选自:H,F,Cl,Br和任选取代的甲基。
- 根据权利要求58-71中任一项所述的式IIa或IIb的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 3选自:氢、任选取代的-OH、任选取代的-SH、和任选取代的C 1-C 6烷基。
- 根据权利要求26-34中任一项所述的式IIa或IIb的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 3选自:任选取代的-CH 2Cl、任选取代的-CH 2SH、任选取代的-CH 2OH、任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的-OH、任选取代的-OCH 3、任选取代的-OCH 2F、任选取代的-OCH 2Cl、任选取代的-OCH 2CN、任选取代的-OCH 2CH 3、任选取代的巯基、任选取代的-SCH 2F、任选取代的-SCH 2Cl、任选取代的-SCH 2CF 3、和任选取代的-SCH 2CN。
- 根据权利要求26-36中任一项所述的式IIa或IIb的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述B选自:任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 任选取代的 其中取代基选自:氕、氘、氚、卤素、-CN、=O、=N-OH、=N-OR、=N-R、-OR、-C(O)R、-C(O)OR、-OC(O)R、-OC(O)OR、-C(O)NHR、-C(O)NR 2、-OC(O)NHR、-OC(O)NR 2、-SR、-S(O)R、-S(O) 2R、-NHR、-N(R) 2、-NHC(O)R、-NRC(O)R、-NHC(O)OR、-NRC(O)OR、-S(O) 2NHR、-S(O) 2N(R) 2、-NHS(O) 2NR 2、-NRS(O) 2NR 2、-NHS(O) 2R、-NRS(O) 2R、C 1-C 6烷基、C 1-C 6烷氧基、芳基、杂芳基、环烷基、杂环烷基、卤素取代的C 1-C 6烷基、和卤素取代的C 1-C 6烷氧基,其中各R独立选自氢、氕、氘、氚、氧、卤素、C 1-C 6烷基、C 1-C 6烷氧基、芳基、杂芳基、环烷基、杂环烷基、卤素取代的C 1-C 6烷基、和卤素取代的C 1-C 6烷氧基。
- 根据权利要求26-39中任一项所述的式IIa或IIb的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述W不存在或W选自:-S(=O)-、-S(=O) 2-、-O-、-S-、-C(=O)-、任选取代的-CH 2NHC(=O)-、任选取代的-NHC(=O)CH 2-、任选取代的-C(=O)NH-、任选取代的-NH-、任选取代的-CH=CH-、-C≡C-、任选取代的C 1-C 6亚烷基、任选取代的-OCH 2-、任选取代的-CH 2O-、任选取代的-SCH 2-、任选取代的-CH 2S-、任选取代的-NHC(=O)-、任选取代的-COCH 2-、任选取代的-CH 2NH-、任选取代的-NHCH 2-、任选取代的-CH(CH 3)-、任选取代的 任选取代的 任选取代的 任选取代的 和任选取代的
- 根据权利要求26-43中任一项所述的式IIa或IIb的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其选自其中,所述X选自-O-,-S-和-NH-;R 4和R 5各自独立地选自以下组:H、F、Cl、-OH、-NH 2和C 1-C 6烷基;所述n选自1、2或3;所述Y 1不存在或选自:羟基、巯基、氨基和C 1-C 6烷基;所述R 1和R 2各自独立地选自氢、氟、氯和甲基;
- 根据权利要求26-45中任一项所述的式IIa或IIb的化合物或其互变异构体、内消旋体、 外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,所述的化合物还包括Linker片段,所述的式IIa或IIb的化合物能够通过Linker片段与配体偶联,所述Linker片段包括L 1片段、L 2片段和/或L 3片段,所述化合物具有以下结构:其中,Tr不存在或Tr为任意基团;L 3选自多肽片段;L 2不存在或选自连接片段;L 1选自偶联单元;R 1、R 2、R 3、R 4和R 5各自独立地为任意基团;B不存在或B为任意基团;W不存在或W为任意基团;CR 4R 5单元各自独立地不被替代或被选自以下组替代:-O-、-S-、-NR-、-S(O)-、-S(O) 2-、-C(=O)-、-C=C-和-C≡C-,其中R 4和R 5可一起形成任选取代的环烷基、任选取代的杂环基、任选取代的桥环基、任选取代的杂桥环基、任选取代的螺环基和任选取代的杂螺环基,n为1-20中的任意整数;X选自:-O-,-S-,-NR-;Y 1为任意基团,m为0至4中的任意整数;Y 2选自-O-,-S-和-NR-;其中取代基选自:氕、氘、氚、卤素、-CN、=O、=N-OH、=N-OR、=N-R、-OR、-C(O)R、-C(O)OR、-OC(O)R、-OC(O)OR、-C(O)NHR、-C(O)NR 2、-OC(O)NHR、-OC(O)NR 2、-SR、-S(O)R、-S(O) 2R、-NHR、-N(R) 2、-NHC(O)R、-NRC(O)R、-NHC(O)OR、-NRC(O)OR、-S(O) 2NHR、-S(O) 2N(R) 2、-NHS(O) 2NR 2、-NRS(O) 2NR 2、-NHS(O) 2R、-NRS(O) 2R、C 1-C 6烷基、C 1-C 6烷氧基、芳基、杂芳基、环烷基、杂环烷基、卤素取代的C 1-C 6烷基、和卤素取代的C 1-C 6烷氧基;其中各R独立选自氢、氕、氘、氚、氧、卤素、C 1-C 6烷基、C 1-C 6烷氧基、芳基、杂芳基、环烷基、杂环烷基、卤素取代的C 1-C 6烷基、和卤素取代的C 1-C 6烷氧基。
- 根据权利要求47所述的式IIa或IIb的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述L 3选自二肽、三肽和四肽;所述二肽选自:GA、GG、AG、EG、EA、GE、DG、DA、GD、VC、VA、AA和VK,所述三肽选自:EAG、EGG、GEG、GEA、DAG、DGG、GDG、GDA、GGA、GAG、GFG、AAG、AAA、VAG、VCG、VKG,所述四肽选自:GGFG、GGAG、GGGG、GEGG、GEAG、GDGG、GDAG、AAAG和EAGG。
- 根据权利要求48所述的式IIa或IIb的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述L 3选自以下组:甘氨酸-甘氨酸-苯丙氨酸-甘氨酸(GGFG)、丙氨酸-丙氨酸-丙氨酸-甘氨酸(AAAG)、甘氨酸-甘氨酸-甘氨酸-甘氨酸(GGGG)、缬氨酸-丙氨酸-甘氨酸(VAG)、缬氨酸-瓜氨酸-甘氨酸(VCG)、丙氨酸-丙氨酸-甘氨酸(AAG)、丙氨酸-丙氨酸-丙氨酸(AAA)、缬氨酸-丙氨酸(VA)、缬氨酸-瓜氨酸(VC)、丙氨酸-丙氨酸(AA)、谷氨酸-丙氨酸-甘氨酸-甘氨酸(EAGG)、甘氨酸- 谷氨酸-丙氨酸-甘氨酸(GEAG)、甘氨酸-谷氨酸-甘氨酸-甘氨酸(GEGG)、谷氨酸-甘氨酸-甘氨酸(EGG)、谷氨酸-丙氨酸-甘氨酸(EAG)、缬氨酸-赖氨酸-甘氨酸(VKG)、甘氨酸-谷氨酸-甘氨酸(GEG)、谷氨酸-丙氨酸(EA)、谷氨酸-甘氨酸(EG)和甘氨酸-谷氨酸(GE)。
- 根据权利要求46-49中任一项所述的式IIa或IIb的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述L 2不存在,或L 2包含或不包含PEG支链或PEG直链。
- 根据权利要求26-45所述的式IIa或IIb的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述的化合物还包括Linker片段,所述的式IIa或IIb的化合物能够通过Linker片段与配体偶联,所述化合物具有以下结构:其中,Tr不存在或Tr为任意基团;L 3选自多肽片段;L 2不存在或选自连接片段;L 1选自偶联单元;通式IVa-1和IVb-1中L 1为连接形式;R 1、R 2、R 3、R 4、R 5、B、W、CR 4R 5、n、X、Y 1和Y 2分别如权利要求26-45中任一项所述;
- 一种偶联物,包含权利要求1-57中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,所述偶联物包含配体-药物偶联物。
- 根据权利要求58所述的偶联物,其中所述配体包括抗体或其抗原结合片段。
- 根据权利要求59所述的偶联物,其中所述抗体选自:人抗体、人源化抗体、嵌合抗体、多特异性抗体、单克隆抗体和多克隆抗体;所述抗原结合片段选自:Fab、Fab’、F(ab’)2、Fv、scFv、双抗体、Fd、dAb、VHH、大抗体和互补决定区(CDR)片段。
- 根据权利要求58-60所述的偶联物,其中所述配体特异性结合选自下组的抗原:AXL,BAFFR,BCMA,BCR–列表组分(BCR–list components),BDCA2,BDCA4,BTLA,BTNL2BTNL3,BTNL8,BTNL9,C10orf54,CCR1,CCR3,CCR4,CCR5,CCR6,CCR7,CCR9,CCR10,CD11c,CD137,CD138,CD14,CD163,CD168,CD 177,CD19,CD20,CD209,CD209L,CD22,CD226,CD248,CD25,CD27,CD274,CD276,CD28,CD30,CD300A,CD33,CD37,CD38,CD4,分化抗原簇40(CD40),CD44,CD45,CD46,CD47,CD48,CD5,CD52,CD55,CD56,CD59,CD62E,CD68,CD69,CD70,CD74,CD79a,CD79b,CD8,CD80,CD86,CD90.2,CD96,CLEC12A,CLEC12B,CLEC7A,CLEC9A,CR1,CR3,CRTAM,CSF1R,CTLA4,CXCR1/2,CXCR4,CXCR5,DDR1,DDR2,DEC-205,DLL4,DR6,FAP,FCamR,FCMR,FcR’s,Fire,GITR,HHLA2,II型HLA(HLA class II),HVEM,ICOSLG,IFNAR,I型干扰素受体亚基(IFNAR1),IFNLR1,IL10R1,IL10R2,IL12R,IL13RA1,IL13RA2,IL15R,IL17RA,IL17RB,IL17RC,IL17RE,IL20R1,IL20R2,IL21R,IL22R1,IL22RA,IL23R,IL27R,IL29R,IL2Rg,IL31R,IL36R,IL3RA,IL4R,IL6R,IL5R,IL7R,IL9R,整合素(Integrins),LAG3,LIFR,MAG/Siglec-4(唾液酸结合性免疫球蛋白样凝集素-4),MMR,MSR1,NCR3LG1,NKG2D,NKp30,NKp46,OX40(CD134),PDCD1,PROKR1,PVR,PVRIG,PVRL2,PVRL3,RELT,SIGIRR,Siglec-1(唾液酸结合性免疫球蛋白样凝集素-1),Siglec-10,Siglec-5,Siglec-6,Siglec-7,Siglec-8,Siglec-9,SIRPA, SLAMF7,TACI,TCR–列表组分/assoc(TCR-listcomponents/assoc),PTCRA,TCRb,CD3z,CD3,TEK,TGFBR1,TGFBR2,TGFBR3,TIGIT,TLR2,TLR4,肿瘤坏死因子α(TNFα),TROY,TSLPR,TYRO,VLDLR,VSIG4,IL2R-y和VTCN1。
- 根据权利要求61所述的偶联物,其中所述配体选自:抗TNFα抗体或其抗原结合片段,抗CD40抗体或其抗原结合片段和抗IFNAR1抗体或其抗原结合片段。
- 根据权利要求58-62所述的偶联物,其中所述配体选自:阿达木单抗(Adalimumab)、Iscalimab(CFZ533)、Anifrolumab(MEDI-546)、英利昔单抗(Infliximab)、阿非莫单抗(Afelimomab)、戈利木单抗(golimumab)、BIIB059、8c11、其衍生物、其生物类似物。
- 根据权利要求58-63所述的偶联物,其中所述配体-药物偶联物具有以下结构:其中,Ab代表能够与靶标结合的配体,N a-I为1至10中的任意数字;Tr不存在或Tr为任意基团;L 3选自多肽片段;L 2不存在或选自连接片段;L 1选自偶联单元;R 1、R 2、R 3、R 4和R 5各自独立地为任意基团;B不存在或B为任意基团;W不存在或W为任意基团;CR 4R 5单元各自独立地不被替代或被选自以下组替代:-O-、-S-、-NR-、-S(O)-、-S(O) 2-、-C(=O)-、-C=C-和-C≡C-,其中R 4和R 5可一起形成任选取代的环烷基、任选取代的杂环基、任选取代的桥环基、任选取代的杂桥环基、任选取代的螺环基和任选取代的杂螺环基,n为1-20中的任意整数;X选自:-O-,-S-,-NR-;Y 1为任意基团,m为0至4中的任意整数;Y 2选自-O-,-S-和-NR-;其中取代基选自:氕、氘、氚、卤素、-CN、=O、=N-OH、=N-OR、=N-R、-OR、-C(O)R、-C(O)OR、-OC(O)R、-OC(O)OR、-C(O)NHR、-C(O)NR 2、-OC(O)NHR、-OC(O)NR 2、-SR、-S(O)R、-S(O) 2R、-NHR、-N(R) 2、-NHC(O)R、-NRC(O)R、-NHC(O)OR、-NRC(O)OR、-S(O) 2NHR、-S(O) 2N(R) 2、-NHS(O) 2NR 2、-NRS(O) 2NR 2、-NHS(O) 2R、-NRS(O) 2R、C 1-C 6烷基、C 1-C 6烷氧基、芳基、杂芳基、环烷基、杂环烷基、卤素取代的C 1-C 6烷基、和卤素取代的C 1-C 6烷氧基;其中各R独立选自氢、氕、氘、氚、氧、卤素、C 1-C 6烷基、C 1-C 6烷氧基、芳基、杂芳基、环烷基、杂环烷基、卤素取代的C 1-C 6烷基、和卤素取代的C 1-C 6烷氧基。
- 根据权利要求58-65所述的偶联物,其中所述配体-药物偶联物具有以下结构:其中,Ab代表能够与靶标结合的配体,N a-I为1至10中的任意数字;所述X选自-O-,-S-和-NH-;R 4和R 5各自独立地选自以下组:H、F、Cl、-OH、-NH 2和C 1-C 6烷基;所述n选自1、2或3;所述Y 1不存在或选自:羟基、巯基、氨基和C 1-C 6烷基;所述R 1和R 2各自独立地选自氢、氟、氯和甲基;
- 一种药物组合物,其包含权利要求1-57中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐和/或权利要求58-68中任一项所述的偶联物,以及任选地药学上可接受的载体。
- 一种影响免疫系统功能的方法,包括向受试者施用权利要求1-57中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐、权利要求58-68中任一项所述的偶联物和/或权利要求69所述的药物组合物。
- 权利要求1-57中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐、权利要求58-68中任一项所述的偶联物和/或权利要求69所述的药物组合物在制备药物中的用途,所述药物用于预防和/或治疗疾病和/或症状,所述疾病和/或症状包含与糖皮质激素受体信号转导相关的疾病和/或症状。
- 根据权利要求72所述的用途,所述疾病和/或症状选自以下组:类风湿关节炎、系统性红 斑狼疮、硬皮病、干燥综合症、强直性脊柱炎、韦格纳肉芽肿病和系统性硬化、自身免疫性溶血性贫血、恶性贫血、特发性血小板减少性紫癜、特发性血小板减少症和血管炎、多发性硬化、重症肌无力和古兰巴雷综症、溃疡性结肠炎、克罗恩病、自身免疫性病和萎缩性胃炎、IgA肾病、原发性肾病综合征、自身免疫性肾小球肾炎、肺肾出血综合征和狼疮肾炎、I型糖尿病、Grave's病、桥本甲状腺炎、原发性肾上腺皮质萎缩和慢性甲状腺炎、银屑病、寻常型天孢疹、皮肤红斑狼疮、皮肌炎和风湿性多肌痛和哮喘。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280041892.2A CN117500816A (zh) | 2021-08-26 | 2022-08-25 | 一种甾体化合物及其缀合物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110988668 | 2021-08-26 | ||
CN202110988668.1 | 2021-08-26 | ||
CN202111592481 | 2021-12-23 | ||
CN202111592481.6 | 2021-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023025248A1 true WO2023025248A1 (zh) | 2023-03-02 |
Family
ID=85322451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/114855 WO2023025248A1 (zh) | 2021-08-26 | 2022-08-25 | 一种甾体化合物及其缀合物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117500816A (zh) |
WO (1) | WO2023025248A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024064779A1 (en) * | 2022-09-22 | 2024-03-28 | Eli Lilly And Company | Glucocorticoid receptor agonists |
Citations (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5235038A (en) | 1991-01-22 | 1993-08-10 | Torry Pines Institute For Molecular Studies | Deletion and substitution analogues of melittin peptide |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US5801227A (en) | 1993-10-01 | 1998-09-01 | Fanslow, Iii; William C. | Antibodies to CD40 |
US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
US5919453A (en) | 1992-03-31 | 1999-07-06 | Laboratoire European De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
US6258562B1 (en) | 1996-02-09 | 2001-07-10 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
WO2001094585A1 (en) | 2000-06-06 | 2001-12-13 | Celltech R & D Limited | Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof |
US7193064B2 (en) | 2001-04-27 | 2007-03-20 | Kirin Beer Kabushiki Kaisha | Anti-CD40 monoclonal antibody |
US7445780B2 (en) | 2000-10-02 | 2008-11-04 | Novartis Vaccines And Diagnostics, Inc. | Antagonistic anti-CD40 antibodies |
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
WO2012131053A1 (en) | 2011-03-30 | 2012-10-04 | Ablynx Nv | Methods of treating immune disorders with single domain antibodies against tnf-alpha |
US20120301488A1 (en) | 2011-04-29 | 2012-11-29 | Yongke Zhang | Anti-cd40 antibodies and methods of use |
WO2013087912A1 (en) | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
US8591900B2 (en) | 2010-03-31 | 2013-11-26 | Boehringer Ingelheim International Gmbh | Anti-CD40 antibodies |
US8669352B2 (en) | 2006-05-09 | 2014-03-11 | Fast Forward Pharmaceuticals B.V. | Antagonistic anti-human CD40 monoclonal antibody |
US20140093497A1 (en) | 2011-03-11 | 2014-04-03 | Emory University | Anti-cd40 antibodies and uses thereof |
US8828396B2 (en) | 2010-11-15 | 2014-09-09 | Novartis Ag | Silent Fc variants of anti-CD40 antibodies |
WO2014152247A1 (en) | 2013-03-15 | 2014-09-25 | Abbvie, Inc. | Improved tnf binding proteins |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
US10182058B2 (en) | 2015-05-07 | 2019-01-15 | Alibaba Group Holding Limited | Method, device and server for managing user login sessions |
CN109476699A (zh) * | 2016-06-02 | 2019-03-15 | 艾伯维公司 | 糖皮质激素受体激动剂及其免疫偶联物 |
CN110291097A (zh) * | 2016-11-08 | 2019-09-27 | 里珍纳龙药品有限公司 | 类固醇类化合物及其蛋白质-偶联物 |
CN111417410A (zh) * | 2017-12-01 | 2020-07-14 | 艾伯维公司 | 糖皮质激素受体激动剂及其免疫缀合物 |
CN111465399A (zh) * | 2017-12-01 | 2020-07-28 | 艾伯维公司 | 抗cd40抗体药物结合物 |
US10831459B2 (en) | 2014-09-09 | 2020-11-10 | Liveperson, Inc. | Dynamic code management |
US11157494B2 (en) | 2016-09-28 | 2021-10-26 | International Business Machines Corporation | Evaluation of query for data item having multiple representations in graph on a sub-query by sub-query basis until data item has been retrieved |
WO2021216913A1 (en) * | 2020-04-22 | 2021-10-28 | Immunext, Inc. | Anti-human vista antibodies and use thereof |
WO2022150637A1 (en) * | 2021-01-07 | 2022-07-14 | Immunext, Inc. | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF |
WO2022166779A1 (zh) * | 2021-02-04 | 2022-08-11 | 上海森辉医药有限公司 | 糖皮质激素受体激动剂的药物偶联物及其在医药上的应用 |
WO2022204099A1 (en) * | 2021-03-23 | 2022-09-29 | Eli Lilly And Company | Carboxy substituted glucocorticoid receptor agonists |
US11521102B2 (en) | 2017-10-24 | 2022-12-06 | Nippon Telegraph And Telephone Corporation | Transformation apparatus, decision apparatus, quantum computation apparatus, and quantum machine learning system |
-
2022
- 2022-08-25 WO PCT/CN2022/114855 patent/WO2023025248A1/zh active Application Filing
- 2022-08-25 CN CN202280041892.2A patent/CN117500816A/zh active Pending
Patent Citations (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5235038A (en) | 1991-01-22 | 1993-08-10 | Torry Pines Institute For Molecular Studies | Deletion and substitution analogues of melittin peptide |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US5919453A (en) | 1992-03-31 | 1999-07-06 | Laboratoire European De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
US5801227A (en) | 1993-10-01 | 1998-09-01 | Fanslow, Iii; William C. | Antibodies to CD40 |
US6258562B1 (en) | 1996-02-09 | 2001-07-10 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
WO2001094585A1 (en) | 2000-06-06 | 2001-12-13 | Celltech R & D Limited | Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof |
US7445780B2 (en) | 2000-10-02 | 2008-11-04 | Novartis Vaccines And Diagnostics, Inc. | Antagonistic anti-CD40 antibodies |
US7193064B2 (en) | 2001-04-27 | 2007-03-20 | Kirin Beer Kabushiki Kaisha | Anti-CD40 monoclonal antibody |
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
US8669352B2 (en) | 2006-05-09 | 2014-03-11 | Fast Forward Pharmaceuticals B.V. | Antagonistic anti-human CD40 monoclonal antibody |
US8591900B2 (en) | 2010-03-31 | 2013-11-26 | Boehringer Ingelheim International Gmbh | Anti-CD40 antibodies |
US9221913B2 (en) | 2010-11-15 | 2015-12-29 | Novartis Ag | Silent Fc variants of anti-CD40 antibodies |
US8828396B2 (en) | 2010-11-15 | 2014-09-09 | Novartis Ag | Silent Fc variants of anti-CD40 antibodies |
US20140093497A1 (en) | 2011-03-11 | 2014-04-03 | Emory University | Anti-cd40 antibodies and uses thereof |
WO2012131053A1 (en) | 2011-03-30 | 2012-10-04 | Ablynx Nv | Methods of treating immune disorders with single domain antibodies against tnf-alpha |
US8778345B2 (en) | 2011-04-29 | 2014-07-15 | Apexigen, Inc. | Anti-CD40 antibodies |
US20120301488A1 (en) | 2011-04-29 | 2012-11-29 | Yongke Zhang | Anti-cd40 antibodies and methods of use |
WO2013087912A1 (en) | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
WO2014152247A1 (en) | 2013-03-15 | 2014-09-25 | Abbvie, Inc. | Improved tnf binding proteins |
US20140294813A1 (en) | 2013-03-15 | 2014-10-02 | Abbvie, Inc. | TNF Binding Proteins |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
US10831459B2 (en) | 2014-09-09 | 2020-11-10 | Liveperson, Inc. | Dynamic code management |
US10182058B2 (en) | 2015-05-07 | 2019-01-15 | Alibaba Group Holding Limited | Method, device and server for managing user login sessions |
CN109476699A (zh) * | 2016-06-02 | 2019-03-15 | 艾伯维公司 | 糖皮质激素受体激动剂及其免疫偶联物 |
US11157494B2 (en) | 2016-09-28 | 2021-10-26 | International Business Machines Corporation | Evaluation of query for data item having multiple representations in graph on a sub-query by sub-query basis until data item has been retrieved |
CN110291097A (zh) * | 2016-11-08 | 2019-09-27 | 里珍纳龙药品有限公司 | 类固醇类化合物及其蛋白质-偶联物 |
US11521102B2 (en) | 2017-10-24 | 2022-12-06 | Nippon Telegraph And Telephone Corporation | Transformation apparatus, decision apparatus, quantum computation apparatus, and quantum machine learning system |
CN111417410A (zh) * | 2017-12-01 | 2020-07-14 | 艾伯维公司 | 糖皮质激素受体激动剂及其免疫缀合物 |
CN111465399A (zh) * | 2017-12-01 | 2020-07-28 | 艾伯维公司 | 抗cd40抗体药物结合物 |
WO2021216913A1 (en) * | 2020-04-22 | 2021-10-28 | Immunext, Inc. | Anti-human vista antibodies and use thereof |
WO2022150637A1 (en) * | 2021-01-07 | 2022-07-14 | Immunext, Inc. | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF |
WO2022166779A1 (zh) * | 2021-02-04 | 2022-08-11 | 上海森辉医药有限公司 | 糖皮质激素受体激动剂的药物偶联物及其在医药上的应用 |
WO2022204099A1 (en) * | 2021-03-23 | 2022-09-29 | Eli Lilly And Company | Carboxy substituted glucocorticoid receptor agonists |
Non-Patent Citations (16)
Title |
---|
"GenBank", Database accession no. DI496971.1 |
A1-LAZIKANI ET AL., JMOI BIOL, vol. 273, 1997, pages 927 - 48 |
ALTSCHUL SF ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402 |
DORONINA ET AL., NAT. BIOTECHNOL., vol. 21, 2003, pages 778 - 784 |
GAY ET AL., MABS, vol. 2, 2010, pages 625 - 638 |
HUSTON ET AL.: "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in Escherichia coli", PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883, XP000872837, DOI: 10.1073/pnas.85.16.5879 |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH |
MATHIEU DONDELINGER ET AL.: "Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition", FRONT. IMMUNOL., 16 October 2018 (2018-10-16) |
MCRAE BL ET AL., J CROHNS COLITIS, vol. 10, no. 1, 2016, pages 69 - 76 |
MUYLDERMANS S., J BIOTECHNOL, vol. 74, 2001, pages 277 - 302 |
NGUYEN VK. ET AL., THE EMBO JOURNAL, vol. 19, 2000, pages 921 - 930 |
TROUT ET AL., PROC. NATL. ACAD. SCI. USA, 1982, pages 626 - 629 |
UMEMOTO ET AL., INT. J. CANCER, 1989, pages 677 - 684 |
VANLSCHOOT P. ET AL., ANTIVIRAL RESEARCH, vol. 92, 2011, pages 389 - 407 |
VINCENT, INT.J.CLIN.PRACT., vol. 54, 2000, pages 190 - 193 |
WARD ET AL.: "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted From Escherichia coli", NATURE, vol. 341, 1989, pages 544 - 546 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024064779A1 (en) * | 2022-09-22 | 2024-03-28 | Eli Lilly And Company | Glucocorticoid receptor agonists |
Also Published As
Publication number | Publication date |
---|---|
CN117500816A (zh) | 2024-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020063673A1 (zh) | 抗b7h3抗体-依喜替康类似物偶联物及其医药用途 | |
TWI779386B (zh) | 抗trop2抗體及其生產方法、及抗trop2抗體-藥物結合物 | |
WO2018140831A2 (en) | Tumor targeting conjugates and methods of use thereof | |
BR112018074922B1 (pt) | Compostos agonistas de receptores de glucocorticoides, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos | |
TW201400131A (zh) | 自行穩定之接合劑共軛物 | |
EP4289857A1 (en) | Drug conjugate of glucocorticoid receptor agonist, and application thereof in medicine | |
KR20200121317A (ko) | 글리피칸 3 항체 및 그의 접합체 | |
KR20220079606A (ko) | 캄프토테신 펩티드 접합체 | |
KR101344611B1 (ko) | 인간 tweak 에 대한 항체 및 이의 용도 | |
WO2018068758A1 (zh) | 抗c-Met抗体-细胞毒性药物偶联物的医药用途 | |
WO2023143365A1 (zh) | Her3抗体药物偶联物及其用途 | |
WO2023025248A1 (zh) | 一种甾体化合物及其缀合物 | |
CA3205707A1 (en) | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses | |
WO2023040793A1 (zh) | 一种抗炎症的化合物及其用途 | |
KR20220131266A (ko) | 단백질-항바이러스 화합물 접합체 | |
CN113121639A (zh) | 澳瑞他汀类似物及其偶联物、其制备方法及其应用 | |
EP4374879A1 (en) | Drug conjugate of eribulin derivative | |
TW202327619A (zh) | 一種甾體化合物及其綴合物 | |
CA3113378C (en) | Sulfomaleimide-based linkers and corresponding conjugates | |
WO2023143351A1 (zh) | 糖皮质激素的药物偶联物 | |
WO2022135332A1 (zh) | 一种甾体偶联物 | |
WO2022171101A1 (zh) | 一种甾体偶联物 | |
CA3220081A1 (en) | Protein-antiviral compound conjugates | |
CN116942845A (zh) | 抗psma抗体、其药物偶联物及其医药用途 | |
WO2024138000A1 (en) | Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22860594 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280041892.2 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022860594 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022860594 Country of ref document: EP Effective date: 20240326 |